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Abstract
This thesis is a work focused on the application of the differential game
theory to HIV therapeutic treatment, where a player is represented by the
immune system of the subject (helped by drug therapy) which opposes the
HIV virus. The aim of our study is to determine the optimal therapy that
allows to prevent viral replication in his body (rather than the complete
eradication of the infection, that remains chronic) so as to reduce the damage
caused to the immune system, and allow greater survival and quality of life.
To this end, our work is subdivided into 2 phases: in the first one we analyze
the related literature in order to identify models and dynamics that describe
the behavior of HIV and the behavior of immune system in the presence of
this virus. In the second one we propose a generalized model which considers
all six classes of antiretroviral drugs and different immune cells dynamics,
with the aim of representing as much as possible the real setting of this
problem. At a later stage, we validate our model with numerical simulations,





Questa tesi e` un lavoro focalizzato sull’applicazione della Teoria dei giochi
differenziali al trattamento terapeutico dell’HIV, in cui un giocatore e` rap-
presentato dal sistema immunitario del soggetto (supportato dalla terapia
farmacologica) al quale si oppone il virus dell’HIV. Lo scopo del nostro
studio e` quello di determinare la terapia ottimale che consente di prevenire
la replicazione virale nel corpo del soggetto stesso, (e non l’eradicazione
completa dell’infezione che rimane cronica) cos`ı da ridurre i danni provocati
al sistema immunitario, e garantirgli una sopravvivenza e una qualita` di
vita certamente maggiori. A tal fine, il nostro lavoro e` stato suddiviso in 2
fasi: nella prima fase abbiamo analizzato la letteratura annessa al fine di
individuare modelli e dinamiche che descrivono il comportamento dell’HIV
ed il comportamento del sistema immunitario in presenza di questo virus.
Nella seconda fase abbiamo proposto un modello generalizzato, che consideri
tutte le sei classi di farmaci antiretrovirali e le dinamiche delle diverse cellule
immunitarie, con l’obiettivo di approssimare al meglio la realta` di questo
problema. Successivamente, siamo passati alla validazione del nostro modello,
con simulazioni numeriche, cercando di determinare il piano strutturato




1 HIV modeling: a review 9
1.1 Variables, Controls and Parameters . . . . . . . . . . . . . . . 9
1.2 Models without infected T cells dynamics . . . . . . . . . . . 10
1.2.1 Basic models . . . . . . . . . . . . . . . . . . . . . . . 10
1.2.2 Models with both uninfected T cells and viruses differ-
entiation . . . . . . . . . . . . . . . . . . . . . . . . . 14
1.2.3 Models with uninfected T cells differentiation and with
immune effectors/precursors . . . . . . . . . . . . . . 14
1.2.4 Models with uninfected T cells differentiation, viruses
differentiation and immune effectors/precursors presence 15
1.3 Models with infected T cells dynamics . . . . . . . . . . . . . 17
1.3.1 Basic Models . . . . . . . . . . . . . . . . . . . . . . . 17
1.3.2 Models with immune effectors/precursors . . . . . . . 20
1.3.3 Models with uninfected T cells differentiation . . . . 22
1.3.4 Models with viruses differentiation . . . . . . . . . . . 24
1.3.5 Models with both uninfected and infected T cells dif-
ferentiation . . . . . . . . . . . . . . . . . . . . . . . . 26
1.3.6 Models with both infected T cells and viruses differen-
tiation . . . . . . . . . . . . . . . . . . . . . . . . . . 27
1.3.7 Models with both uninfected and infected T cells dif-
ferentiation and viruses differentiation . . . . . . . . . 32
1.3.8 Models with uninfected T cells differentiation, viruses
differentiation and immune effectors/precursors presence 34
1.3.9 Models with uninfected and infected T cells differen-
tiation, with viruses differentiation and with immune
effectors/precursors . . . . . . . . . . . . . . . . . . . 35
1.4 Parameters Analysis . . . . . . . . . . . . . . . . . . . . . . . 36
1.5 Review conclusions . . . . . . . . . . . . . . . . . . . . . . . . 38
2 A new model 41
2.1 Variables, Controls and Parameters . . . . . . . . . . . . . . . 47
x Introduction
2.2 Payoff . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 49
2.3 Dynamics . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 50
2.4 Nash Equilibria . . . . . . . . . . . . . . . . . . . . . . . . . . 61
2.5 Connection between Nash equilibrium and ESS . . . . . . . . 74
3 Numerical Solution 79
3.1 Numerical integration . . . . . . . . . . . . . . . . . . . . . . 82
3.1.1 Composite rectangle formula . . . . . . . . . . . . . . 82
3.1.2 Composite trapezoid formula . . . . . . . . . . . . . . 83
3.1.3 Composite Cavalieri-Simpson formula . . . . . . . . . 83
3.2 Various instances . . . . . . . . . . . . . . . . . . . . . . . . . 84
3.3 Conclusions . . . . . . . . . . . . . . . . . . . . . . . . . . . . 91
A Differential Games 93
A.1 Nash equilibria . . . . . . . . . . . . . . . . . . . . . . . . . . 94
A.2 Necessary condition for Nash equilibria . . . . . . . . . . . . . 95
B Parameters 99
C The algorithms 103
C.1 Mathemathica functions for symbolic calculations . . . . . . . 103
C.2 Matlab function for numerical calculations . . . . . . . . . . . 132
Bibliografy 273
Introduction
HIV is a virus whose genetic code consists of a ribonucleic acid, RNA;
it belongs to the retroviruses family, characterized by the presence of an
enzyme, DNA-polymerase RNA-independent, capable of transcribing the
genetic code RNA into DNA. This ability allows the virus to integrate his
genome into the one of the cells it infects such that the integrated virus
would not be defeated nor by the immune response nor by drugs.
It is now established that HIV is the result of mutations in various
strains of SIV (Simian Immunodeficiency Virus). Such mutations made it
able to progressively infect humans. The jump of species would have occurred
around the 1930s in some regions of West Sub-Saharan Africa. Strain HIV-1
derives from an immunodeficiency virus found in chimpanzee Pan troglodytes
troglodytes (SIVcpz), on the other hand HIV-2 derives from a virus which
affects the monkeys Sooty Mangabey (SIVsmm). The former is responsible for
the current pandemic worldwide, the latter has a very limited infectivity and
pathogenicity and it is mainly limited to its places of origin. Recently it has
been isolated in black people from the endemic areas of Western countries.
The strains of HIV-1 can be classified into four groups: the “major” group
M, the “outlier” group O and two new groups, N and P. These four groups
may represent four separate introductions of simian immunodeficiency virus
into humans.
Figure 1: HIV types, groups and subtypes.
Group O appears to be restricted to west-central Africa and group N
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(a strain discovered in 1998 in Cameroon) is extremely rare. In 2009 a new
strain closely relating to gorilla simian immunodeficiency virus was discovered
in a Cameroonian woman. It was designated HIV-1 group P [89]. More than
90% of HIV-1 infections belong to HIV-1 group M and, unless specified, our
considerations will be related to HIV-1 group M only.
Within group M there are at least nine genetically distinct subtypes of
HIV-1. These are subtypes A, B, C, D, F, G, H, J and K [137].
Occasionally, two viruses of different subtypes can meet in the cell of
an infected person and mix together their genetic material to create a new
hybrid virus (a process similar to sexual reproduction, and sometimes called
“viral sex”) [14]. Many of these new strains do not survive for long, but those
that infect more than one person are known as “circulating recombinant
forms” or CRFs. For example, the CRF A/B is a mixture of subtypes A and
B.
The classification of HIV strains into subtypes and CRFs is a complex
issue and the definitions are subject to changes as new discoveries are made.
Some scientists talk about subtypes A1, A2, A3, F1 and F2 instead of A and
F, though others regard the former as sub-subtypes.
One of the CRFs is called A/E because it is thought to be a result
from hybridization between subtype A and some other “parent” subtype E.
However, no one has ever found a pure form of subtype E. Confusingly, many
people still refer to the CRF A/E as “subtype E” (in fact it is most correctly
called CRF01AE) [54].
A virus isolated in Cyprus was originally placed in a new subtype I,
before being reclassified as a recombinant form A/G/I. It is now a common
thought that this virus represents an even more complex CRF comprised of
subtypes A, G, H, K and unclassified regions, so that the designation “I” is
no longer used [33].
“Since the discover of the epidemic, almost 70 million people have been
infected with the HIV virus and about 35 million people have died of AIDS.
Globally, 34 million [31.4-35.9 million] people were living with HIV at the
end of 2011. An estimated 0.8% of adults aged 15-49 years worldwide are
living with HIV, although the burden of the epidemic continues to vary
considerably between countries and regions. Sub-Saharan Africa remains
most severely affected, with nearly 1 in every 20 adults (4.9%) living with
HIV and accounting for 69% of the people living with HIV worldwide.” [137]
Our body has an immune system that, in a healthy person, can deal
with infections due to bacteria and viruses. It has two main ways to get rid
of pathogens: the first one is a system that tends to remove all pathogens
regardless of their biological nature (such as the acid in the stomach). The
second one is a specific immune response adopted to the pathogen agent,
and it is characterized by the response given by lymphocytes . In this paper
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we focus on the second one.
Lymphocytes, which derive from the bone marrow and mature in the lym-
phatic system, are activated by a specific antigen, or foreign substance. They
are divided in T-lymphocytes and in B-lymphocytes, moreover T lympho-
cytes are subdivided in T-helper and T-cytotoxic.
The tasks of the lymphocytes varies depending on their type: T-lymphocytes
are activated by the antigens present on the surface of macrophage cells,
B-Lymphocytes are activated by antigens vacant in the blood. Therefore,
while the T-lymphocytes recognize the presence of intracellular pathogens
and are effective against cells already infected, B-lymphocytes recognize the
extracellular pathogens in the blood, in particular toxins and free bacteria.
The role of T-helper cells helps us to understand the close relationship
between the two types of immune response and how important it is that
lymphocytes interact amoung each other. Whether it is a Cytotoxic T-
cell or a B-lymphocyte, it is necessary the presence of a T-helper cell for
their activation; then the Cytotoxic T-cells destroy infected cells, while B-
lymphocytes release specific antibodies that trigger chemical processes or
recall macrophage cells that phagocytize the antigen. The importance of
T-helper cells consists in the adjustment function for both immune systems.
After exposure to an antigen some particular cells remain on our lymphatic
and blood system, the so called T-memory and B-memory cells, that will be
present for the remainder of life and will facilitate the task of the immune
system in the event of a second exposure to a particular agent pathogen. This
is essentially why the vaccines are useful in preventing diseases. Unfortunately
many viruses mutate frequently, changing for example the external proteins
of their coating.
HIV is characterized by its marked tendency to mutate: mutations are
errors that individual viral particles make in replicative cycles. Each error
leads to the appearance of a virus more or less different from the original
one. Mutations are mostly “disadvantageous” for the viral species as mutated
viruses tend to disappear. Nevertheless some mutations are “beneficial” and
allow mutated viruses to acquire drug resistance and immune response. Its
aptitude for changing is one of the most effective mechanisms used by HIV
to evade our immune response and treatment.
HIV has different transmission modalities: among these the more impor-
tant are sexual, blood and vertical (mother to child). The most common
is sexual (85%), followed by contact with infected blood or blood products.
In developing countries particularly important is vertical transmission: this
can occur during pregnancy to trans-placental passage (20-40%), during
childbirth (40-70%), and finally during early breastfeeding (15-20%).[137]
HIV can be suppressed by a combination of antiretroviral therapy (ART)
consisting of three or more antiretroviral (ARV) drugs. ART does not cure
HIV infection but controls viral replication within a person’s body and allows
an individual’s immune system to strengthen and regain the capacity to
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fight off infections. With ART, people living with HIV can live healthy and
productive lives.
More than 9.7 million people living with HIV in low- and middle-income
countries were receiving ART at the end of 2012. Of this, about 640 000 were
children. This is over 30-fold increase in the number of people receiving ART
in developing countries between 2003 and 2012, and close to a 20% increase
in just one year (from 8 million in 2011 to 9.7 million in 2012).
In 2012, 62% of the estimated 1.5 million pregnant women living with HIV
in low- and middle-income countries received effective antiretroviral drugs to
avoid transmission to their children, up from 48% in 2010.[137]
The transmission of HIV from an HIV-positive mother to her child during
pregnancy, labour, delivery or breastfeeding is called vertical (as seen above)
or mother-to-child transmission (MTCT). In the absence of any intervention
HIV transmission rates are between 15-45%. MTCT can be nearly fully
prevented if both the mother and the child are provided with antiretroviral
drugs throughout the stages when infection could occur.
World Health Organization (WHO) recommends a range of options for
prevention of MTCT (PMTCT), which includes providing ARVs to mothers
and infants during pregnancy, labour and post-natal period, or offering life-
long treatment to HIV-positive pregnant women regardless of their CD4
count. New guidelines for PMTCT has issued in 2013.
Zidovudine (ZDV), alias Azidothymidine (AZT), a nucleoside analog
reverse-transcriptase inhibitor (NRTI), was the first drug capable of stemming
the effects of the syndrome and was used in 1987. The tendency of the virus
to develop resistance mutations and the high toxicity of the drug led the
researchers to drop out of monotherapy in 1991 and to start using two-drug
therapies. Finally, the discovery of protease inhibitors in 1996 [78] has enabled
a highly effective new drug protocol, based on three viral inhibitors, which
constitutes the current standard therapy, known as HAART [136] (Highly
Active Antiretroviral Therapy).
Drugs commonly used in anti-retroviral therapy (ART) have as their objective
the reduction and containment of replication of new copies of the virus. Every
single day the body of an HIV positive person, if not submitted to ART
treatment, produces millions of copies of the virus; HIV uses a specific type
of lymphocytes cells (CD4+ T) as factories to reproduce millions of copies
of themselves. With some particular proteins, HIV can build copies equal to
itself within the infected cells and then make them “sprout” outside, ready
to infect other CD4+ T cells. The most important proteins necessary to the
survival and replication of the virus are the reverse transcriptase, the protease
and the fusion ones. These protein chains are targeted by specific drugs that
enter the infected cells and block their activity. Such drugs are named reverse
transcriptase inhibitors, protease inhibitors and fusion inhibitors according
to the protein they are related to [135].
Actually there are more than 20 approved antiretroviral drugs, divided into 6
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different pharmacological classes. Anti-retroviral drugs are broadly classified
by the phase of the retrovirus life-cycle that the drug inhibits:
 nucleoside/nucleotide reverse transcriptase inhibitors (NRTI);
 non-nucleoside reverse transcriptase inhibitors (NNRTI);
 protease inhibitors (PI);
 fusion inhibitors (FI);
 coreceptor antagonists;
 integrase inhibitors (II).
Figure 2: Schematic description of the mechanism of the five classes of currently
available antiretroviral drugs against HIV.
Here’s a detailed description of the above drugs.
 Nucleoside reverse transcriptase inhibitors (NRTI) and nucleotide re-
verse transcriptase inhibitors (NtRTI) are nucleoside and nucleotide
analogues which inhibit reverse transcription. NRTIs are chain termina-
tors such that once incorporated, work by preventing other nucleosides
from also being incorporated because of the absence of a 3′ OH group;
they both act as competitive substrate inhibitors. Examples of NRTIs
include deoxythymidine, zidovudine, stavudine, didanosine, zalcitabine,
abacavir, lamivudine, emtricitabine, and tenofovir [23].
 Non-Nucleoside reverse transcriptase inhibitors (NNRTI) inhibit reverse
transcriptase by binding to an allosteric site of the enzyme; NNRTIs act
as non-competitive inhibitors of reverse transcriptase. NNRTIs affect
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the handling of substrate (nucleotides) by reverse transcriptase by
binding near the active site and causing “molecular arthritis”. NNRTIs
can be further classified into 1st generation and 2nd generation NNRTIs.
1st generation NNRTIs are more rigid in structure and resistance can
quickly be developed against them. Because 2nd generation NNRTIs
have a more flexible structure, they can adjust more readily and resist
mutation more effectively. NNRTIs include, for example nevirapine,
delavirdine, efavirenz, and rilpivirine [23].
 Protease inhibitors block the viral protease enzyme necessary to produce
mature virions upon budding from the host membrane. Particularly,
these drugs prevent the cleavage of gag and gag/pol precursor pro-
teins. Virus particles produced in the presence of protease inhibitors
are defective and mostly non-infectious. Examples of HIV protease
inhibitors are Lopinavir, Indinavir, Nelfinavir, Amprenavir and Riton-
avir. Maturation inhibitors have a similar effect by binding to gag, but
development of two experimental drugs in this class, Bevirimat and
Vivecon, was halted in 2010. Resistance to some protease inhibitors is
high. Second generation drugs have been developed that are effective
against otherwise resistant HIV variants [118].
 Entry inhibitors (or fusion inhibitors) interfere with binding, fusion
and entry of HIV-1 to the host cell by blocking one of several targets.
Maraviroc and enfuvirtide are the two currently available agents in
this class. Maraviroc works by targeting CCR5, a co-receptor located
on human helper T-cells. Caution should be used when administering
this drug however due to a possible shift in tropism which allows HIV
to target an alternative co-receptor such as CXCR4. In rare cases,
individuals may have a mutation in the CCR5 delta gene which results
in a nonfunctional CCR5 co-receptor and in turn, a means of resistance
or slow progression of the disease. However as mentioned previously,
this can be overcome if an HIV variant that targets CXCR4 becomes
dominant [51]. To prevent fusion of the virus with the host membrane,
enfuvirtide can be used. Enfuvirtide is a peptide drug that must be
injected and acts by interacting with the N-terminal heptad repeat
of gp41 of HIV to form an inactive hetero six-helix bundle, therefore
preventing infection of host cells [3].
 Integrase inhibitors inhibit the enzyme integrase, which is responsible
for integration of viral DNA into the DNA of the infected cell. There are
several integrase inhibitors currently under clinical trial, and raltegravir
became the first to receive FDA approval in October 2007. Raltegravir
has two metal binding groups that compete for substrate with two
Mg2+ ions at the metal binding site of integrase. Another clinically
approved integrase inhibitor is Elvitegravir [91].
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The initial therapeutic drug regimen is generally based on a combination
among 3 of the above mentioned drugs. Typical combinations involve the
conjunctive use of either two NRTIs and one NNRTI, or one PI (with or
without boosting with Ritonavir) in combination with two NRTIs [64, 91].
When to start antiretroviral therapy is subject to debate [99, 114]. The
World Health Organization recommends antiretrovirals in all adolescents,
adults and pregnant women with a CD4 count less than 500/µl with this
being especially important in those with counts less than 350/µl or those
with symptoms regardless of CD4 count [137]. This is supported by the
fact that beginning treatment at this level reduces the risk of death [103].
The United States in addition recommends them for all HIV-infected people
regardless of CD4 count or symptoms; however it makes this recommendation
with less confidence for those with higher counts [137]. While the WHO also
recommends treatment in those who are co-infected with tuberculosis and
those with chronic active hepatitis B [137]. Once treatment is begun, it
is recommended that it is continued without breaks or “holidays”. Many
people are diagnosed only after treatment ideally should have begun. The
desired outcome of treatment is a long term plasma HIV-RNA count below
50 copies/mL. Levels to determine if treatment is effective are initially
recommended after four weeks and once levels fall below 50 copies/mL checks
every three to six months are typically adequate. Inadequate control is
deemed to be greater than 400 copies/mL. Based on these criteria treatment
is effective in more than 95% of people during the first year [114].
Benefits of treatment include a decreased risk of progression to AIDS
and a decreased risk of death.[121] In the developing world treatment also
improves physical and mental health [104]. With treatment there is a 70%
reduced risk of acquiring tuberculosis. Additional benefits include a decreased
risk of transmission of the disease to sexual partners and a decrease in mother-
to-child transmission [137]. The effectiveness of treatment depends to a large
part on compliance [99]. Reasons for non-adherence include poor access to
medical care [76], inadequate social supports, mental illness and drug abuse
[56]. The complexity of treatment regimens (due to pill numbers and dosing
frequency) and adverse effects may reduce adherence [66]. Even though cost
is an important issue with some medications [77], 47% of those who needed
them were taking them in low and middle income countries as of 2010 and
the rate of adherence is similar in low-income and high-income countries
[110].
Specific adverse events are related to the antiretroviral agent taken [65].
Some relatively common adverse events include: lipodystrophy syndrome,
dyslipidemia, and diabetes mellitus, especially with protease inhibitors. Other
common symptoms include diarrhea [65, 15], and an increased risk of car-
diovascular disease [6]. Newer recommended treatments are associated with
fewer adverse effects. Certain medications may be associated with birth
defects and therefore may be unsuitable for women hoping to have children
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[99].
The treatment guidelines specifically for the US are set by the United States
Department of Health and Human Services (DHHS). The current guidelines
for adults and adolescents were stated on December 1, 2009 [79]. Because HIV
disease progression in children is more rapid than in adults, and laboratory
parameters are less predictive of risk for disease progression, in particular for
young infants, treatment recommendations from the DHHS have been more
aggressive in children than in adults; guidelines were published November 3,
2005 [127].
Treatment recommendations for children are slightly different from those for
adults. In the developing world, as of 2010, 23% of children who were in need
of treatment had access [110]. Both the World Health Organization and the
United States recommend treatment for all children less than twelve months
of age [137]. The United States recommends in those between one year and
five years of age treatment in those with HIV RNA counts of greater than
100 000 copies/mL, and in those more than five years treatments when CD4
counts are less than 500/µl.
Administration of antiretroviral drugs should be daily and uninterrupted;
it requires care and precision in the observance of schedules, even in relation
to meals and to use of other drugs. Faithful adherence to the prescriptions is
necessary to maintain effectiveness over time. Omission of a few doses leads
to a reduction in the quantities of drugs in plasma, therefore the residual
level could be lower than the one necessary to inhibit the virus. This allows
the resumption of viral replication that leads inexorably to the emergence of
resistant virus. Resistant mutants are destined to persist, making the drug
ineffective, even if the intake of drugs is carried out according to the rhythms
and the correct doses. Insufficient adherence to the prescriptions and the
consequent emergence of resistant mutants are the main causes of treatment
failure.
Goal of drug therapy is to prevent viral replication in the body (rather than
the complete eradication of the infection, that remains chronic) so as to
reduce the damage caused to the immune system and allow greater survival
and quality of life. HIV-infected individuals, who may promptly discover
their state and rely on expert team, can trust in expectancy and quality
of life not dissimilar to those suffering from other chronic diseases, such as
hypertension or diabetes [136]. It is rather a crucial issue the study of HIV
biological evolution and of its relationship with the immune system, in order
to determine a therapy policy that can defeat it.
Chapter 1
HIV modeling: a review
In this work we analyze about a hundred articles of approximately 50
authors who tackle HIV topic throughout the formulation of dynamical
systems and in some cases of Optimal Control problems. Our aim is to
present an existing review of the examined literature and to classify the
related works basing on the following criteria:
1. Does the model considers T lymphocytes infected by the viruses?
2. Does the model presents different types of infected T lymphocytes?
3. Does the model presents different types of T lymphocytes?
4. Does the model presents different types of HIV viruses?
5. Does the model considers the immune effectors/precursors?
In the following sections we describe the analyzed models focusing on
their characteristics and presenting a reference model for each group. In
Sect. 1.1 we introduce all variables and parameters necessary to describe the
models. Sect. 1.2 considers models without infected T cells dynamics, and it
is splitted into 4 sub-sections. Whilst Sect. 1.3 treats models with infected
T cells dynamics, and it is splitted into 9 sub-sections. We describe the
dynamics of the virus and of the immune system and highlight the existing
optimal control approach. Finally in Sect. 1.4 we try to achieve a frequency
analysis of the different values assigned to the parameters commonly used in
the analyzed models. Sect. 1.5 concludes.
1.1 Variables, Controls and Parameters
We unify the notation of variables, controls and parameters and of their
units of measurement, so as to facilitate the models’ comparison. Trying, at
the same time, to be linked to the literature notation as much as possible.
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Table 2.2 lists possible actions of immune system or therapy or virus: It
should be noted that in some models these parameters are considered as
simple parameters, in others as functions and still others controls, in any case
their values are between 0 and 1. Each table presents entries in alphabetical
order, for readability.
The main variables considered in the analyzed models are Uninfected
CD4+ T cell population size (T ) and HIV population size (V ). Our immune
system is constituted by T cells; these once infected by the virus (T i) may
either remain latently infected (T l), and act as healthy cells (with a slightly
different death rate) or activate (T a) and start to produce new free virions.
Models that consider this differentiation of infected T cells use variables
following the notation indicated in Table 2.1. Some models allows for differen-
tiation of uninfected T cells and viruses: considering for example macrophages
and monocyties (M) or wild-type virus (V1) and mutant virus (V2). Some
very few variables and parameters are not presented in the tables as they
are specific of a given model so that they will be introduced and described
only in the related section.
In Optimal Control sub-sections initial and final time are denoted by t0
and tf respectively.
Table 1.1: Controls and/or parameters (∈ [0, 1]).
Symbol Description
u Percentage of chemotherapy effect
uj Efficacy/dosage of drug j
ud Viral suppressing drugs
uib Immune boosting
upi Efficacy/dosage of protease inhibitor
urti Efficacy/dosage of reverse transcriptase inhibitor
uv Mutation rate of virus
1.2 Models without infected T cells dynamics
These models date back to the ’90s and consider only the dynamics of
uninfected T cells (T ) and viruses (V ), regardless of infected T lymphocytes.
Models of this section are splitted into 2 parts: basic models, which do not
provide any T cells and viruses differentiation, and models which consider
target cells and virions differentiation together with host immune response.
1.2.1 Basic models
A basic group of models is constituted by works of Kirschner et al. [47]
and Joshi [40], where T-cells and viruses evolution are described through a
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Table 1.2: Variables (Unit of measure: cells/mm3).
Symbol Description
IP Immune Precursor Cytotoxic T Lymphocyte population size
IE Immune Effector Cytotoxic T Lymphocyte population size
M Uninfected macrophage/monocyte population size
M i Infected macrophage/monocyte population size
T Uninfected CD4+ T cell population size
T i Infected CD4+ T cell population size
T l Latently infected CD4+ T cell population size
T a Actively infected CD4+ T cell population size
V HIV population size
V I Infectious HIV population size
V NI Non-infectious HIV population size
system of two coupled differential equations. Authors do not consider infected
T-cells, neither T-cells and viruses differentiation, nor immune response. The
dynamics of the reference system are
T˙ (t) = s1 −
s2V (t)
b1 + V (t)







b2 + V (t)





b1 + V (t)
represents the source/proliferation of uninfected CD4+ T cells and includes
both an external (not plasma) contribution of cells from sources such as
the thymus and lymph nodes, and an internal (plasma) contribution from
CD4+ T cells differentiation. The immune boosting contributes to increase
the number of uninfected T-cells and this is explicated by the term uib(t)T (t).
On the other hand T-cells decrease both by the effect of spontaneous decay
and the presence of the HIV virus. These behaviours are formalized by terms
−µTT (t) and −k1V (t)T (t) respectively.






b2 + V (t)
is a source of virus that accounts for viral contributions to the plasma from
both external compartments, such as the lymph system as well as virus
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Table 1.3: Parameters (Unit of measure: 1/day).
Symbol Description
bE Maximum birth rate for immune effectors
c Cytotoxic T Lymphocyte (CTL) activation rate
dE Maximum death rate for immune effectors
ir Death rate of infected cells due to immune response
ir,j Death rate of infected cells type j due to immune resp.
k Rate T convert to specific immune reaction cells
k′ Rate T convert to unspecific immune reaction cells
k2 Rate T
l convert to actively infected
k2,j Rate T
l type j convert to actively infected
k4 Rate free virus infects mac/mono cells
µIE Natural death rate for immune effectors (CTL)
µIP Natural death rate of CTL precursors
µT Death rate of uninfected CD4+ T cells
µTj Death rate of uninfected CD4+ T type j cells
µT i Death rate of infected CD4+ T cells
µT ij
Death rate of infected CD4+ T type j cells
µT l Death rate of latently infected CD4+ T cells
µT lj
Death rate of latently infected CD4+ T type j cells
µTa Death rate of actively infected CD4+ T cells
µTaj Death rate of actively infected CD4+ T type j cells
µV Death rate of free virus
pi Growth rate of viruses
piw Growth rate of type w viruses
ΠM Rate of free virus production by infected macrophages
q Growth rate of CTL eff. due to inf. cells and CTL prec.
r rate of growth for CD4+ T cell population
produced by infected cells in the plasma [34]. This source is counteracted by
the therapy ud(t). Also viruses die, at a rate −µvT (t) which is proportional
to the number of uninfected T-cells. Parameters s1, s2, b1, b2, g are assumed
positive and constant.
Kirschner et al. [47] consider a given exponential function in place of
the control uib(t). In other terms, they assume that the enhancement of the
immune system causes an increase of the CD4+ T cells proportional to the
population of these cells at the rate c1te
−c2t/day. This choice assumes that
the drug efficiency decays exponentially, and its effect is not instantaneous.
They further assume that the virus growth rate does not depend on the viral
suppressing drig control (ud).
1.2 Models without infected T cells dynamics 13
Table 1.4: Parameters.
Symbol Description U.m./Value
A “Weight” on the benefit and cost of therapy ∈ [0,+∞]
Ad “Weight” of viral suppressing drug ∈ [0,+∞]
Aib “Weight” of immune boosting ∈ [0,+∞]
EM Equilibrium number for mac/mono population
cells
mm3
f Treat. efficacy reduction/rel. efficacy in virus population ∈ [0, 1]
fk Treat. k efficacy reduction/rel. efficacy in virus population ∈ [0, 1]
g Input rate of external viral source cells
mm3×day
g′ Growth rate of virions due to infected cells virionscell×day
g′w Growth rate of virions type w due to infected cells
virions
cell×day
k1 Rate CD4 T cells becomes infected by free virus
mm3
virions×day
k1,w Rate CD4 T cells becomes infected by virus type w
mm3
virions×day
kM1,w Rate M cells becomes infected by virus type w
mm3
virions×day
k3 Rate infected mac/mono infects CD4+ T cells
mm3
cells×day
Kb Saturation constant for immune effector birth
cells
mm3
Kd Saturation constant for immune effector death
cells
mm3
λE Immune effector production (source) rate
cells
mm3×day
N Number of free virus produced by T infected cells virionscell










p′ Specific immune response rate cells
mm3×day
p′w Specific immune response rate against virus w
cells
mm3×day
ρj Average number virions infecting a type j cell
virions
cell
s′ Unspecific immune response rate cells
mm3×day
s′w Unspecific immune response rate against virus w
cells
mm3×day
s1 Source/production of CD4+ T cells
cells
mm3×day
s1,j Source/production of CD4+ T type j cells
cells
mm3×day
s2 Source/production of CD4+ T cells
cells
mm3×day
s2,j Source/production of CD4+ T type j cells
cells
mm3×day
s Source/production of CD4+ T cells cells
mm3×day
sj Source/production of CD4+ T type j cells
cells
mm3×day




Joshi in [40] uses the optimal control theory to tackle the HIV therapy









T (t)− (Aibu2ib(t) +Adu2d(t))] dt, (1.2)
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where parameters Aib and Ad are positive and constant whilst controls uib
and ud are specified in Table 2.2.
1.2.2 Models with both uninfected T cells and viruses differ-
entiation
De Boer et al. in [24, 25] treat the diversity and virulence thresholds
in AIDS. In this context they propose a model which takes into account
uninfected T cells and viruses differentiation as follows (for j = 1, 2, . . . , n)




− 1− nνVj(t) + νjVj(t)
)
















where n is the number of viral strains, Tj represents the immune response
at different established quasispecies viruses Vj , and Tn+1 represents the
immune response at a new mutant virus Vn+1. Parameters νj and νn+1 are
the “average” virulences of established and mutant strains respectively. Again
s1 and s2 are positive parameters and pi is the growth rate of viruses.
1.2.3 Models with uninfected T cells differentiation and with
immune effectors/precursors
Hraba et al. [35] and Zarei et al. [130] consider infected T cells differenti-
ation and they split these cells into immature (T imm) and mature (Tmat).
Such differentiation constitutes an original topic which is not present in any
other model of the analyzed literature. The reference model is the following




− k1V (t)IE(t)T imm(t)





piV (t)− irIE(t)V (t)
I˙E(t) =
(






where β is the amplifying coefficient of the linear feedback effect of Tmat
cells decrease on the influx of T imm cells. Parameter τ represents the rate of
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maturation of T imm cells into Tmat cells, finally parameter α is the prolifera-
tion rate of immune effector cells (IE) under the antigenic stimulation by
HIV products.
Optimal control approach






= tf − λ
∫ tf
t0
u2rti(t) dt , (1.5)
where parameter λ is used to set the relative importance between minimiz-
ing the systemic side effects on the body and maximizing the survival time tf .
1.2.4 Models with uninfected T cells differentiation, viruses
differentiation and immune effectors/precursors pres-
ence
This group of works is constituted essentially by Nowak works [69, 70,
71, 72, 73] in collaboration with different authors, i.e. May, Anderson and
McLean.
The peculiarity of these models is the presence of unspecific (i.e. cross-reactive
Tg) and strain specific (Tj) immune reactions. Authors assume that each
mutant j induces the production of certain immune agents (CD4 T cells). A
fraction of these agents is specifically directed only against that particular
mutant strain (e.g., via the immunodominant loop). An other fraction is
directed against more conserved sites (e.g., the gag or pol gene products or
conserved regions within env protein) and hence the agent is able to react
with several different mutant strains. Therefore immunological responses to
the virus are characterized by both a specific response to individual strains
(which direct immunological attack against that specific strain) and a non-
specific general response (that acts against all strains).
Each mutant can kill all CD4 T cells regardless of their specificity to a
particular mutant.
In [69] Nowak et al. formulated the following model [69] (for j =
1, 2, . . . , n)
T˙j(t) = cVj(t)I
P







pi − s′Tg(t)− p′Tj(t)
)






16 1. HIV modeling: a review
where CIP is the production rate of precursors (I
P
j ) of immune cells. These
precursors are removed at rate µIP , and either are infected/killed by the virus
(at rate k1) or turned into activated cells by contact with the viral strain j
(at rate c). Notice that activated/target cells Tj can proliferate (at rate r) or
can be infected/killed by the virus (at rate k1). Furthermore observe that
these equations do not consider T-cells and viruses natural death rates.
In [70] Nowak et al. assume that target cells (T ) can be converted to
specific and unspecific immune reaction cells at rates k and k′ respectively.
Authors also include the population dynamics of the total number of CD4+
cells including those not directed against HIV, denoted by (T ). The model,
adopted also by Wodarz in [125], is (for j = 1, 2, . . . , n)











































Authors neglect the possibility that mutation leads to mutants already in the
system, because the number of immunologically different mutants appears to
be very large [68, 74].
Subsequently, Nowak et al. in [71] propose different types of conversion
immune reaction rates for each viral strain and formulate a new reproductive
rate function. Related differential equations are as follows (for j = 1, 2, . . . , n)






























where Πj is a constant background replication rate which denotes replication
of the virus in cells other than of the CD4+ type (such as macrophages and
monocytes). Notice that, despite the article is very dated, it also allows for
uninfected cells differentiation, in fact it considers cells as macrophages and
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monocytes.
Finally in [73] Nowak et al. consider dynamics of immune responses
against multiple HIV epitopes.
1.3 Models with infected T cells dynamics
A large number of works also consider the dynamics of infected T lym-
phocytes introducing new variables that represent contaminate lymphocytes.
In this models it is necessary to consider the rate of infection (k1) to which
healthy T cells are infected by virus. The first two groups of models (Sub-Sect.
1.3.1 and 1.3.2) do not consider any kind of differentiation, while other groups
(Sub-Sect. 1.3.3, 1.3.4, 1.3.5, 1.3.6, 1.3.7, 1.3.3, 1.3.2, 1.3.8, 1.3.9) introduce
uninfected and infected T-cells differentiation and viruses differentiation.
1.3.1 Basic Models
This sub-section contains models that together with T-cells and virus
evolution consider also infected T-cells.
Subsection is splitted into 2 parts: the first one with deterministic models,
the second one with stochastic or fuzzy models.
Deterministic models
The work of reference of this group does not consider the latently infected
or actively infected T lymphocytes but only infected lymphocytes. More-
over viruses are counteracted by reverse transcriptase inhibitors or protease
inhibitors. Connected works are [17, 38, 85, 87, 88, 90]. Equations under
“imperfect” RT inhibitors can be written as














βT (t)V (t)− µT iT i(t)
V˙ (t) = NµT iT
i(t)− µV V (t).
(1.9)
PIs on the other hands do not block infection, but rather block the protease
enzyme so that the virus particles produced are non infectious. Consequently
two types of virus particles come out when PIs are used. The first type is
given by the infectious virus particles that still continue to infect CD4+ T
cells and the second one is given by the non infectious type. Equations under
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PIs can be written as follows





− µTT (t)− βT (t)V (t)







V˙NI(t) = ηpi(t)NµT iT
i(t)− µV VNI(t).
(1.10)
In equations (1.9) and (1.10) the inhibitors block infection by reducing the
value of β and perfect inhibition occurs when β = 0. (The estimation of
parameters β given in [37] is β = 7.5× 10−6/mm3 × day).
Furthermore ηrti (0 ≤ ηrti(t) ≤ 1) is the effectiveness or combined effectiveness
of the RT inhibitors used. Perfect inhibition occurs when ηrti = 1 and there
is no inhibition when ηrti = 0.
Parameter ηpi (0 ≤ ηpi(t) ≤ 1) is the combined effectiveness of the used
PIs. Perfect inhibition occurs when ηpi = 1 and there is no inhibition when
ηpi = 0.
Note the presence of the multiplicative term NµT i that characterizes models
belonging to this group, where N is the number of free virus produced by T
infected cells and µT i is the death rate of infected CD4+ T cells. Another






that represents the production of T-cells due to cloning in the presence of
an antigen, taking into account the maximum number of lymphocytes (Tmax).




θ + V (t)
− µTT (t) + rT (t)
(
1− T (t) + T
l(t) + T a(t)
Tmax
)
− k1,0e−α1u1V (t)T (t)
T˙ l(t) = ωk1,0e
−α1u1V (t)T (t)− µT lT l(t)− k2,0e−α2u2T l(t)
T˙ a(t) = (1− ω)k1,0e−α1u1V (t)T (t) + k2,0e−α2u2T l(t)− µTaT a(t)
V˙ (t) = β2(β2 −N0)e−β1tµTaT a(t)− k1,0e−α1u1V (t)T (t)− µV V (t).
(1.11)
“Basically, T cells are stimulated to proliferate with rate
rT (t)
(
1− T (t) + T
l(t) + T a(t)
Tmax
)
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in the presence of antigen and HIV. Without the presence of HIV, the rate
of generation is
s1θ
θ + V (t)
In the presence of free HIV (V ), uninfected cells (T ) can be infected to became
T l or T a cells, depending on probability of the cells to become actively or
latently infected with rate ω. The T l cells can be activated to become T a
cells. The activation rate is k2. The T
a cells are short living and will normally
be killed upon activation with death rate µTa . The T, T
l cells and V free
viruses have finite life and the death rates in this model are µT , µT l and µV
respectively. When T a cells die, free viruses V are released with rate
β2(β2 −N0)e−β1t
Drugs such as reverse transcriptase inhibitors (zidouvine and lamivudine) and
protease inhibitors (saquinavir, indinavir and ritonavir) affect the dynamics




that appears both in uninfected T cells and viruses equations (1.11) is in-
troduced because the authors assume that a virion can infect only a single cell.
Stochastic and Fuzzy models [53]
Papers of Dalal et al. [22], Gregio et al. [32], Tan et al. [105, 106] and
Tuckwell et al. [109] present stochastic models, where the evolution of T
cells and viruses is similar to the one of the deterministic formulation apart
from the assumption of stochasticity for the death rates. Dalal et al. in [22]
introduce randomness into the model by replacing the parameters µt, µT i , µV
by
µT −→ µT + σ1B˙1(t) µT i −→ µT i + σ1B˙1(t) µV −→ µV + σ2B˙2(t).
Their model is the following
dT (t) =
[













T (t)V (t)− µT iT i(t)
]
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where B1(t) and B2(t) are independent standard Brownian motions; σ1 and
σ2 are the intensities of the noise (in [22] σ1 = 0.1 and σ2 = 0.1).
Tuckewell et al. [109] propose another stochastic model that considers
latently and actively infected T cells too as follows
dT (t) =
[
s1 − µTT (t)− k1,1)T (t)V (t)
]
dt− σ[k1,1T (t)V (t)] dW (t)
dT l(t) =
[
k1,1T (t)V (t)− µT lT l(t)− k2T l(t)
]
dt
− σ[k1,1pT (t)V (t)] dW (t)
dT a(t) =
[
k1,1(1− p)T (t)V (t)− µTaT a(t) + k2T l(t)
]
dt
− σ[k1,1(1− p)T (t)V (t)] dW (t)
dV (t) =
[
g′T l(t)− k1,2T (t)V (t)− µV V (t)
]
dt
− σ[k1,2T (t)V (t)] dW (t).
(1.13)
Parameter p gives the percentage of infected cells which are latent (in [109]
p = 0.1) and σ is the additional noise term. Note that k1,1 and k1,2 are the
infection rates per virion and uninfected T cells respectively.
In order to model the dynamical systems of HIV under uncertainty Lin
et al. [53] and Zarei et al. [131] apply a fuzzy approach. We do not go into
the details of these models because both the formulations and the type
of parameters they adopt are not comparable to the ones of the classical
literature.
Optimal control approach



















where the last term is included to force uninfected T cells to increase with
treatment.
1.3.2 Models with immune effectors/precursors
In this sub-section a new immune response is taken into account. The
works of Anderson et al. [2], Wodarz et al. [120, 121, 122, 123, 124, 125, 126],
Bonhoeffer et al. [7], Kubiak et al. [48], Shim et al. [102], Culshaw et al. [20],
Radisavljevic-Gajic [93], Jin et al. [39], Kalams et al. [43], Rosemberg et al.
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[96], Saah et al. [97], Schmitz et al. [100], Thomsem et al. [107, 108], and
Pannocchia et al. [80] introduce the dynamics of immune effectors/precursors.
The reference model is the following
T˙ (t) = s1 − µTT (t)− k1(1− fu(t))V (t)T (t)
T˙ i(t) = k1(1− u(t))V (t)T (t)− µT iT i(t)− irIE(t)T i(t)
I˙P (t) = cT (t)T i(t)IP (t)− cqT i(t)IP (t)− µIP IP (t)
I˙E(t) = cqT i(t)IP (t)− µIEIE(t)
V˙ (t) = g′T i(t)− µV V (t).
(1.15)
The authors consider infected T cells of a generic type, and include immune
effectors (IE) and/or immune precursors (IP ) in the dynamics.
Bonhoeffer et al. in [7] consider an alternative virus progression, also
considering quiescent cells.
Wodarz’ papers exploit the assumption that a cell can be infected by two
viruses at the same time, more precisely by the wild type virus (T i1) only,
by the escape mutant virus (T i2) only, or finally by both two virus strains
simultaneously (T i1,2). The dynamics of these models are
T˙ (t) = s1 − µTT (t)− k1,1
(











T˙ i1(t) = k1,1
(













1(t)− µTT i1(t)− irT i1(t)IE(t)
T˙ i2(t) = k1,2
(














T˙ i1,2(t) = k1,1
(




T i2(t) + k1,2
(















Notice that there is not the virus equation: Wozard et al. claim that explicit
inclusion of free virus population does not change the results described here.
Cells infected by the wild-type strain die as a result of virus replication at a
rate µT i1
, and are killed by CTL at a rate ir. Cells infected with the escape
mutant died at a rate µT i2
and are not killed by CTL. Finally, cells infected
with both strains are killed by CTL at a rate ir, and are assumed to be killed
by the virus at the rate determined by the faster killing strain, denoted by
µT ii
in the model.
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At last, Pannocchia et al. [80] introduce a new variable R which represents
the index of the aggressiveness of the virus and they formulate the following
dynamics
T˙ (t) = s1 − µTT (t)−R(t)V (t)T (t)
T˙ i(t) = R(t)V (t)T (t)− µT iT i(t)− irIE(t)T i(t)
I˙P (t) = cT (t)T i(t)IP (t)− cqT i(t)IP (t)− µIP IP (t)
I˙E(t) = cqT i(t)IP (t)− µIEIE(t)










In the case of untreated HIV-infected individual, index R increases linearly
at a rate proportional to a given constant R0 = 1× 10−8 ml/(copies× day)2,
(see [80]).
Parameter g′ represents the growth rate of virions due to infected cells and
in general (see e.g. models in Sub-Sect. 1.3.1) it is assumed to be
g′ = NµT i .
Coefficients frti and fpi are assumed to take value between 0.5 and 0.9.
Optimal control approach















1.3.3 Models with uninfected T cells differentiation
All models of Sect. 1.2 consider T-cells without any kind of differentiation.
This sub-section contains models without immune effectors/precursors, and
with no viruses differentiation, but with uninfected T cells differentiation as
proposed by Perelson et al. [83, 84, 86], Kirschner et al. [44, 46], Butler et al.
[16] and Fister et al. [30].
“Stimulation of the T cell by antigen can lead to the production of new
virus particles that bud from the surface of the infected cell. The budding
can take place very rapidly, leading to the lysis of the host cell (this seem to
be the case in T4 cell infection), or it can take place slowly and spare the
host cell, as seen in macrophages an monocytes.
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Perelson (1989) and Perelson et al. (1993) modelled these events by consider-
ing cells that are uninfected, cells that are latently infected, i.e., that contain
the virus but are not producing it, cells that are actively infected, i.e., that are
producing virus, and the population of free viral particles. They described the
dynamics of these population by the system of ordinary differential equations
that we give below”.[44]
The reference model used in papers [16, 30, 44, 46, 83, 84, 86] is the following
T˙ (t) =
s1
1 + V (t)
− µTT (t) + rT (t)
(
1− T (t) + T
l(t) + T a(t)
Tmax
)
− (1− u(t))k1V (t)T (t)
T˙ l(t) =
(
1− u(t))k1V (t)T (t)− µT lT l(t)− k2T l(t)
T˙ a(t) = k2T
l(t)− µTaT a(t)
V˙ (t) = NµTaT
a(t)− k1V (t)T (t)− µV V (t).
(1.19)
Observe that again it appears the multiplicative term NµTa as a growth rate.
This model has some common terms with previous formulations. In par-




1− T (t) + T




already described in Sect. 1.3.1 and the rate of generation of uninfected T
cells without the presence of HIV term
s1
1 + V (t)
similar to the one already described in Sub-Sect. 1.2.1 and 1.3.1.
Kirschner and Perelson in [44] propose an extended variant of (1.19),
that includes the population of macrophages and monocytes.The dynamics




θ + V (t)
− µTT (t) + rT (t)
(
1− T (t) + T
l(t) + T a(t)
Tmax
)
− k1V (t)T (t)− k3Ma(t)T (t)
T˙ l(t) = k1V (t)T (t) + k3M
a(t)T (t)− µT lT l(t)− k2T l(t)
T˙ a(t) = k2T
l(t)− µTaT a(t)
V˙ (t) = Nz(t)µTaT
a(t) + ΠMz(t)M
a(t)− k1V (t)T (t)− µV V (t)
M˙(t) = µMEM − µMM(t)− k4V (t)M(t)
M˙a(t) = k4V (t)M(t)− µMaMa(t),
(1.20)
where z(t) is a term which reduces the effects of viral replication. In particular
z(t) =
{
1 outside the treatment period
P during the time of AZT treatment.
The authors assume that constant P is proportional to the dose of the drug.
It can also be interpreted as the effectiveness of the drug in halting viral
reproduction.
Notice that there is no latently infected macrophage population, since the
virus seems to replicate once inside them, [44].
Optimal control approach
In [16], [30] and [46], an optimal control approach is tackled in order to










1.3.4 Models with viruses differentiation
Another type of differentiation can be made among the viruses. This
sub-section contains models without immune effectors/precursors and unin-
fected and infected T cells differentiation, but with viruses differentiation.
Works of Bonhoeffer et al. [9], Mare´e et al. [58] and Ribeiro et al. [94, 95]
are included in this group. All models in this section are also characterized
by the presence of the parameter s that represents a selection coefficient.
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Ribiero et al. in [94] present a basic model, and afterwards expand it to
consider resistant mutants that differ by two mutation errors during reverse
transcriptase phase. Their model considers five variables: uninfected T cells,
cells infected by wild type virus, two types of cells infected by one-error
mutant and cells infected by two-errors mutant. We report only the reference
model, as the extended one is closely related to it.
T˙ (t) = s1 − µTT (t)− k1
[
T i1(t) + (1− s)T i2(t)
]
T (t)
T˙ i1(t) = k1
[
(1− uv)T i1(t) + (1− s)uvT i2(t)
]
T (t)− µT iT i1(t)




1(t) + (1− s)(1− uv)T i2(t)
]
T (t)− µT iT i2(t).
(1.22)
Observe that the authors do not consider a separate equation for the free
virions, but simply assume that virion abundance is proportional to infected
cell abundance.
Ribiero et al. in [95] present a multistrain model linked to the previous
one, where the selection coefficient (sk) changes with the different virus strain,
in addition probability of mutation is taken into account. The dynamics are
T˙ (t) = s1 − µTT (t)− T (t)
l∑
j=0
k1(1− u)(1− sj)T ij (t)
T˙ ij (t) =
l∑
k=0
k1(1− u)(1− sk)uj,kv T ik(t)− µT iT ik(t),
(1.23)
where sk is the selection coefficient of k-th virus strain and the matrix u
j,k
v
describes the probability of mutation of strain k into strain j during reverse
transcription. The authors also assume that cells infected by mutant j are
produced either by infection of a susceptible cell with mutant j or by muta-
tion of strain k into strain j during infection.
Bonhoeffer et al. in [9] and Mare´e at al. in [58] use a different model
considering wild-type virus (V1) and mutant virus (V2) as follows
T˙ (t) = αF (t)T i(t)− µT iT i(t)
V˙1(t) = αF (t)V1(t)− µV V1
V˙2(t) = α(1− s)F (t)V2(t)− µV V2,
(1.24)
where α = g′k1/β appears as a generalized replication rate combining infection
k1, production g
′ and clearance β. Function F (t), 0 ≤ F (t) ≤ 1 represents
target cells availability (and/or other factors limiting viral replication).
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1.3.5 Models with both uninfected and infected T cells dif-
ferentiation
This sub-section contains models with uninfected and infected T cells dif-
ferentiation, without immune effectors/precursors and viruses differentiation.
The reference model we describe is used by Adams et al. [1], Banks et al. [4, 5],
Neri et al. [67] and Jang et al. [36]. This model entails two co-circulating
populations of target cells: T1 and T2. In Adams et al. [1], T2 corresponds to
macrophage/monocyte population size.
Observe that also a multidrug treatment is considered and, as in [132, 133,
134], all effects of HAART medication are combined and represented by
control variables. The dynamics are














V (t)T1(t)− µT iT i1(t)− ir,1IE(t)T i1(t)











T i1(t) + T
i
2(t)
)− µV V (t)
− [k1,1ρ1(1− urti(t))V (t)T1(t) + k1,2ρ2(1− furti(t))V (t)T2(t)]
I˙E(t) = λE +
bE
(

























k1,1ρ1(1− urti)V (t)T1(t) + k1,2ρ2(1− furti)V (t)T2(t)
]
is included
in the V˙ equation in order to account for the removal of free virus taking
places when free virions infect a T1 or T2 cell. The model considers the
possibility that more viruses can be responsible for each new infection, that
is, a cell can be infected by ρi > 1 viruses. Observe that again it appears the
multiplicative term NµT i as a growth rate.
This specific model presents also immune effectors, but in the others models
below, immune effectors are not consider.
Banks et al. [4, 5] also consider infectious and non-infectious viruses, by
means of the two variables VI and VNI respectively. The differential equations
with these variables are
V˙I(t) = (1− upi)NµT i
(




− [k1,1ρ1(1− urti)VI(t)T1(t) + k1,2ρ2(1− furti)VI(t)T2(t)]
V˙NI(t) = upiNµT i
(
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Optimal control approach
Two are the optimal control approaches belonging to this group.
Jang et al. [36] minimize the objective function:
























where Q,S, P are the utilities of having a level of virus and immune effectors
as close as possible to the steady state. In fact V˜ and I˜E are virus and
immune effectors “healthy” steady states.







IE(t)− I˜E)2 + α2 + β2]dt, (1.28)
where α = (α1, α2, . . .) define the RTI medication schedule. Specifically, each
αk of even place gives the length (in days) of the kth ON-medication period
whereas each αk of odd place gives the length of the kth OFF-medication
period. The schedule for PI medication is defined in the same way by an
integer vector β = (β1, β2, . . .).
1.3.6 Models with both infected T cells and viruses differen-
tiation
This sub-section contains models with infected T cells and viruses differ-
entiation, without immune effectors/precursors and with not uninfected T
cells differentiation.
Some authors introduce the game theoretical approach in order to consider
the interaction between the immune system/therapy and HIV virus.[128, 129]
Works belonging to this sub-section are: McLean et al. [61, 62], Bonhoeffer
et al. [8], Jung et al. [42], Di Mascio et al. [28], Jolly et al. [41], Levy et al.
[50], Chen et al. [18], Dang et al. [21], Velichenko et al. [112, 113], Sattentau
et al. [98], Luo et al. [55], Wu et al. [128, 129].
In [128] Wu et al. present a basic model where T cells infected by resistant
virus release copies of the resistant virus into the bloodstream. Besides, they
hypothesize that T cells infected by the sensitive virus, however, can release
copies of both sensitive and resistant viruses, where the fraction of resistant
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viruses uv is the virus control. The model appears as




Vs(t)T (t)− k1,rVr(t)T (t)




Vs(t)T (t)− µT isT is(t)
















where Vs(t), Vr(t) are the number of sensitive viruses and mutated viruses,
and T is(t), T
i
r(t) are T-cells infected by sensitive or resistant viruses.
In the viruses equations, the source of viruses not depend on NµT i as in
previous groups of models but on pis and pir (growth rate of sensitive or
resistant viruses respectively, see Table 2.4).
In [129] Wu et al. extend the previous model considering 4 types of viral
population: wild-type virus with TW10 epitope, mutant virus with only
T242N mutation, mutant virus with only G248A mutation, mutant virus
with both T242N and G248A mutations; and 3 type of T-cells: unifected
T-cells, infected T-cells, Cytotoxic T Lymphocytes (CTL).
Luo et al. [55] present this model




















Vs(t)T (t)− µT isT is(t) + λs






Vr(t)T (t)− µT irT ir(t) + λr
V˙s(t) = NsµT isT
i
s(t)− µVsVs(t)




where ξk,i is the maximum effectiveness of antiviral regimen ui on virus strain
vk (they use ξ and not f , see Table 2.4). There is also a contribution due
to the activation from long-lived reservoir at rate λk. Notice that ui are not
controls variables but parameters. This model is arbitrarily scalable to any
number of viral species.
Bonhoeffer in [8] gives two variants, the first one considers the presence
of two strains of viruses: wild-type virus (V1) and mutant virus (V2), so there
will be cells infected by the former (named T i1) and cells infected by the latter
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(named T i2). Dynamics are
T˙ (t) = s1 − µTT (t)− k1,1V1(t)T (t)− k1,2V2(t)T (t)
T˙ i1(t) = k1,1(1− uv)V1(t)T (t) + k1,2uvV2(t)T (t)− µT iT i1(t)












As we have seen in Sub-Sect. 1.3.2, g′1 and g′2 are the growth rates of virions
due to infected cells (see Table 2.4) and specifically g′ = NµT i as we have
seen in Sub-Sect. 1.3.2.
The second model proposed by Bonhoeffer, splits the infected T cells in
productively infected cells (T a1 ), latently infected cells (T
l
1), chronic producers
(T a2 ), defectively infected (T
l
2) cells, and their dynamics are as follows
T˙ (t) = s1 − µTT (t)− k1V (t)T (t)
T˙ a1 (t) = k1q1V (t)T (t)− µTa1 T a1 (t)
T˙ l1(t) = k1q2V (t)T (t)− µT l1T
l
1(t)
T˙ a2 (t) = k1q3V (t)T (t)− µTa2 T a2 (t)
T˙ l2(t) = k1q4V (t)T (t)− µT l2T
l
2(t)
V˙ (t) = g′1T
a




2 (t)− µV V (t).
(1.32)
Finally Di Mascio et al. in [28] aver that latently infected cells (T l), if acti-
vated, read the viral DNA and may begin viral production, i.e. they convert
into T a cells. This model contains productively infected cells (T a), long-lived
infected cells (Ma), and latently infected cells (T l). It also incorporates both
infectious (VI) and non-infectious (VNI) virions.
Observe that delays (τrti and τpi) are introduced to take into account that
antiretroviral drugs are not instantly active (pharmacological delay) and that
the pharmacological delay for reverse trancriptase inhibitors (RTI) may be
different from the protease inhibitors (PI) one.
They assume for simplicity that the number of uninfected CD4+ T cells (T )
and long-lived cells (M) remain constant during the period of observation.
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V˙NI = upih(t− τpi)NµTaT a(t) + upih(t− τpi)g′MMa(t)− µV VNI(t),
(1.33)
where h(t− τ) is a Heavyside function, which is 0 for t < τ and 1 for t ≥ τ .
Velichenko et al. propose in [112, 113] a model which is very similar to
the one presented by Wu et al. in [128]. They take into account the action
of medicinal drugs on a virus throughout two functions: η1(t) and η2(t),
asserting that medicaments do not act on either the resistant group of viruses
nor on CD4+ T cells damaged by a resistant virus. Function η1(t) describes
the suppression by chemotherapy of the process of infection of CD4+ T
cells while η2(t) describes the suppression of the inflow of viruses from the
lymphoid system. The dynamics are





Vs(t)T (t)− µTT (t)− k1,sη1(t)Vs(t)T (t)
− k1,rVr(t)T (t)







































At a later stage the authors introduce the following formulation for functions
η1(t) and η2(t)
η1(t) = e
−c1(t−t0) η2(t) = max{e−c2(t−t0), c3}.
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They first assume these functions as exogenously given, after that they
consider also the treatment process and therefore declare the following













The threshold function Gr(V ) describes the inflow of a resistant from the
lymphoid system and it is defined as follows
Gr(V ) =
{
0 V < V0
Gs V ≥ V0
where V0 is named resistance threshold.
McLean et al. in [61, 62] assume that there exist errors in replication, in
the sense that a percentage Q of infections is “faithful” and produces progeny
of the parent type, whilst remaining percentage (1 − Q) of the infections
produces progeny of different parent type. Many mutations will be lethal,
and the infective parameters (k1,s and k1,r) take this into account.
The reference model is
T˙ (t) = s1 − µTT (t)− k1,s(1− urti)Ts(t)T (t)− k1,r(1− furti)Tr(t)T (t)
T˙ is(t) = Qk1,s(1− urti)Ts(t)T (t) + (1−Q)k1,r(1− furti)Tr(t)T (t)
− µT iT is(t)
T˙ ir(t) = (1−Q)k1,s(1− urti)Ts(t)T (t) +Qk1,r(1− furti)Tr(t)T (t)
− µT iT ir(t),
(1.36)
where it is assumed that, in absence of Zidovine, sensitive strains have a
fitness advantage over resistant ones (thus k1,s > k1,r). Parameter f is the
relative efficacy of Zidouvine at blocking new infections with resistant virus.
Notice that there isn’t any virus equations and the terms
k1,s(1− urti)Ts(t)T (t) k1,r(1− furti)Tr(t)T (t)
depend on Ts and Tr respectively, rather than on Vs and Vr.
Furthermore in [61] McLean et al. propose a model of interactions between
HIV and other pathogens.
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Optimal control approach
Velichenko et al. [112, 113] use an optimal control approach minimizing







A− T (t)]2 T (t) < A
0 T (t) ≥ A
where A is an endogenous threshold [111].
An interesting approach is given within this group of models by Wu et al.
[128] who tackle the HIV problem in a differential game context.


























The authors prove the existence and the uniqueness of a Nash Equilibrium and
find it numerically using the forward-backward sweeping method, proposed
by Velichenko et al. in [113].
1.3.7 Models with both uninfected and infected T cells dif-
ferentiation and viruses differentiation
The most general approach is given by Wein et al. [116, 117], Flint et al.
[31] and Kutch [49] who take into account all variables (apart from immune
effectors/precursors). The differentiation is given in T-cells (both uninfected
and infected) and in viruses. The presence of macrophages differentiation
(M,M i1,M
i
2) characterizes this model with respect to models presented in
Sub-Sect. 1.3.3.
Wein et al. in their works [116, 117] assume that reverse errors in tran-
scription of strain i in cells infected by strain j occur with probability Qi,j .
Thus the mutation probability Q1,2 is the probability that wild-type virus
(V1) is transformed into a partially drug-resistant mutant strain (V2) during
reverse transcriptase. Whilst Qi,i is the frequency of error-free transcription.
Parameters αi denote the fraction of new cells infected by virus strain i that
are blocked by the RT inhibitors in the drug regimen, and βi denote the
1.3 Models with infected T cells dynamics 33
fraction of newly produced virions of strain i that are rendered non-infectious
by protease inhibitors (PI). The dynamics of the reference model are
T˙ (t) = s1,T + rT (t)
(








− k1,1(1− α1)V I1 (t)T (t)− k1,2(1− α2)V I2 (t)T (t)








M˙(t) = s1,M − µMM(t)− kM1,1(1− α1)V I1 (t)M(t)
− kM1,2(1− α2)V I2 (t)M(t)
M˙ i1(t) = Q1,1k
M




M˙ i2(t) = Q1,2k
M




V˙ I1 (t) = (1− β1)N1µT i1T
i
1(t) + (1− β1)NM1 µM i1M
i
1(t)− µV1V I1 (t)
V˙ I2 (t) = (1− β2)N2µT i2T
i
2(t) + (1− β2)NM2 µM i2M
i
2(t)− µV2V I2 (t)











Authors omit latently infected cells, which do not appear to play a large role
for them and assume that the strength of immune response is constant over
the time period under study. Indeed the model does not explicitly incorporate
any immune response to the virus. Authors assume that immune response
effects are incorporated into constant parameters that describe the death
rate of productively infected short (µT ) and long-lived (µM ) cells and the
rate of clearance of free virus particle (µV ).











infected T cells and 3 viruses strains: normal viruses (V1), RTI resistant
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viruses (V2), PI resistant viruses (V3)
T˙ (t) =
s1
1 + V1(t) + V2(t) + V3(t)
+ rT (t)
(





























V1(t)T (t)− µTT l1(t)− k2T l1(t)
T˙ a1 (t) = k2T
l







1 (t)− k1V1(t)T (t)− µV V1(t)
T˙ l2(t) = k1V2(t)T (t)− µTT l2(t)− k2T l2(t)
T˙ a2 (t) = k2T
l







2 (t)− k1V2(t)T (t)− µV V2(t)




V3(t)T (t)− µTT l3(t)− k2T l3(t)
T˙ a3 (t) = k2T
l
3(t)− µTaT a3 (t)
V˙3(t) = NµTaT
a
3 (t)− k1V3(t)T (t)− µV V3(t),
(1.41)
where parameter f models drug efficacy, just to take into account the effec-
tiveness of the delivery (see Table 2.4).
Optimal control approach



















1.3.8 Models with uninfected T cells differentiation, viruses
differentiation and immune effectors/precursors pres-
ence
Wilson et al. in [119] propose a model that considers uninfected T cells
and viruses differentiation, and that includes also immune effectors. Criteria
characterising this group of models are the same as those already seen in Sub-
Sect. 1.2.4, with exception that here infected T lymphocytes are considered.
In this model, v(m, t) denotes the population of virus strain identified by a
given fitness level m at time t. Authors regard the non-negative parameter m
as a continuous variable. For mathematical convergence and to reduce their
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assumptions, Wilson et al. define the domain of m to be finite, such that




v(m, t) dm .
Analogously s(m, t) is the total number of T lymphocytes with specificity for
viral antigen and fitness level between m and m+ dm at time t. Therefore










where i(m, t) represents the population (at time t) of cells infected by virus
with fitness level equal to m.





b1 + v(m, t)
− µT s(m, t)− k1V (t)s(m, t)
∂i(m, t)
∂t












h(m,m′)v(m′, t) dm′ − uV (1− P0)v(m, t)
+ Nk2i(m, t)− µV v(m, t),
(1.43)




P0 if m = m
′
αe−β(m−m′)2 if m 6= m′
1.3.9 Models with uninfected and infected T cells differen-
tiation, with viruses differentiation and with immune
effectors/precursors
One of the most general model in HIV literature has been proposed by
Kirschner and Webb in 1996,[45] and considers all criteria seen in Sect. ??.
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The peculiarity of this model is the dependence on the cells age of dynamics.
Denoted by T i(t, a), the density of infected T cells with age of infection a at
time t, the total infected T cell population at time t is given by∫ amax
0
T i(t, a) da,






1 + V (t)
− µTT (t) + rT (t) V (t)
b1 + V (t)
− k1V (t)T (t) +
∫ a1
0






= −µT iT i(t, a)− rT i(t, a)
V (t)
b2 + V (t)





b2 + V (t)
∫ amax
a1
T i(t, a)da− irT (t)V (t)
+
gV (t)
b2 + V (t)
.
(1.44)
Treatment corresponds to the function γ(t, a, p), which is periodic in time t
with period p, it depends on the age a of cellular infection andit is given by
the expression




−βp 0 ≤ a ≤ a1 and 0 ≤ t ≤ p
αp
(1− e−βp) e
−β(t−p) 0 ≤ a ≤ a1 and p ≤ t ≤ 2p
...
0 a > a1
where α represents the total daily drug dosage in chemotherapy and β
indicates the decay rate of AZT based on half-life of 1 hour.
1.4 Parameters Analysis
The aim of this section is to investigate the different values of parameters
used in each model and to calculate the frequencies of such values in the
cited literature. The most peculiar parameters in the previous models are
listed below together with their unit of measurement.
1.4 Parameters Analysis 37
c : Cytotoxic T Lymphocyte (CTL) activation rate [1/day].
g : Input rate of external viral source [cells/(mm3 · day)].
g′ : Growth rate of virions due to infected cells [cells/(mm3 · day)].
ir : Death rate of infected cells due to immune response [1/day].
k1 : Rate CD4 T cells becomes infected by free virus (mm
3/(virions·day)).
k2 : Rate T
l convert to actively infected [1/day].
µIE : Natural death rate for immune effectors (CTL) [1/day].
µIP : Natural death rate of CTL precursors [1/day].
µT : Death rate of uninfected CD4+ T cells [1/day].
µT i : Death rate of infected CD4+ T cells [1/day].
µV : Death rate of free virus [1/day].
N : Number of free virus produced by T infected cells [virions/cell].
pi : Growth rate of viruses [1/day].
q : Growth rate of CTL eff. due to inf. cells and CTL prec [1/day].
r : Rate of growth for CD4+ T cell population [1/day].
Tmax : Maximum CD4+ T cell population level [cells/mm
3].
We don’t go into details about the evaluation of these values, we only limit
ourselves to a statistical analysis on their adoption in the models we presented.
Table 1.5 shows us their frequencies
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Table 1.5: Frequency of parameter values
Symbol Use frequency 1° value partial frequency 2° value partial frequency
c 13% 0.03-0.3 88% others 12%
g 12% 25 57% 30 29%
g′ 17% 0-36 50% 100-300 50%
ir 15% 1-2 67% 0.00074-0.05 33%
k1 67% 2.4× 10−5 27% 2.5− 8× 10−4 20%
k2 13% 0.003 75% 0.036-0.3 25%
µIE 22% 0.1 92% others 8%
µIP 8% 0.001 100% others 0%
µT 60% 0.01-0.09 44% < 0.01 17%
µT i 70% 0.1-0.9 55% 0.01-0.09 21%
µV 52% 1-9 65% < 1 13%
N 30% ≥ 1000 56% < 1000 44%
pi 12% 1-10 86% others 14%
q 8% 0.5 75% others 25%
r 22% 0.03 57% 0.01 14%
s1 73% 10 52% 1-7 25%
s2 17% 31.98 50% 1-3 40%
Tmax 17% 1500 70% 1700 20%
1.5 Review conclusions
We have presented a review of the literature on modelling studies for HIV
and AIDS topics. Most models are formulated in terms of dynamical systems
and optimal control problems; stochastic and fuzzy models are also proposed
although only in few papers. A recent game theory approach has been studied
and, in our opinion, it constitutes the more effective approach in order to take
into account both the viral activity and the immune system/drugs action.
We think that there should be standard assumptions on parameters’
evaluation because we have found some discrepancies among their values. We
believe it is necessary a list of all the possible parameters that are involved
in models of this type, and a detailed study of the probability distribution of
their values, through the medical literature.
Finally there is a need to build more realistic models that incorporate all
properties presented in this review, considering all six classes of antiretroviral
drugs and determining optimal structured treatment interruption (STI)
schedules for medications. Infact administration of antiretroviral drugs should
be daily and uninterrupted; it requires care and precision in the observance
of schedules, even in relation to meals and to use of other drugs. Faithful
adherence to the prescriptions is necessary to maintain effectiveness over
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time. Omission of a few doses leads to a reduction in the quantities of drugs
in plasma, therefore the residual level could be lower than the one necessary
to inhibit the virus. This allows the resumption of viral replication that
leads inexorably to the emergence of resistant virus. Resistant mutants are
destined to persist, making the drug ineffective, even if the intake of drugs
is carried out according to the rhythms and the correct doses. Insufficient
adherence to the prescriptions with the consequent emergence of resistant
mutants are the main causes of treatment failure.
Therefore it becomes necessary a model that simulates the behavior of the
immune system and of the HIV virus, so as to determine what is the optimal
therapy to be administered to the patient in order to prevent viral replication
in his body (rather than the complete eradication of the infection, that
remains chronic) so as to reduce the damage caused to the immune system
and to allow greater survival and quality of life. HIV-infected individuals,
who may promptly discover their state and rely on expert team, should trust
in expectancy and quality of life not dissimilar to those suffering from other
chronic diseases, such as hypertension or diabetes [136].
The study of HIV biological evolution and of its relationship with the immune
system is rather a crucial issue in order to determine an efficient therapy




In Chapter 1 we presented a review of the literature related to HIV
modelization in the Optimal Control context and we classified the works
basing on the following criteria
 Does the model considers T lymphocytes infected by the viruses?
 Does the model presents different types of infected T lymphocytes?
 Does the model presents different types of T lymphocytes?
 Does the model presents different types of HIV viruses?
 Does the model considers the immune effectors/precursors?
Now we propose a model that considers all 5 criteria above indicated,
that is as general as possible, allowing complexity.
Our model present 27 variables (Table 2.1) and 8 controls (Table 2.2), among
these we have 6 controls for the therapy and 2 controls for the virus. It is
very complex, and it consider in general the dynamics of 4 types of cells:
1. HIV viruses;
2. CD4+ T Helper cells;
3. macrophage cells;
4. immune precursor/effector Cytotoxic T lymphocyte cells.
Each of these categories is subdivided into subcategories. Now we analyze
each category.
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1. HIV viruses. As explained in Chapter 1 there are many different
types of HIV, and considers all the different types is not possible due
to the computational complexity that would result.
Therefore, in line with the related literature, as seen in [128], we consider
only two types of viruses
(a) drug sensitive viruses (Vs);
(b) drug resistant viruses (Vr).
Within the subcategory of sensitive viruses there are many strains
of virus, and within subcategory of resistant viruses there are many
strains of virus. In general, these strain of viruses can be wild type
viruses or escape mutant viruses or combination of them.
The HIV controls are the mutation rates of viruses, and precisely
 the mutation rate from sensitive to other sensitive viruses (uvs,s);
 the mutation rate from sensitive to resistant viruses (uvs,r);
 the mutation rate from resistant to other resistant viruses (uvr,r);
 the mutation rate from resistant to sensitive viruses (uvs,r);
where we suppose that uvs,s = 1 − uvs,r, i.e the mutation rate from
sensitive to other sensitive viruses and the mutation rate from sensitive
to resistant viruses are complementary. Similarly uvr,r = 1− uvr,s.
2. CD4+ T Helper cells category is subdivided into
(a) generic CD4+ T Helper cells also said naive T cells. They are
mature T cells that did not meet yet their antigen (Ag). In fact
through the process of lymphocyte recirculation, they circulate
continuously between the blood and secondary or periferical lym-
phoid tissues (such as the lymph nodes, the spleen and mucosa-
associated lymphoid tissue as Peyer’s patches) then return directly
in the bloodstream through the spleen or through the thoracic
duct.
In this way, the naive T cells patrol the body in search of the Ag,
coming into contact with thousands of Antigen Presenting Cell
(APC or B7 molecules) , so check out all Major Histocompatibility
Complex (MHC) peptide complex .
If the naive T lymphocyte do not encounters the specific Ag,
within a relatively short time, it leaves the peripheral lymphoid
tissue and recirculates between the blood and the tissues, until it
meets the Ag or it dies and it is replaced by a new lymphocyte
that expresses different receptors.
In this way you have a spare of the T cell receptor (TCR) reper-
toire and the number of circulating lymphocytes is constant.
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If naive T lymphocytes recognize the specific Ag (presented by
APC cells in the peripheral lymphoid tissue) there is their activa-
tion, their proliferation or clonal expansion through 2-4 mitosis
per day for 3-5 days and their differentiation into effector cells
capable to destroy infected cells or to activate other cells of the
immune system.
Finally, lymphocytes leave the lymph nodes trough the efferent
lymphatic vessels or they leave the spleen through the trabecular
vessels.
In our model this cells, can be
i. uninfected generic CD4+ T Helper cells (Th), these represent
healthy naive T cells;
ii. infected generic CD4+ T Helper cells, these represent naive T
cells infected by viruses. “Stimulation of the T cell by antigen
can lead to the production of new virus particles that bud
from the surface of the infected cell. The budding can take
place very rapidly, leading to the lysis of the host cell (this
seem to be the case in T4 cell infection), or it can take place
slowly and spare the host cell, as seen in macrophages an
monocytes.
Perelson (1989) and Perelson et al. (1993) modelled these
events by considering cells that are uninfected, cells that
are latently infected, i.e., that contain the virus but are not
producing it, cells that are actively infected, i.e., that are pro-
ducing virus, and the population of free viral particles. They
described the dynamics of these population by the system of
ordinary differential equations that we give below”.[44]
Therefore we subdivided this category in 4 subcategories
[16, 17, 30, 44, 46, 83, 84, 86]
A. latently naive T cells, infected by sensitive viruses (T lh,s);
B. actively naive T cells, infected by sensitive viruses (T ah,s);
C. latently naive T cells, infected by resistant viruses (T lh,r);
D. actively naive T cells, infected by resistant viruses (T ah,r).
(b) CD4+ T Helper cells strain specific for sensitive viruses, as we
seen in Nowak works [69, 70, 71, 72, 73] the main points are the
following
 the immune response to viral infection creates a subpopulation
of lymphocytes that are specific for a particular virus strain
and that attack only this particular viral strain;
 the immune response to the virus is also characterized by a
response that is specific to the virus, but it acts against all
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strains. In other words, it acts against the parts of the virus
preserved by the mutations;
 each mutation of the initial viral infection can cause the death
of all lymphocytes, as these can be directed to parts of the
virus variables or preserved.
In our model this cells can be:
i. uninfected CD4+ T Helper cells strain specific for sensitive
viruses (Ts), these represent healthy CD4+ T Helper cells
strain specific for sensitive viruses;
ii. infected CD4+ T Helper cells strain specific for sensitive
viruses. We subdivided also this category in 4 subcategories
[16, 17, 30, 44, 46, 83, 84, 86]
A. latently CD4+ T Helper cells strain specific for sensitive
viruses, infected by sensitive viruses (T ls,s);
B. actively CD4+ T Helper cells strain specific for sensitive
viruses, infected by sensitive viruses (T as,s);
C. latently CD4+ T Helper cells strain specific for sensitive
viruses, infected by resistant viruses (T ls,r);
D. actively CD4+ T Helper cells strain specific for sensitive
viruses, infected by resistant viruses (T as,r).
(c) CD4+ T Helper cells strain specific for resistant viruses.
Similarly to what we saw in the previous point in our model this
cells can be:
i. uninfected CD4+ T Helper cells strain specific for resistant
viruses (Tr), these represent healthy CD4+ T Helper cells
strain specific for resistant viruses;
ii. infected CD4+ T Helper cells strain specific for resistant
viruses. We subdivided also this category in 4 subcategories
[16, 17, 30, 44, 46, 83, 84, 86]
A. latently CD4+ T Helper cells strain specific for resistant
viruses, infected by sensitive viruses (T lr,s);
B. actively CD4+ T Helper cells strain specific for resistant
viruses, infected by sensitive viruses (T ar,s);
C. latently CD4+ T Helper cells strain specific for resistant
viruses, infected by resistant viruses (T lr,r);
D. actively CD4+ T Helper cells strain specific for resistant
viruses, infected by resistant viruses (T ar,r).
(d) CD4+ T Helper cells unspecific for sensitive and resistant viruses.
Similarly to what we saw in the previous point in our model this
cells can be:
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i. uninfected CD4+ T Helper cells unspecific for sensitive and
resistant viruses (Tg), these represent healthy CD4+ T Helper
cells unspecific for sensitive and resistant viruses;
ii. infected CD4+ T Helper cells unspecific for sensitive and
resistant viruses. We subdivided also this category in 4 sub-
categories [16, 17, 30, 44, 46, 83, 84, 86]
A. latently CD4+ T Helper cells unspecific for sensitive and
resistant viruses, infected by sensitive viruses (T lg,s);
B. actively CD4+ T Helper cells unspecific for sensitive and
resistant viruses, infected by sensitive viruses (T ag,s);
C. latently CD4+ T Helper cells unspecific for sensitive and
resistant viruses, infected by resistant viruses (T lg,r);
D. actively CD4+ T Helper cells unspecific for sensitive and
resistant viruses, infected by resistant viruses (T ag,r).
3. Macrophages. We extend our model by including the macrophage/
monocyte (mac/mono) cell population. According to [63], there are
approximately 6000/mm3 white blood cells in a healthy human. No
more than 5% of these are in mac/mono population. Approximately
10% of these cells are CD4+ [81]. The reasons for including the
macrophage/monocyte cell populations are many. HIV is cytopathic
in T4 cells; however, macrophages/monocytes survive once infected,
and slowly bud new virus particles. They therefore, play a role as a
viral source referred to as a reservoir. Notice the fact that infected
macrophages appears to be able to infect T4 cells through presentation
of antigen [57]. Macrophages have a long life span, so we take the per
capita death rate of uninfected cells to be 0.005/day [27].
We have assumed that there is no latently infected macrophages popu-
lation since the virus seems to always replicate inside them [44].
We also assume that macrophages produce virus at a slow constant
rate, sparing the host cell, so there is only natural death for these cells
and not death by bursting like that for infected T4 cells.
In our model also macrophages can be
(a) uninfected macrophages (Mh), these represent healthy macrophage/
monocyte population cells
(b) infected macrophages, these represent macrophage/monocyte pop-
ulation cells infected by viruses. We subdivided also this category
in 2 subcategories [44]
i. actively macrophages infected by sensitive viruses (Mah,s);
ii. actively macrophages infected by resistant viruses (Mah,r).
4. Immune precursor/effector Cytotoxic T lymphocytes. Cyto-
toxic T lymphocyte (CTL) are also know as CD8+ lymphocytes or as
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TC cells. They have a lytic capability and eliminate the virus infected
cells along with the tumor cells. Most cytotoxic T cells express T-cells
receptors (TCRs) that can recognize a specific antigen peptide bound
to class I MHC molecules, present on all nucleated cells, and a gly-
coprotein called CD8, which is attracted to non-variable portions of
the class I MHC molecule. The affinity between CD8 and the MHC
molecule keeps the TC cell and the target cell bound closely together
during antigen-specific activation. Effector CTLs (in our model Ie) are
generated from CTL precursors (in our model Ip). The naive TC cells
are also known as CTL precursors and their activation leads to the
differentiation of effector CTLs from them.
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2.1 Variables, Controls and Parameters
Here we present variables, controls, and parameters of our model. As
already anticipated the model provides
 27 variables (Table 2.1);
 8 controls (Table 2.2);
 98 parameters (Table 2.3 and Table 2.4).
Note that values assigned to all parameters in our instances are listed in
Appendix B.
Table 2.1: Variables (Unit of measure: cells/mm3)
Symbol Description
Ip Immune Precursor Cytotoxic T Lymphocytes
Ie Immune Effector Cytotoxic T Lymphocytes
Mh Uninfected macrophages
Mh,j Macrophage infected by viruses j
Th Uninfected CD4+ T Helper cells
Ts Uninfected CD4+ T Helper cells strain specific for Vs
Tr Uninfected CD4+ T Helper cells strain specific for Vr
Tg Uninfected CD4+ T Helper cells unspecific for Vs and Vr
T li,j Latently infected CD4+ Ti cells infected by virus j
T ai,j Actively infected CD4+ Ti cells infected by virus j
Vs HIV drugs sensitive viruses
Vr HIV drugs resistant viruses
Table 2.2: Controls (∈ [0, 1])
Symbol Description
uco Dosage of coreceptor CCR5 antagonists
ufi Dosage of fusion inhibitors
uib Immune boosting
uii Dosage of integrase inhibitors
upi Dosage of protease inhibitors
urt Dosage of reverse transcriptase inhibitors
uvi,j Mutation rate from virus Vi to virus Vj
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Table 2.3: Parameters (Unit of measure: 1/day)
Symbol Description
c Cytotoxic T Lymphocyte (CTL) activation rate
ij Death rate of cells infected by viruses Vj due to immune response
k Rate Th convert to specific immune reaction cells (Ts or Tr)
k′ Rate Th convert to unspecific immune reaction cells (Tg)
k2 Rate latently infected cells convert to actively infected cells
µi Natural death rate of type i cells
pis Growth rate of sensitive viruses (Vs)
pir Growth rate of resistant viruses (Vr)
q Growth rate of Ie due to infected cells and Ip
r rate of growth for CD4+ T Helper cell population
Table 2.4: Parameters
Symbol Description U.m./Value
Ai Weight on the benefit i and cost of therapy i ∈ [0,+∞]
Bi,j Weight of viral mutation from strain i to strain j ∈ [0,+∞]
b2 Half saturation constant mm
3
g Input rate of external viral source cells
mm3×day
Ie0 Initial value of I
e cells cells
mm3
Ip0 Initial value of I
p cells cells
mm3
k1,j Rate CD4 T cells becomes infected by viruses j
mm3
virions×day
kM1,j Rate macrophages becomes infected by viruses j
mm3
virions×day
k3 Rate infected macrophages infects CD4+ T cells
mm3
cells×day
M0h Initial value of Mh cells
cells
mm3
Ma,0h,j Initial value of actively Mh cells infected by viruses Vj
cells
mm3
θi Scaling parameter for type i cells
p′j Specific immune response rate against viruses Vj
cells
mm3×day
Qi,j Percentage of i cells that recognize the virus j ∈ [0, 1]
ρj Average number of virions j infecting a cell
virions
cell
s1,j Source/production of type j cells
cells
mm3×day
s′j Unspecific immune response rate against viruses Vj
cells
mm3×day
T 0i Initial value of Ti cells
cells
mm3
T l,0i,j Initial value of latently Ti cells infected by viruses Vj
cells
mm3
T a,0i,j Initial value of actively Ti cells infected by viruses Vj
cells
mm3
Tmax Maximum CD4+ T Helper cell population level
cells
mm3




































with Γ = {h, s, r, g} and Ω ∈ {co, fi, ib, ii, pi, rt}.






































with Γ = {h, s, r, g} and Θ = {s, r}.
As already said notice that uvs,s = 1− uvs,r and uvr,r = 1− uvr,s because in this
model for simplicity we consider only 2 type of viruses: sensitive (Vs) and
resistant (Vr) to drugs. Therefore the viruses mutations can be respectively
1. from sensitive to other sensitive viruses;
2. from sensitive to resistant viruses;
3. from resistant to other resistant viruses;
4. from resistant to sensitive viruses.
We suppose that mutations of point 1 and 2 are complementary, that is
uvs,s = 1− uvs,r.
Analogously we suppose that matutation of point 3 and 4 are complementary,
that is uvr,r = 1− uvr,s.
In this model the state functions is
x(t) =
(
Th(t), Ts(t), Tr(t), Tg(t),Mh(t), I
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while the controls are given by
u1(t) =
(









for the immune system - therapy andthe virus, respectively.
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Vs(T ) + Vr(t)
)





























(proposed by Kirschner et al. [47], Caetano et al. [17] and Joshi [41]) is
the source/proliferation of uninfected CD4+ Th cells and includes both an
external (not plasma) contribution of cells from sources, such as the thymus














represents the production of Th-cells due to cloning in the presence of an
antigen, taking into account the maximum number of lymphocytes (Tmax).
The element
uib(t)Th(t)
represents the immune boosting that depends on control uib that allows an
increase of the immune barriers proportional to the number of Th cells.
The term
−µThTh(t)











represents the number of healthy naive cells infected by sensitive viruses, it
is proportional to the number of sensitive viruses (Vs) and naive T cells (Th).







are the actions of fusion inhibitors and coreceptor
antagonists against the infection of healthy cells. These drugs interfere with
binding, fusion and entry of HIV to the host cell by blocking one of several
target cells. Finally (1−QTh,Vs
)
is the portion of generic CD4+ T Helper
cells that does not recognize and does not obstruct sensitive viruses.










with the difference that fusion inhibitors and coreceptor antagonist can not
counteract Th cells infection by resitant viruses (Vr).
The elements
−k(Vs(t) + Vr(t))Th(t)− k′(Vs(t) + Vr(t))Th(t)
represent the number of Th cells converted to Ts, Tr or Tg cells respectively.
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is the number of Th cells contaminated by infected macrophages.
We now consider healthy Ts cells (2.4). For these types of cells the positive
contribute is given only by
kVs(t)Th(t) + uib(t)Ts(t).
As described above uib represents the immune boosting and Ts the number
of naive T-cells converted in CD4+ T Helper cells strain specific for sensitive
viruses (Vs). They have certainly a negative contribute given by the their
natural death
−µTsTs(t).
Also uninfected CD4+ T Helper cells strain specific for sensitive viruses (Ts)























Healthy Tr and Tg cells have dynamics (2.5), (2.6) which are similar to the
one of healthy Ts cells (2.4).
The dynamics for the uninfected macrophages, CD8+ CTL precur-

































T ai,j(t)− µIeIe(t) (2.9)




a natural death element
−µMhMh(t),









Notice that drugs that counteract the Vs infections in these cells are the
reverse transcriptase inhibitors (RTI) and protease inhibitors (PI), where
the first ones inhibit reverse transcription, the second ones block the viral
protease enzyme necessary to produce mature virions upon budding from
the host membrane. These drugs prevent the cleavage of gag and gag/pol
precursor proteins.
About immune precursors/effectors (Ip, Ie) dynamics (2.8),(2.9) we ex-
tend the model presented by Wodarz and Nowak in [120] by replacing infected
T-cells with actively infected Th, Ts, Tr and Tg cells (
∑
T ai,j).
In this regard in the presence of free HIV (Vs or Vr), uninfected cells (Th) can
be infected to became latently or actively infected cells. The latently infected
cells (T lh,j with j ∈ {s, r}) can be activated to become actively infected cells
(T ah,j with j ∈ {s, r}) with an activation rate denoted by k2.
The dynamics for infected Th cells are the following





































T lh,s(t)− µTah,sT ah,s(t)
− isIe(t)T ah,s(t) (2.11)














h,r(t)− k2T lh,r(t) (2.12)







h,r(t)− µTah,rT ah,r(t)− irIe(t)T ah,r(t) (2.13)
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The actively infected cells are short living and will normally be killed upon
activation with death rate µTah,j , j ∈ {s, r}.
In equation (2.10) we represent dynamics of latently Th cells infected by













represent healthy Th-cells infected by Vs and healthy Th-cells contaminated













is the number of infected cells that convert from latently to actively infected.
This process is counteract by reverse trascriptase and integrase inhibitors
which inhibit reverse trascription and integration of viral DNA respectively.








as seen in (2.10); this gives the number of infected cells that convert from
latently to actively infected.




The first one is the natural death of actively infected lymphocytes while the
second one is a novelty introduced by our model; it represent the number
of actively infected naive T cells (T ah,s) killed by CTL effectors (I
e), at a
constant rate is. Of course this number is proportional to the number of
immune effectors (Ie).
Similar considerations can be observed for equations (2.12) and (2.13) with
the variation that there are not drugs that can counteract resistant viruses.
Moreover the action of CTL effectors occurs at a constant rate ir.
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The dynamics for infected Ts cells are the following



































T ls,s(t)− µTas,sT as,s(t)
− isIe(t)T as,s(t) (2.15)












− µT ls,rT ls,r(t)− k2T ls,r(t) (2.16)







s,r(t)− µTas,rT as,r(t)− irIe(t)T as,r(t) (2.17)
As said for naive T lymphocytes (Th) the same holds for equations (2.14),
(2.15), (2.16), (2.17) of Ts cells.
The dynamics for infected Tr cells are the following



































T lr,s(t)− µTar,sT ar,s(t)
− isIe(t)T ar,s(t) (2.19)












− µT lr,rT lr,r(t)− k2T lr,r(t) (2.20)







r,r(t)− µTar,rT ar,r(t)− irIe(t)T ar,r(t) (2.21)
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As said for naive T lymphocytes (Th) the same holds for equations (2.18),
(2.19), (2.20), (2.21) of Tr cells.
The dynamics for infected Tg cells are the following



































T lg,s(t)− µTag,sT ag,s(t)
− isIe(t)T ag,s(t) (2.23)












− µT lg,rT lg,r(t)− k2T lg,r(t) (2.24)







g,r(t)− µTag,rT ag,r(t)− irIe(t)T ag,r(t) (2.25)
As said for naive T lymphocytes (Th) the same holds for equations (2.22),
(2.23), (2.24), (2.25) of Tg cells.


















= kM1,rVr(t)Mh(t)− µMah,rMah,r (2.27)
Notice, we assumed that there is no latently infected macrophage population
since the virus seems to replicate once inside them. We also assume that
macrophages produce virus at a slow constant rate, sparing the host cell, so
there is only natural death, not death by bursting like that for infected T
cells [44].
These equations presents two infections rate, the former (kM1,s) related to
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sensitive viruses (Vs), the latter related to resistant viruses (Vr).
Finally, we hypothesize that reverse transcriptase and protease inhibitors
can counteract macrophages infected by sensitive viruses [116, 117], while
there are not drugs to counteract resistant viruses.

































































































Sensitive viruses equation (2.28) presents 3 positive and 4 negative contributes.































The first one is a source of virus that accounts for viral contributions to
the plasma from both external compartments, such as the lymph system,
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as well as virus produced by infected cells in the plasma [34]. This source is
counteracted by the protease inhibitors therapy upi(t).
The second one represents the growth of sensitive viruses at a constant rate
pis. This growth is counteracted by protease inhibitors, and it is proportional
to the number of actively infected cells contaminated by sensitive viruses
and to the mutation rate from sensitive to other sensitive viruses (uvs,s).
Finally the third one represents the growth (at a constant rate pir) of resistant
viruses that mutate into sensitive viruses (at a rate 1 − uvr,r = uvr,s). Also
this growth is counteracted by protease inhibitors, and it is proportional
to the number of actively infected cells, contaminated by resistant viruses.
Parameters b2, g, pis, pir are assumed positive and constant.




















− (s′sTg(t) + p′sTs(t))Vs(t),
where the first and second one indicate that viruses which infect lymphocytes
are not free to circulate in the blood, and so they can not infect other cells
at the same time. The constant ρs indicates the average number of sensitive
virions infecting a cell: in our numerical simulations we set this number equal
to 1, but the model permits also other values for this parameter, that is a
cell could be infected by more viruses.
Also viruses die, see the third negative term.
The fourth negative term represents the number of sensitive virions blocked
by specific immune response (represented by Ts cells) and by unspecific
immune response (represented by Tg cells).
For what concerns resistant viruses dynamics (2.28), considerations are the
same just viewed for sensitive viruses, with the only difference that protease
inhibitors can not counteract Vr.
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The boundary conditions are the following
Th(t0) = T
0
h Ts(t0) = T
0















































































h,r Vs(t0) = V
0
s Vr(t0) = V
0
r (2.30)






i,j(tf ), Vj(tf ) ∈ R+ (2.31)
u1(t) ∈ [0, 1]
u2(t) ∈ [0, 1] (2.32)






r,s(t) = 1 (2.33)
To conclude each therapy control, that represents the various drugs dosage,
is assumed to vary within the range [0, 1].
The HIV-controls, represent the mutation rates of viruses, lay in the same
range.
Observation: One proposed is a generalized model , and it can be ap-
plied to any simpler formulation just resetting appropriate parameter values
thus overlooking certain variables, such as macrophages (Mh), immune effec-
tors/precursors (Ie, Ip) or CD4+ T Helper cells unspecific for sensitive and
resistant viruses (Tg).
One possible approach to this problem would be a predator-prey model
(Lotka-Volterra model [115]), as the following
x˙ = ax− bxy − ex2
y˙ = −cy + dxy − fy2,
where x are the preys, a is the preys growth rate, bxy is the number of
contacts per unit of time between preys and predators and finally ex2 term
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reflects the prey internal competition due to the limitation of external re-
sources. Variable y describes the predators: they have a natural decaying
rate −cy proportional to their current number; their number increase at a
rate dxy proportional to their number y and the number x of their preys;
finally fy2 represents the predator internal competition due to the limited
number of available prey.
In our context T-lymphocytes would have the role of predator and HIV the
role of prey, at the beginning. After that T-lymphocytes become prey and
HIV the predator, which is in its turn preyed by drug therapy.
Such alternate behaviours make the problem different from the predator-prey
one.
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2.4 Nash Equilibria
Equations (2.1)-(2.29) constitute a differential game between immune
system-therapy and HIV. In order to find a Nash Equilibrium, let’s introduce
the Hamiltonian functions for the two players. For therapy
HTher
(






















































































































Vs(T ) + Vr(t)
)




































































































































s,r(t)− µTas,rT as,r(t)− irIe(t)T as,r(t)
}














































































































































































































2.4 Nash Equilibria 65
And for HIV virus
HHIV
(
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s,r(t)− µTas,rT as,r(t)− irIe(t)T as,r(t)
}














































































































































































































The model is difficult to analyze due to the high number of variables and
constraints. Let’s simplify it by relaxing the constraints on the state variables
(2.31), assuming that






i,j(tf ), Vj(tf ) ∈ R (2.36)
and verify ex-post their validity. So that the transversality conditions are
λ1,j(tf ) = 0, j = 1, 2, . . . , 27,
λ2,j(tf ) = 0, j = 1, 2, . . . , 27. (2.37)
From conditions
λi,0 ∈ {0, 1}, i = 1, 2,(
λi,0, λi,j(t)
) 6= 0, i = 1, 2 j = 1, 2, . . . , 27, (2.38)
we obtain that
λ1,0 = λ2,0 = 1. (2.39)
2.4 Nash Equilibria 69









































(− 1 + upi(t)))−Br,s(− 1 + uvr,r(t))
= 0
(2.41)












but we do not make explicit these equations, because they are very long and
complex.



























(− 1 + upi(t)))
Br,s
(2.44)
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that is a negative definite matrix (Bs,r > 0 and Br,s > 0).
Therefore the Hamiltonian function for these controls is concave, and the
optimal strategy for HIV is
uv
∗
s,s(t) = min{1,max{0, uˆvs,s(t)}} (2.46)
uv
∗
r,r(t) = min{1,max{0, uˆvr,r(t)}} (2.47)
We can see that from the transversality conditions (2.37) it follows that
uv
∗
s,s(tf ) = u
v∗
r,r(tf ) = 1. (2.48)
Since uvs,r(t) is the mutation rate from sensible viruses to resistant viruses,
from equations (2.33) we obtain that uvs,r(t) = 1 − uvs,s(t) and uv
∗
s,r(t) =
1− uv∗s,s(t). Analogously uv
∗





s,r(tf ) = u
v∗
r,s(tf ) = 0 (2.49)
Let’s consider now the necessary conditions for the immune system-




(− 1 + ufi(t))Vs(t) ·
·
[


















Tg(t)−QTg ,VsTg(t) + Th(t)−QTh,VsTh(t)
+ Tr(t)−QTr,VsTr(t) + Ts(t)−QTs,VsTs(t)
)]
= 0 (2.50)




(− 1 + uco(t))Vs(t) ·
·
[


















Tg(t)−QTg ,VsTg(t) + Th(t)−QTh,VsTh(t)























































· (− 1 + uvr,r(t))− pisuvs,s(t)(Mah,r(t) + T ag,r(t) + T ah,r(t)


















































but we do not explicit them, because they are very long and complex.
From these equations we obtain stationary points for the control u1(t) =(
uco(t), ufi(t), uib(t), uii(t), upi(t), urt(t)
)
. Again we do not explicit them.
Similarly the 6× 6 Hessian matrix for the controls of immune system-therapy(





−Aco h1,2(t) 0 0 0 0
h1,2(t) −Afi 0 0 0 0
0 0 −Aib 0 0 0
0 0 0 −Aii 0 h4,6(t)
0 0 0 0 −Api h5,6(t)



























(QTh,Vs − 1)Th(t) + (QTs,Vs − 1)Ts(t)
+ (QTr,Vs − 1)Tr(t) + (QTg ,Vs − 1)Tg(t)
]}
, (2.58)
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h4,6(t) = k2
[(− λ1,12(t) + λ1,13(t))T ls,s(t)
+
(− λ1,16(t) + λ1,17(t))T lr,s(t)
+
(− λ1,20(t) + λ1,21(t))T lg,s(t)
+








Here the principal minor of 1st order of Hessian matrix is
−Aco
that is negative.
The determinant of the principal minor of 2nd order is
det H˜′′Ther,2 = Aco Afi − h21,2(t) (2.61)
and is negative if and only if
Aco Afi > h
2
1,2(t). (2.62)
The determinant of the principal minor of 3rd order is
−Aib · det H˜′′Ther,2. (2.63)
The determinant of the principal minor of 4th order is
Aii ·Aib · det H˜′′Ther,2. (2.64)
The determinant of the principal minor of 5th order is
−Api ·Aii ·Aib · det H˜′′Ther,2. (2.65)
Finally the determinant of the principal minor of 6th order, such as the
determinant of Hessian matrix, is








det H˜′′Ther,2 = Aco Afi − h21,2(t) > 0 (2.67)
and
Art Api Aii − h24,6(t) Api − h25,6(t) Aii > 0, (2.68)
the Hessian matrix is negative definite, therefore the Hamiltonian function
HTher
(
x, u1, u2, λ1(t), λ2(t), t
)




, for all t ∈ [t0, tf ].
Unfortunately functions h1,2(t), h4,6(t) and h5,6(t) are not apriory known, so
we can’t apply the Mangasarian and Arrow theorems at this general setting.
Hence we will verify these conditions ex-post.
1where λ1(t) =
(




λ2,1(t), λ2,2(t), . . . , λ2,27(t)
)
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2.5 Connection between Nash equilibrium and ESS
A widely used issue in biology is the concept of Evolutionary Stable
Strategy (ESS), born from the work of John Maynard Smith and George
Robert Price [59, 60]. They first used this approach to explain phenomena
such as
 the prevalence of a fair relationship male/female in an animal population
[19],
 or relationships between prey and predators and attitudes related to
this struggle (Hawk-Dove Game [19]).
Given a population of players, an ESS is a strategy that is adopted by the
population (in our case is adopted by HIV population), whose particularity
is the stability in the face of attempts, by the population, to change its
trajectory.
The introduction of this concept also allows us to justify the use of game
theory in a population of virus. Viruses are not able to control their strategy,
they reproduce themselves and are subject to the force of natural selection.
Even just the fact that the payoff of HIV represents the reproductive success
(i.e. the number of virus products) helps us to understand that the concept
of ESS will be useful in our consideration.
As suggested by Nowak in [75], let us explore a game with more than
2 strategies. The payoff for the strategy Si versus strategy Sj is given by
E(Si, Sj).
1. The strategy pair (Sk, Sk) is a strict Nash equilibrium if and only if
this is true for both players and
E(Sk, Sk) > E(Si, Sk) ∀i 6= k.
2. The strategy pair (Sk, Sk) is a Nash equilibrium if and only if this is
true for both players and
E(Sk, Sk) ≥ E(Si, Sk) ∀i.
3. The strategy pair (Sk, Sk) is a ESS if ∀i 6= k we have
E(Sk, Sk) > E(Si, Sk)
or [
E(Sk, Sk) = E(Si, Sk) and E(Sk, Si) > E(Si, Si)
]
2.
2Maynard Smith’s second condition
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Note that the ESS guarantees that the selection will oppose any poten-
tial invader. The same is true for a strict Nash equilibrium, but not for
a Nash equilibrium.
If E(Sk, Ek) = E(Sj , Sk) and E(Sk, Sj) < E(Sj , Sj), then Sk is still a
Nash equilibrium, but the selection will favor Sj invading Sk. Thus it
makes sense to add fourth definition.
4. The strategy pair (Sk, Sk) is stable against invasion by selection (let us
called “weak ESS”) if ∀i 6= k we have either
E(Sk, Sk) > E(Si, Sk)
or
E(Sk, Sk) = E(Si, Sk) and E(Sk, Si) ≥ E(Si, Si).
If a strategy is a strict Nash equilibrium (SNE) then it is also an ESS. If a
strategy is an ESS is also a weak ESS (WESS). If a strategy is a weak ESS
is also a Nash equilibrium (NE). Thus strict Nash equilibrium implies ESS
implies weak ESS implies Nash equilibrium:
SNE ⇒ ESS ⇒WESS ⇒ NE.
Back to our model, we want to show that the Nash equilibrium charac-
terized by the additional conditions∣∣∣∣ ∂uii∂uvs,s
∣∣∣∣+ ∣∣∣∣ ∂uii∂uvr,r
∣∣∣∣ < 1 (2.69)∣∣∣∣ ∂upi∂uvs,s
∣∣∣∣+ ∣∣∣∣ ∂upi∂uvr,r
∣∣∣∣ < 1 (2.70)∣∣∣∣ ∂urt∂uvs,s
∣∣∣∣+ ∣∣∣∣ ∂urt∂uvr,r
∣∣∣∣ < 1 (2.71)∣∣∣∣∂uvs,s∂urt
∣∣∣∣ < 1 (2.72)∣∣∣∣∂uvr,r∂urt
∣∣∣∣ < 1 (2.73)
is an ESS, and we will prove that proving that it is SNE.
Note that if there is a Nash equilibrium does not rule out that there may be
an infinite number of Nash equilibria.
We do not report for each control, the expressions of solution of maximum
equations (2.40), (2.41), (2.50), (2.51), (2.52), (2.53), (2.54), (2.55) because
they are very large and complex.
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Proposition 2.5.1. Suppose that the couple of strategies (Therapy, HIV)
is characterized by the solution of maximum equations (2.40), (2.41), (2.50),
(2.51), (2.52), (2.53), (2.54), (2.55) and that these strategies are subject to
the additional conditions mentioned above (2.69), (2.70), (2.71),(2.72), (2.73)
then
1. The Nash equilibrium is unique.
2. From any starting point, iterations defined by strategies converge to
this unique Nash equilibrium.
Proof. We now set up uniqueness and convergence together by showing that,
for each control, the expressions of solution of maximum equations (2.40),
(2.41), (2.50), (2.51), (2.52), (2.53), (2.54), (2.55) are a contraction mappings.
According to Contractions Lemma (Banach Cacciopoli, [26, page 117]), let
M be an Euclidean complete space and let f : M → M be a mapping. In
addition, consider any vector norm. Let d(·) be the distance function by the
vector norm. We have
d(f(u), f(v)) = ||f(u)− f(v)|| (2.74)
≤
∣∣∣∣∣∣∣∣∂f∂x
∣∣∣∣∣∣∣∣||(u− v)|| = ∣∣∣∣∣∣∣∣∂f∂x
∣∣∣∣∣∣∣∣d(u, v). (2.75)
The matrix norm used here is induced by the vector norm too. The inequality
follows from the property of hte matrix norm. Hence, it is clear that if we
have the Jacobian ||∂f/∂x|| < 1− , everywhere for some positive  value, we
can let k = 1−  < 1, and applies the contaction mapping theorem.
We now derive conditions using || · ||∞, for the expressions of solution of
maximum equations (2.40), (2.41), (2.50), (2.51), (2.52), (2.53), (2.54), (2.55)





The complete form of Jacobian is given as follows
J =

0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0
0 0 0 0 0 0 ∂uii∂uvs,s
∂uii
∂uvr,r





0 0 0 0 0 0 ∂urt∂uvs,s
∂urt
∂uvr,r
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It follows, therefore, that












From the hypothesis (2.69), (2.70), (2.71),(2.72), (2.73) we conclude 0 <
||J ||∞ < 1. Hence the expressions of solution of maximum equations (2.40),
(2.41), (2.50), (2.51), (2.52), (2.53), (2.54), (2.55) are contraction mappings,
and bothuniqueness and global convergence are guaranteed.
It has been proven that if the best response is unique, then the Nash
equilibrium is a strict Nash equilibrium [82]. Thus, it is proven that our Nash




The optimal control problems which permits to calculate the Nash equi-







subject to x′(t) = g(t, x(t), u(t))
x(t0) = x0
x(tf ) ∈ R
u(t) ∈ [0, 1]m. (3.1)
Even if an analytical solution would be preferable, in certain conditions we are
unfortunately obliged to find a numerical solution, using an algorithm that
approximates the optimal control u∗. The necessary condition for optimality
are
x′(t) = g(t, x(t), u(t)), x(t0) = x0, (3.2)
λ′(t) = −∂H
∂x




= fu(t, x, u) + λ(t)gu(t, x, u) in u
∗. (3.4)
The third equation, the optimality condition, can be manipulated to find a
representation of u∗ in terms of t, x and λ. In these terms it is replaced in
the differential equations for x, λ, and the first two equations form a problem
with boundary values at two different points. The fact that one is initial
(for the state) and one is the final (for the adjoint equation) and the fact
that the state does not depend on the values of the adjoint function, it gives
us the ability to create an efficient and intuitive algorithm: the algorithm
Forward-Backward Sweep [52].
Let’s break the interval [t0, tf ] at the points t0 = b1, b2, . . . , bN , bN+1 = tf ;
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these points are equally spaced by the same constant step h. The approx-
imation will be a vector ~u = (u1, u2, . . . , uN+1), where ui ≈ u(bi). Taken
as an approximation of the state and of the adjoint function the vectors
~x = (x1, . . . , xN+1) e ~λ = (λ1, . . . , λN+1), the steps of the algorithm are the
following
Step 1 Make an initial prediction for the ~u on the range.
Step 2 Using the initial condition x1 = x(t0) = x0 and the values of ~u, solve
~x forward in the time according to his differential equation.
Step 3 Using the transverality condition λN+1 = λ(tf ) = 0 and the values
of ~u e ~x, solve ~λ backward in the time according to his SDE.
Step 4 Update ~u inserting the new calculated values for ~x e ~λ in the char-
acterization of optimal control.
Step 5 Convergence control: if the values of variables in this iteration and
in the previous are sufficiently close, we output the current value as
solution. Otherwise, return to step Step 2
Usually the initial choice ~u ≡ 0 is sufficient, if you shouldn’t divide for u,
otherwise it is better to opt for a different initial choice.
In Step 4, controls are usually updated through a convex combination
between the previous value of the control and the last calculated one. This
procedure speeds the convergence. With regard to Step 2 and 3, any solver
of differential equations can be applied. A common method is the routine
Runge-Kutta of 4th order [92], in this case, given a step h, the equation
x′(t) = f(t, x(t)) and x(t), the approximation of x(t+ h) is
x(t+ h) ≈ x(t) +
h
6
(k1 + 2k2 + 2k3 + k4) (3.5)
where















k4 = f(t+ h, x(t) + hk3).
(3.6)
There are a lot of tests for convergence. Often it is sufficient to require
that||u − oldu|| = ∑N+1i=1 |ui − oldui| is small, where ~u is the vector of
estimated values of control during the current iteration and ~oldu the vector
of values of the previous iteration. Therefore we require that
||~u− ~oldu||
||~u|| ≤ δ, (3.7)
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where δ is the accepted tolerance. Let’s make a small adjustment to allow to
enter the null control (~u ≡ 0), multiplying both sides by ||~u||. Therefore we
wish that








|ui − oldui| ≥ 0. (3.9)
In our model this request is made only on the state and on the adjoint
variables, and not on the control.
Another way to proceed is to explicit u∗ with respect to t, x and λ. In this
case Step 1 is not performed on the control, but on the state and adjoint
variables; the convergence test runs on these variables, after the vector ~u
is calculated separately the vector. This way of acting is not wrong, but it
can easily lead to errors in the transcription of the code. if possible, it is
advisable to calculate the control u∗ and then test the convergence.
In our model unfortunately theory don’t help us. Therefore, we try to
solve the problem numerically.
We have a system with 81 differential equations of the first order which are
strongly non linear, more precisely
 27 equations on the states;
 54 equations on the adjoint variables;
 27 boundary conditions for the states at time t0;
 54 boundary conditions for the adjoint variables at time tf ;
therefore we must adopt a FORWARD-BACKARD SWEEP approach [52].
For the realization of the algorithm we have used Mathematica, for the
symbolic calculus, and Matlab for the numeric calculus. The reason for this
choice is linked to the fact that Matlab is very weak from the point of view
of the symbolic computation and Mathematica is very weak from the point
of view of the numerical calculation. Therefore we have opted to use a com-
bination of them, so that one method could fill in the gaps of the other.
As mentioned in Section 2.4, Hamiltonian concavity with respect to HIV
is guaranteed, whereas with respect to therapy controls, this concavity is not
guaranteed and it must be checked ex post. In this regard, our algorithm
(at each iteration forward, at each iteration backward, and to each of the 4
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where uˆ2(t) is a stationary point; and it assigns to the therapy controls the
value between 0, 1, and uˆ1(t) that maximizes the Hamiltonian function at
that time.
The convergence request is given by the equation (3.9) on state and
adjoint variables, but in our algorithm we verify also the validity of ESS
condition (2.69), (2.70), (2.71), (2.72), (2.73) to ensure uniqueness and con-
vergence of found Nash equilibrium.
3.1 Numerical integration





(where f is an arbitrary continuous function in [a, b]) is not determinable
analytically, or even if it is possible, the final expression can be too complex
and therefore its numerical evaluation is subject to large errors. Sometimes,
as in the case of the approximation, the integrand function f(x) is not known
in analytical form, but only in a finite number of points. Therefore it is
interesting to have numerical methods that can approximate the value of
the integral from a finite number of values of the integrand function. This is
possible by using the so-called numerical quadrature formulas.
In this work we propose 3 different methods [92]
1. composite rectangle method;
2. composite trapezoid method;
3. composite Cavalieri-Simpson method.
3.1.1 Composite rectangle formula
A simple procedure to approximate I(f) consists to subdivided [a, b] into
sub-intervals
Ii = [xi, xi+1], i = 0, 1, . . . , N,
with
xi = a+ ih, i = 0, 1, . . . , N, h = (b− a)/N.
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Now, for all sub-intervals Ii we substitute f integral with the integral of a
polynomial f¯ that approximates f on Ii. The easiest solution is to use a




and we obtain the composed rectangle formula







where R(f) is the error and it is possible to demonstrate that if f is continu-




h2f ′′(ξ), ξ ∈ [a, b] (3.13)
3.1.2 Composite trapezoid formula
Where to approximate the f integral on Ii you use the interpolating
polynomial of degree 1 in the extreme nodes xk and xk+1, we formulate the











where R(f) is the error and it is possible to demonstrate that for C2(a, b)
functions
R(f) = −(b− a)
12
h2f ′′(ξ), ξ ∈ [a, b] (3.15)
3.1.3 Composite Cavalieri-Simpson formula
We proceed in a similar way to what is done to derive the composite
trapezoid formula. The only difference is that now, on each interval Ii, the
function f will be replaced with the interpolating polynomial of degree 2 in
















where R(f) is the error and it is possible to demonstrate that for all f ∈
C4(a, b)
R(f) = −(b− a)
180
h4f (4)(ξ), ξ ∈ [a, b] (3.17)
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3.2 Various instances
We have proved that concavity of the virus Hamiltonian function is
guaranteed by the 2× 2 Hessian matrix (2.45). According to the observed
instances, in general, the concavity for the Hamiltonian of therapy controls
is not assured. However, with different parameter values, we can obtained
instances in which this concavity holds.
We first present a situation where Hamiltonian concavity for therapy
controls is guaranteed. In this context our algorithm, for every iteration (or
in every subinterval in which the integration interval is subdivided) and for
each of the four degrees of Runge Kutta routine is more simple and converges




(where uˆ(t) is a stationary point) and this can be done just because the
therapy and HIV Hamiltonians are both concave. Values assigned to all
adjoint variables λi,j(t) at time t0 are 0.1, and this allows therapy Hamiltonian
function to be concave.
The instance here presented is characterized by a high drugs toxicity, moreover
drugs are very effective, in fact, small doses force it to reduce the virus
mutation rates uvr,s and u
v
s,r (for parameters value see Appendix B).
Figure 3.1: 1st instance with concave therapy Hamiltonian.
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As shown in Figure 3.1, the first six graph represent therapy dosages and
the last two the HIV mutations.
Fusion inhibitors (ufi) and coreceptor antagonist (uco), are used for the same
scope that of interfering with binding, fusion and entry of HIV to the host
cell and blocking one of several targets, in fact their dosages are the same
for all 1000 days.
Also integrase (uii) and reverse transcriptase inhibitors (urt) are used in the
same phase of virions creation that is the reverse trascription from RNA
to DNA. Their dosage are very similar for the first 100 days, but integrase
inhibitors are also used around 600 days to cope with rising of mutation rate
from resistant to sensitive viruses (uvr,s).
Immune boosting (uib) seems to have a pattern of cyclic type (as it is the
nature of such drugs whose purpose is to strengthen the immune system) but
by following an appropriate cyclicity in fact as you can see the second cycle
of therapy begins when the viruses mutation rate are now null and void.
Protease inhibitors (upi) block the viral protease enzyme necessary to produce
mature virions upon budding from the host membrane. These drugs are very
efficient in fact they are used approximately 25 days.
For what concerns HIV, the mutation rate from sensitive to resistant
viruses (uvs,r) is maximum for the first 500 days, then begin to decrease
thanks to drug effects and vanishes around 600 days when there is a tail
strike of mutation rate from resistant to sensitive viruses (uvr,s) that however
is completely canceled by the action of integrase inhibitors (uii).
The payoff for therapy and HIV are listed in Table 3.1. The high drugs
toxicity induces to elevated costs for the immune system, leading to a negative
payoff, that musts be interpreted only as costs for the patient.
Table 3.1: 1st instance: payoff.
Numerical integration method Therapy payoff HIV payoff
Composite rectangle method -40479 177.3520
Composite trapezoids method -40480 177.3520
Composite Cavalieri-Simpson method -40480 177.3488
In spite of this, analyzing the trends of the graphs of different lymphocytes,
we can ensure that the lymphocyte count is, for the entire time interval,
around 1000 cells/mm3 (see Figure 3.2).
Therefore our aim is to determine a therapy that allows to prevent viral
replication with side effects, for the immune system, that are the lowest
possible.
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Figure 3.2: 1st instance: lymphocytes, macrophage and CTL dynamics.
The white blood cell count is definitely one of the most important tests
to verify the presence of HIV virus: it is an indicator of the health status of
a patient and is one of the key factors in determining when to start HAART
and prophylaxis for opportunistic infections. The tests usually measure the
white blood cells present in the sample and calculate the percentage of CD4+
T-lymphocytes. This value can be variable between different individuals and
influenced by factors that affect the white blood cells in general, such as
drug use and the presence of acute infections. In general, the percentage of
CD4+ T-cells is stable and it can be a parameter for evaluating the immune
functions of a patient. Usually, it has a level of 500-1000 cells/cm3 in a
healthy patient, below this threshold, we can think of a possible infection to
damage the immune system.
Finally, in this instance, the ESS condition (2.69), (2.70), (2.71), (2.72),
(2.73) presented in Section 2.5 are met therefore the instance presented has
an unique Nash equilibria that is also an evolutionary stable strategy.
Let us consider no-concave therapy instances: in these cases the optimal
therapy controls are not necessarily given by equation (3.18) and more local
optimal points may exist. In order to find the global optimum, our algorithm
in every subinterval in which the integration interval is subdivided and for
each of the four degrees of Runge Kutta routine, assigns to therapy controls
the value between
0, 1, uˆ(t)
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(where uˆ(t) is a stationary point). This procedure expands the processing
time because at each step, it checks therapy controls which maximize the
Hamiltonian for 8 times:
 4 times (one for each of the 4 degrees of Runge Kutta) during forward
process, in calculation of variables;
plus
 4 times (one for each of the 4 degrees of Runge Kutta) during backward
process, in calculation of adjoint variables.
Therefore, at each iteration the algorithm will perform a search for the
optimal therapy sequence that maximizes the Hamiltonian function 8 times
within a 36 × 6 (= 729× 6) matrix
These not concave instances are generally characterized by a low drugs toxicity,
therefore, in these cases, the payoff of the player immune system/therapy is
much higher. Notice a situation in which the drugs are less effective, therefore,
it is required a prolonged intake over time.
Numerical simulation for this instance regards values randomizations at time
t0 of adjoint variables λi,j(t). We first present in Figure 3.3 an instance with
all adjoint variables at time t0 initialized to 0.1.
Figure 3.3: 2nd instance with no concave therapy Hamiltonian and λi,j(t0) = 0.1.
HIV uvs,r mutation rate is maximum for about 600 days then begins to
decrease thanks to action of therapy controls uco, ufi and urt, upi. Finally it
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vanishes around 700 days. Also in this instance there is a final contribution
by the mutation rate uvr,s, that is completely torn down by the combined
actions of uii and urt.
Note that around the 400th day there is a positive peak for uvr,s and conse-
quently a negative peak for uvs,r. The mutation rate from resistant to sensitive
viruses is immediately counteracted by integrase and reverse trascriptase
inhibitors.
Immune boosting (uib) continues to have a cyclical dosage, whilst protease
inhibitors are used only the first 100 days.
The payoff for therapy and HIV are listed in Table 3.2
Table 3.2: 2nd instance with λi,j(t0) = 0.1: payoff.
Numerical integration method Therapy payoff HIV payoff
Composite rectangle method 1411.7 171.9974
Composite trapezoids method 1411.7 171.9975
Composite Cavalieri-Simpson method 1411.5 171.9336
The non-concavity of the Hamiltonian functions of therapy controls, does
not allow us to affirm that the just proposed therapy in Figure 2 is the
optimal one. It is therefore necessary to perform the randomizations on the
initial values of the adjoint variable lambda, in order to identify the values
of λi,j(t0) that make at least a suboptimally therapy.
We made the choice of these initial values in the range [−100, 100], and after
multiple randomizations we verified that the higher immune system-therapy
payoffs were obtained for initial values of λi,j(t) in the range [0, 1]. At this
point, we performed a further randomization, this time much more precise,
on 100 different instances with adjoint variable values λi,j(t0) ∈ [0, 1], getting
the below results (Figure 3.4 and Table 3.3).
Recall that these randomizations have high computational times, for example
the last numerical simulation took 37182 seconds i.e. about 11 hours.
3.2 Various instances 89
Figure 3.4: Instances randomization for λi,j ∈ [0, 1].
Table 3.3: Instances randomization: payoff.
Integration method Therapy max Therapy mean Corresponding HIV1 HIV mean2
Composite rectangle 2002.1 1654.4 171.6968 171.9550
Composite trapezoids 2002.1 1654.4 171.6974 171.9555
Cavalieri-Simpson 2000.2 1653.2 171.3787 171.6368
Finally, we stored the values of λi,j(t) at time t0 that maximized the
randomization and we replace them in the search algorithm of the optimal
therapy, getting the following chart.
1HIV payoff corresponding to maximum therapy payoff obtained with the randomization.
2HIV mean obtained with the randomization.
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Figure 3.5: 2nd instance with no concave therapy Hamiltonian and λi,j(t0) assigned
using randomization results.
In this instance the HIV mutation rate from sensitive to resistant (uvs,r)
viruses is most of the times equal to zero, except for a positive peak around
the 700th day. Obviously this peak corresponds to a negative peak by the
mutation rate from resistant to sensitive (uvr,s) viruses. This last rate is
constantly at the maximum level: this is not a thing to fear because if all
the viruses become drug sensitive then the therapeutic treatments would
be able to eradicate easily the infection. In addition, the final increment
of integrase (uii) and reverse transcriptase (urt) inhibitors avoids further
positive peaks by uvs,r. Notice that the immune boosting remains constantly
equal to 1, because the increase of lymphocytes is not dangerous and can not
cause an increase of preys for viruses, as these tend to be all drugs sensitive
and therefore easily countered by drugs. The payoff for therapy and HIV of
this “no-concave” instance are listed in Table 3.4.
Table 3.4: 2nd instance with λi,j(t0) assigned using randomization results: sub-
optimally payoff.
Numerical integration method Therapy payoff HIV payoff
Composite rectangle method 2002.1 171.6968
Composite trapezoids method 2002.1 171.6974
Composite Cavalieri-Simpson method 2000.2 171.3787
As expected, values meet as seen in Table 3.3, and the ESS conditions
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(2.69), (2.70), (2.71), (2.72), (2.73) presented in Section 2.5 are not verified,
in fact it is not an unique Nash equilibrium and it is not an evolutionary
stable strategy.
3.3 Conclusions
In this work we have presented an application of differential Game The-
ory to a medical-therapeutic context for the HIV treatment, suggested by
article [128]. We carried out a literature analysis, to study the different
approaches used in this field. Our aim was to formulate a model that could
be as close as possible to the real dynamics between HIV and Human immune
system, in the context of differential games and, at the same time, that it was
solvable. The model consists of 27 state functions and 8 controls (6 for the
therapy and 2 for HIV). The optimality necessary conditions to obtain the
Nash equilibrium of the game lead us to a system of 81 differential equations
(27 equation for state variables and 54 for adjoint variables) of the first order
which are strongly non-linear and are subjected to two different types of
boundary conditions: at the initial time (t0) for the state functions and at
the final time (tf ) for the adjoint functions.
We designed an algorithm that uses the Runge Kutta routine of 4th order [92],
while the question of the boundary conditions at different times for different
variables has been entrusted through the Forward-Backward Sweep algorithm
[52]. All this in order to determine the optimal therapy in specific instances
where it is guaranteed or not the concavity of the immune system-therapy
Hamiltonian function. When concavity is not guaranteed, we have found a






Although the proposed model is not too complex, the fact that these
variables were “intertwined” with each other has made it very difficult to
manage, and it was difficult to analyze even the large equations that formed
it. One of major problems we encountered was the need to use the software
Mathematica and Matlab in symbiosis. Symbolic computation was carried
out by Mathematica, while the numerical calculation by Matlab. Certainly
one tool that would allow optimal management of both the symbolic and
numerical calculation would have simplified the issue.
During this work, I realized that although specialist softwares as Mathematica
and Matlab have within them appropriate routines for solving differential
equations, they do not provide within these routines, the way to assign, at
each step, controls values.
We believe it would be appropriate to validate our model on known
clinical situations of patients who have been continuously monitored both
with regard to the count of immune cells and the administered therapy.
A possible further extension of this model could be obtained in matching
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the Game Theory approach with the Fuzzy system issue, paying attention to
the unavoidable complexity increase.
Finally it is necessary to go much more in-depth in the study of parameters
validation, in order to standardize them and to determine the probability
distribution of their values, starting from drugs toxicity costs.
Appendix A
Differential Games
A game is said dynamic if at least one player can use a strategy that
evolves at each instant of time, and that can refer to the previous actions,
both his own and those of the opponent. In order to analyze a dynamic game,
we need to know the order the players adopt to take their choices and what
type of information is available to them. Assuming all actions as observable
by all players, we will say perfect information game, on the contrary we will
say incomplete information game.
Let’s consider a game with N players who know at each instant t their
past actions up to time t− 1. A differential game is a dynamic game, played
in continuous time. Two distinctive features of differential games are
 a set of variables that characterize the state of the dynamic system at
any instant of time during the course of the game;
 a set of differential equations that describes the time evolution of state
variables.
Differential games may vary depending on what information each player
has, and this depends not only on the information it uses, but also on the
information it holds. It cans play using only on the temporal information,
typical of the open-loop strategies, or using the entire history of actions, like
Markovian strategies, in which decisions are influenced by the time t and the
state vector at time t. In our analysis we focused on open-loop strategies.
Let’s consider a game in a time range [0, T ] with T finite or for an unlimited
time span [0,+∞). The state of the game for any time t is described by the
vector x(t) ∈ X where X ⊆ Rn is the space of states and the initial state
is a fixed constant x0 ∈ X. At each instant of time t ∈ [0, T ], each player
i ∈ {1, 2, . . . , N} chooses a control ui(t) from a set of admissible controls
U i(x(t), u−i(t), t) ⊆ Rmi , where the vector u−i(t) represents controls of other
players, that is
u−i(t) = (u1(t), u2(t), . . . , ui−1(t), ui+1(t), . . . , uN (t)). (A.1)
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The state of the system evolves according to the differential equation
x˙(t) = f(x(t), u1(t), u2(t), . . . , uN (t), t), x(0) = x0, (A.2)
where the function
f : Ω −→ Rn (A.3)
with
Ω = {(x, u1, . . . , uN , t)|x ∈ X, t ∈ [0, T ], ui ∈ U i(x, u−i, t), i = 1, . . . , N}.
(A.4)





itF i(x(t), u1(t), u2(t), . . . , uN (t), t)dt+ e−r
iTSi(x(T )).
(A.5)
The function F i : Ω 7→ R represents the instantaneous payoff of player i, ri
its discount rate, and Si : X 7→ R scrap function, understood as a payoff
at the final time T . In the case that T = +∞ we assume that S(x) = 0,
∀x ∈ X.
A.1 Nash equilibria
A Nash equilibrium of a differential game is a N -uple of strategies
(ϕ1, ϕ2, . . . , ϕN ) such that, given the equilibrium strategy of the opponent,
no player has an incentive to change its strategy. All the opponents of the
player i use a Markov strategy uj(t) = ϕj(x(t), t), j 6= i, then the player i is







1(t), u2(t), . . . , uN (t), t)dt+e−r
iTSi(x(T ))
(A.6)
subjects to the conditions
x˙(t) = f iϕ−i(x(t), u
i(t), t) x(0) = x0 u
i(t) ∈ U iϕ−i(x(t), t), (A.7)
where
F iϕ−i(x, u
i, t) =F i(x, ϕ1(x, t), . . . , ϕi−1(x, t), ui, ϕi+1(x, t), . . . , ϕN (x, t), t),
f iϕ−i(x, u
i, t) =f(x, ϕ1(x, t), . . . , ϕi−1(x, t), ui, ϕi+1(x, t), . . . , ϕN (x, t), t),
U iϕ−i(x, u
i, t) =U i(x, ϕ1(x, t), . . . , ϕi−1(x, t), ϕi+1(x, t), . . . , ϕN (x, t), t).
(A.8)
Given each (N − 1)-uple ϕ−i = (ϕ1, . . . , ϕi−1, ϕi+1, . . . , ϕN ) of functions
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Definition A.1.1. The N-uple (ϕ1, ϕ2, . . . , ϕN ) of functions ϕi : X ×
[0, T ] 7→ Rmi, i ∈ {1, 2, . . . , N} is said Markovian Nash equilibria if, for
all i ∈ {1, 2, . . . , N}, a solution of optimal control ui(·) that maximizes
J i
ϕ−i(u
i(·)) exist and it is given by the Markovian strategy ui(t) = ϕi(x(t), t).
A.2 Necessary condition for Nash equilibria
(Pontryagin Maximum Principle)
The Pontryagin Maximum Principle provides necessary optimality condi-
tions for optimal control problems, it is a valuable tool for many applications
in several contexts.
Let’s define a function H with real values
H(x, u, λ, t) = F (x, u, t) + λf(u, x, t). (A.9)
The domain of the function H is the set
{(x, u, λ, t)|x ∈ X,u ∈ U(x, t), λ ∈ Rn, t ∈ [0, T ]}.
The function H is called Hamiltonian function and it plays an important
role in the Maximum Principle of Pontryagin. The function λ, associated
with the state variable x, is called the adjoint function. Let’s also define the
maximized Hamiltonian H∗ : X × Rn × [0, T ] 7→ R
H∗(x, λ, t) = max{H(x, u, λ, t)|u ∈ U(x, t)}. (A.10)
Before stating the necessary conditions for the optimality of a solution, we
introduce the following theorem which instead gives us sufficient conditions
for an optimal solution [12, 13, 29, 101].
Theorem A.2.1. We consider the problem expressed by equations
x˙(t) = f(x(t), u(t), t) (A.11)
and the boundary condition
x(0) = x0 ∈ X, (A.12)
where u(t) = (u1(t), u2(t), . . . , um(t)) ∈ Rm is the vector of actions chosen
by the player at time t. The set of eligible actions at time t, given the state
of the system x, is given by U(x, t) ∈ Rm. The constant x0 is known and
the function f is defined on Ω = {(x, u, t)|x ∈ X,u ∈ U(x, t), t ∈ [0, T ]} and
taking values in Rn, hence f(x, u, t) is an n-dimensional vector. The player





e−rtF (x(t), u(t), t)dt+ e−rTS(x(T )) (A.13)
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where r ≥ 0 is the discount rate, F (x, u, t) the instantaneous utility due to
the choice of the control, and S(x(T )), the final value due to the state x(T ).
now we define the Hamiltonian function and maximezed Hamiltonian func-
tion. We assume that the state space X is convex and that the scrap function
S is of class C1, and concave. Let u(·) be an admissible control with a corre-
sponding state x(·).
 If there exists an absolutely continuous function λ : [0, T ] 7→ Rn such
that the maximality condition
H(x(t), u(t), λ(t), t) = H∗(x(t), λ(t), t), (A.14)
the adjoint equation
λ˙(t) = rλ(t)−H∗x(x(t), λ(t), t), (A.15)
and the transversality conditions
λ(T ) = S′(x(T )) (A.16)
are fulfilled, and such that the function x 7→ H∗(x, λ(t), t) is concave
and differentiable with respect to the state variable x for all t ∈ [0, T ],
then u(·) is an optimal control.
 If the set of admissible controls, U(x, t) does not depend on x, the result
remains true unless you replace the equation (A.15) with
λ˙(t) = rλ(t)−Hx(x(t), u(t), λ(t), t). (A.17)
If the scrap function S(x(t)) = 0 and the discount rate r = 0, it gets a




F (x(t), u(t), t)dt, (A.18)
soggetto a x˙(t) = f(x(t), u(t), t),
x(t0) = x0,
xi(T ) = x
T
i , i = 1, . . . , l,
xi(T ) ≥ xTi , i = l + 1, . . . , r,
xi(T ) ∈ R, i = r + 1, . . . , n,
u(t) ∈ U(x, t) ∈ Rm.
(A.19)
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We define the Hamiltonian functions as follows
H(x, u, λ, t) = λ0F (x, u, t) +
n∑
i=1
λi(t)fi(x, u, t), (A.20)
and we state the following necessary conditions for the optimality of a
solution.
Theorem A.2.2. Let u∗(t) be an optimal control continuous piecewise,
defined on [0, T ], which is associated to the state function x∗(t). Then there
exists a constant λ0 ∈ R and a continuous function of class C1 piecewise
λ : [0, T ] 7→ Rn such that for all t ∈ [0, T ], are valid the following conditions:
(i) (λ0, λ(t)) 6= 0 ∈ Rn+1;
(ii) u∗(t) maximize H(x∗(t), u, λ(t), t) for u ∈ U(x, t);
(iii) except for the t where u∗(t) is discontinuous, p˙(t) = −∂H(x∗(t),u∗(t),λ(t),t)∂x ;
(iv) λ0 ∈ {0, 1};
(v) λi(T ) ∈ R, i = 1, . . . , l,
λi(T ) ≥ 0 e λi(T )(xi(T )− xTi ) = 0, i = l + 1, . . . , r,




The sets of parameter values we presented in the numerical Section 3.2
are very similar to the ones most commonly used in the related literature (see
Section 1.4). We have modified only the death rate of cells infected by viruses
Vs or Vr due to immune response (is and ir respectively). We deliberately
kept these parameters close to zero, in order to obtain the two instances
concave and not concave. The two instances mainly differ from each other
for the drugs toxicity parameters, again to consider concave and not concave
properties.
Table B.1 shows the values we assigned to drugs toxicity and mutation
costs for both instances. Table B.2 shows all common parameter values for
both instances. Finally Table B.3 contains boundary conditions.
Table B.1: Weights
Symbol Description 1st instance 2nd instance
Aco Coreceptor antagonists toxicity 10
6 10
Afi Fusion inhibitors toxicity 10
6 10
Aib Immune boosting toxicity 1 1
Aii Integrase inhibitors toxicity 10
2 10
Api Protease inhibitors toxicity 2× 102 10
Art Reverse transcriptase inhibitors toxicity 10
6 10
Bs,r Mutation costs from sensitive to resistant viruses 10
−10 10−10
Br,s Mutation costs from resistant to sensitive viruses 10
−11 10−11
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Table B.2: Common parameters at both instances
Symbol Description Value
b2 Half saturation constant 1 mm
3
c Cytotoxic T Lymphocyte (CTL) activation rate 0.03 1
day
g Input rate of external viral source 25 cells
mm3×day
is Death rate of cells infected by Vs due to immune response 10
−308 1
day
ir Death rate of cells infected by Vr due to immune response 10
−308 1
day
k Rate Th convert to specific immune reaction cells (Ts or Tr) 10
−6 1
day
k′ Rate Th convert to unspecific immune reaction cells (Tg) 10−6 1day
k1,s Rate CD4 T cells becomes infected by Vs 0.0003
mm3
virions×day
k1,r Rate CD4 T cells becomes infected by Vr 0.00005
mm3
virions×day
kM1,s Rate macrophages becomes infected by Vs 0.00467
mm3
virions×day
kM1,r Rate macrophages becomes infected by Vr 0.001
mm3
virions×day
k2 Rate latently infected cells convert to actively infected cells 0.003
1
day
k3 Rate infected macrophages infects CD4+ T cells 10
−6 mm3
cells×day
µTh Death rate of uninfected CD4+ Th cells 0.02
1
day
µTs Death rate of uninfected CD4+ Ts cells 0.02
1
day
µTr Death rate of uninfected CD4+ Tr cells 0.02
1
day
µTg Death rate of uninfected CD4+ Tg cells 0.02
1
day
µMh Death rate of uninfected Mh cells 0.005
1
day
µIp Death rate of uninfected I
p cells 0.001 1
day
µIe Death rate of uninfected I
e cells 0.1 1
day
µT li,s
Death rate of latently infected T li,s cells 0.1
1
day






Death rate of latently infected T li,r cells 0.2
1
day












Death rate of actively infected Mah,r cells 0.07
1
day
µVs Death rate of sensitive viruses Vs 2.4
1
day
µVr Death rate of resistant viruses Vr 5
1
day
θi Scaling parameter for type i cells 1
pis Growth rate of sensitive viruses (Vs) 8
1
day
pir Growth rate of resistant viruses (Vr) 5
1
day
p′s Specific immune response rate against Vs 0.020
cells
mm3×day
p′r Specific immune response rate against Vr 0.001
cells
mm3×day
q Growth rate of Ie due to infected cells and Ip 0.5 1
day
QTh,Vs Percentage of Th cells that recognize the virus Vs 0
QTh,Vr Percentage of Th cells that recognize the virus Vr 0
QTs,Vs Percentage of Ts cells that recognize the virus Vs 0.90
QTs,Vr Percentage of Ts cells that recognize the virus Vr 0
QTr,Vs Percentage of Tr cells that recognize the virus Vs 0
QTr,Vr Percentage of Tr cells that recognize the virus Vr 0.90
QTg,Vs Percentage of Tg cells that recognize the virus Vs 0
QTg,Vr Percentage of Tg cells that recognize the virus Vr 0
r rate of growth for CD4+ T Helper cell population 0.03 1
day
ρs Average number of virions Vs infecting a cell 1
virions
cell
ρr Average number of virions Vr infecting a cell 1
virions
cell
s1,Th Source/production Th cells 1
cells
mm3×day
s1,Mh Source/production of macrophages 1
cells
mm3×day
s′s Unspecific immune response rate against Vs 9.7
cells
mm3×day
s′r Unspecific immune response rate against Vr 0.0009
cells
mm3×day










Ie0 Initial value of I
e cells 10
Ip0 Initial value of I
p cells 10
M0h Initial value of Mh cells 1
T 0h Initial value of Th cells 900
T 0s Initial value of Ts cells 100
T 0r Initial value of Tr cells 100
T 0g Initial value of Tg cells 1
T l,0i,s Initial value of latently Ti cells infected by viruses Vs 10
T a,0i,s Initial value of actively Ti cells infected by viruses Vs 0
T l,0i,r Initial value of latently Ti cells infected by viruses Vs 10
T a,0i,r Initial value of actively Ti cells infected by viruses Vr 0
Ma,0h,s Initial value of actively Mh cells infected by viruses Vs 10
Ma,0h,r Initial value of actively Mh cells infected by viruses Vr 10
V 0s Initial value of viruses Vs 500




C.1 Mathemathica functions for symbolic calcula-
tions
In this section we present the Mathematica code needed for symbolic
calculations.
The last part named “NDSolve” shows the statements required to solve the
system of 81 differential equations of first order nonlinear mentioned in
Chapter 3. Unfortunately, this instruction does not lead to any result, hence
the need to intervene with Matlab for the numerical computations.
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campi vettoriali 
X={x1, x2, x3, x4, x5, x6, x7, x8, x9, x10, x11, x12, x13, x14, x15, x16, x17, x18, x19, x20, 
x21, x22, x23, x24, x25, x26, x27}; 
XT[t_]:={x1[t], x2[t], x3[t], x4[t], x5[t], x6[t], x7[t], x8[t], x9[t], x10[t], x11[t], x12[t], x13[t], 
x14[t], x15[t], x16[t], x17[t], x18[t], x19[t], x20[t], x21[t], x22[t], x23[t], x24[t], x25[t], 
x26[t], x27[t]}; 
U1={u11, u12, u13, u14, u15, u16}; 
U1T[t_]:={u11[t], u12[t], u13[t], u14[t], u15[t], u16[t]}; 
U2={u21, u22}; 
U2T[t_]:={u21[t], u22[t]}; 
L1={l11, l12, l13, l14, l15, l16, l17, l18, l19, l110, l111, l112, l113, l114, l115, l116, l117, 
l118, l119, l120, l121, l122, l123, l124, l125, l126, l127}; 
L1T[t_]:={l11[t], l12[t], l13[t], l14[t], l15[t], l16[t], l17[t], l18[t], l19[t], l110[t], l111[t], 
l112[t], l113[t], l114[t], l115[t], l116[t], l117[t], l118[t], l119[t], l120[t], l121[t], l122[t], 
l123[t], l124[t], l125[t], l126[t], l127[t]}; 
L2={l21, l22, l23, l24, l25, l26, l27, l28, l29, l210, l211, l212, l213, l214, l215, l216, l217, 
l218, l219, l220, l221, l222, l223, l224, l225, l226, l227}; 
L2T[t_]:={l21[t], l22[t], l23[t], l24[t], l25[t], l26[t], l27[t], l28[t], l29[t], l210[t], l211[t], 
l212[t], l213[t], l214[t], l215[t], l216[t], l217[t], l218[t], l219[t], l220[t], l221[t], l222[t], 
l223[t], l224[t], l225[t], l226[t], l227[t]}; 
T[{th_, ts_, tr_, tg_, mh_, ip_, ie_, thsl_, thsa_, thrl_, thra_, tssl_, tssa_, tsrl_, tsra_, trsl_, 
trsa_, trrl_, trra_, tgsl_, tgsa_, tgrl_, tgra_, mhsa_, mhra_, vs_, vr_}, {uco_, 
ufi_,uib_,uii_,upi_,urt_}, {ussv_, urrv_}]:=(s1th*oth)/(oth+vs+vr)+ 
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TS[{th_, ts_, tr_, tg_, mh_, ip_, ie_, thsl_, thsa_, thrl_, thra_, tssl_, tssa_, tsrl_, tsra_, trsl_, 
trsa_, trrl_, trra_, tgsl_, tgsa_, tgrl_, tgra_, mhsa_, mhra_, vs_, vr_}, {uco_, 
ufi_,uib_,uii_,upi_,urt_}, {ussv_, urrv_}]:=k*vs*th+uib*ts-muts*ts-k1s*(1-ufi)*(1-uco)*(1-
qtsvs)*vs*ts-k1r*(1-qtsvr)*vr*ts-k3*(mhsa+mhra)*ts; 
TR[{th_, ts_, tr_, tg_, mh_, ip_, ie_, thsl_, thsa_, thrl_, thra_, tssl_, tssa_, tsrl_, tsra_, trsl_, 
trsa_, trrl_, trra_, tgsl_, tgsa_, tgrl_, tgra_, mhsa_, mhra_, vs_, vr_}, {uco_, 
ufi_,uib_,uii_,upi_,urt_}, {ussv_, urrv_}]:=k*vr*th+uib*tr-mutr*tr-k1s*(1-ufi)*(1-uco)*(1-
qtrvs)*vs*tr-k1r*(1-qtrvr)*vr*tr-k3*(mhsa+mhra)*tr; 
TG[{th_, ts_, tr_, tg_, mh_, ip_, ie_, thsl_, thsa_, thrl_, thra_, tssl_, tssa_, tsrl_, tsra_, trsl_, 
trsa_, trrl_, trra_, tgsl_, tgsa_, tgrl_, tgra_, mhsa_, mhra_, vs_, vr_}, {uco_, 
ufi_,uib_,uii_,upi_,urt_}, {ussv_, urrv_}]:=kprimo*(vs+vr)*th+uib*tg-mutg*tg-k1s*(1-
ufi)*(1-uco)*(1-qtgvs)*vs*tg-k1r*(1-qtgvr)*vr*tg-k3*(mhsa+mhra)*tg; 
MH[{th_, ts_, tr_, tg_, mh_, ip_, ie_, thsl_, thsa_, thrl_, thra_, tssl_, tssa_, tsrl_, tsra_, trsl_, 
trsa_, trrl_, trra_, tgsl_, tgsa_, tgrl_, tgra_, mhsa_, mhra_, vs_, vr_}, {uco_, 
ufi_,uib_,uii_,upi_,urt_}, {ussv_, urrv_}]:=s1mh-mumh*mh-k1sm*(1-urt)*(1-upi)*vs*mh-
k1rm*vr*mh; 
IP[{th_, ts_, tr_, tg_, mh_, ip_, ie_, thsl_, thsa_, thrl_, thra_, tssl_, tssa_, tsrl_, tsra_, trsl_, 
trsa_, trrl_, trra_, tgsl_, tgsa_, tgrl_, tgra_, mhsa_, mhra_, vs_, vr_}, {uco_, 
ufi_,uib_,uii_,upi_,urt_}, {ussv_, 




IE[{th_, ts_, tr_, tg_, mh_, ip_, ie_, thsl_, thsa_, thrl_, thra_, tssl_, tssa_, tsrl_, tsra_, trsl_, 
trsa_, trrl_, trra_, tgsl_, tgsa_, tgrl_, tgra_, mhsa_, mhra_, vs_, vr_}, {uco_, 
ufi_,uib_,uii_,upi_,urt_}, {ussv_, urrv_}]:=c*q*ip*(thsa+thra+tssa+tsra+trsa+trra+ 
tgsa+tgra)-muie*ie; 
THSL[{th_, ts_, tr_, tg_, mh_, ip_, ie_, thsl_, thsa_, thrl_, thra_, tssl_, tssa_, tsrl_, tsra_, trsl_, 
trsa_, trrl_, trra_, tgsl_, tgsa_, tgrl_, tgra_, mhsa_, mhra_, vs_, vr_}, {uco_, 
ufi_,uib_,uii_,upi_,urt_}, {ussv_, urrv_}]:=k1s*(1-ufi)*(1-uco)*(1-
qthvs)*vs*th+k3*mhsa*th-muthsl*thsl-k2*(1-urt)*(1-uii)*thsl; 
THSA[{th_, ts_, tr_, tg_, mh_, ip_, ie_, thsl_, thsa_, thrl_, thra_, tssl_, tssa_, tsrl_, tsra_, trsl_, 
trsa_, trrl_, trra_, tgsl_, tgsa_, tgrl_, tgra_, mhsa_, mhra_, vs_, vr_}, {uco_, 
ufi_,uib_,uii_,upi_,urt_}, {ussv_, urrv_}]:=k2*(1-urt)*(1-uii)*thsl-muthsa*thsa-is*ie*thsa; 
THRL[{th_, ts_, tr_, tg_, mh_, ip_, ie_, thsl_, thsa_, thrl_, thra_, tssl_, tssa_, tsrl_, tsra_, trsl_, 
trsa_, trrl_, trra_, tgsl_, tgsa_, tgrl_, tgra_, mhsa_, mhra_, vs_, vr_}, {uco_, 
ufi_,uib_,uii_,upi_,urt_}, {ussv_, urrv_}]:=k1r*(1-qthvr)*vr*th+k3*mhra*th-muthrl*thrl-
k2*thrl; 
THRA[{th_, ts_, tr_, tg_, mh_, ip_, ie_, thsl_, thsa_, thrl_, thra_, tssl_, tssa_, tsrl_, tsra_, trsl_, 
trsa_, trrl_, trra_, tgsl_, tgsa_, tgrl_, tgra_, mhsa_, mhra_, vs_, vr_}, {uco_, 
ufi_,uib_,uii_,upi_,urt_}, {ussv_, urrv_}]:=k2*thrl-muthra*thra-ir*ie*thra; 
TSSL[{th_, ts_, tr_, tg_, mh_, ip_, ie_, thsl_, thsa_, thrl_, thra_, tssl_, tssa_, tsrl_, tsra_, trsl_, 
trsa_, trrl_, trra_, tgsl_, tgsa_, tgrl_, tgra_, mhsa_, mhra_, vs_, vr_}, {uco_, 





TSSA[{th_, ts_, tr_, tg_, mh_, ip_, ie_, thsl_, thsa_, thrl_, thra_, tssl_, tssa_, tsrl_, tsra_, trsl_, 
trsa_, trrl_, trra_, tgsl_, tgsa_, tgrl_, tgra_, mhsa_, mhra_, vs_, vr_}, {uco_, 
ufi_,uib_,uii_,upi_,urt_}, {ussv_, urrv_}]:=k2*(1-urt)*(1-uii)*tssl-mutssa*tssa-is*ie*tssa; 
TSRL[{th_, ts_, tr_, tg_, mh_, ip_, ie_, thsl_, thsa_, thrl_, thra_, tssl_, tssa_, tsrl_, tsra_, trsl_, 
trsa_, trrl_, trra_, tgsl_, tgsa_, tgrl_, tgra_, mhsa_, mhra_, vs_, vr_}, {uco_, 
ufi_,uib_,uii_,upi_,urt_}, {ussv_, urrv_}]:=k1r*(1-qtsvr)*vr*ts+k3*mhra*ts-mutsrl*tsrl-
k2*tsrl; 
TSRA[{th_, ts_, tr_, tg_, mh_, ip_, ie_, thsl_, thsa_, thrl_, thra_, tssl_, tssa_, tsrl_, tsra_, trsl_, 
trsa_, trrl_, trra_, tgsl_, tgsa_, tgrl_, tgra_, mhsa_, mhra_, vs_, vr_}, {uco_, 
ufi_,uib_,uii_,upi_,urt_}, {ussv_, urrv_}]:=k2*tsrl-mutsra*tsra-ir*ie*tsra; 
TRSL[{th_, ts_, tr_, tg_, mh_, ip_, ie_, thsl_, thsa_, thrl_, thra_, tssl_, tssa_, tsrl_, tsra_, trsl_, 
trsa_, trrl_, trra_, tgsl_, tgsa_, tgrl_, tgra_, mhsa_, mhra_, vs_, vr_}, {uco_, 
ufi_,uib_,uii_,upi_,urt_}, {ussv_, urrv_}]:=k1s*(1-ufi)*(1-uco)*(1-qtrvs)*vs*tr+k3*mhsa*tr-
mutrsl*trsl-k2*(1-urt)*(1-uii)*trsl; 
TRSA[{th_, ts_, tr_, tg_, mh_, ip_, ie_, thsl_, thsa_, thrl_, thra_, tssl_, tssa_, tsrl_, tsra_, trsl_, 
trsa_, trrl_, trra_, tgsl_, tgsa_, tgrl_, tgra_, mhsa_, mhra_, vs_, vr_}, {uco_, 
ufi_,uib_,uii_,upi_,urt_}, {ussv_, urrv_}]:=k2*(1-urt)*(1-uii)*trsl-mutrsa*trsa-is*ie*trsa; 
TRRL[{th_, ts_, tr_, tg_, mh_, ip_, ie_, thsl_, thsa_, thrl_, thra_, tssl_, tssa_, tsrl_, tsra_, trsl_, 
trsa_, trrl_, trra_, tgsl_, tgsa_, tgrl_, tgra_, mhsa_, mhra_, vs_, vr_}, {uco_, 
ufi_,uib_,uii_,upi_,urt_}, {ussv_, urrv_}]:=k1r*(1-qtrvr)*vr*tr+k3*mhra*tr-mutrrl*trrl-
k2*trrl; 
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TRRA[{th_, ts_, tr_, tg_, mh_, ip_, ie_, thsl_, thsa_, thrl_, thra_, tssl_, tssa_, tsrl_, tsra_, trsl_, 
trsa_, trrl_, trra_, tgsl_, tgsa_, tgrl_, tgra_, mhsa_, mhra_, vs_, vr_}, {uco_, 
ufi_,uib_,uii_,upi_,urt_}, {ussv_, urrv_}]:=k2*trrl-mutrra*trra-ir*ie*trra; 
TGSL[{th_, ts_, tr_, tg_, mh_, ip_, ie_, thsl_, thsa_, thrl_, thra_, tssl_, tssa_, tsrl_, tsra_, trsl_, 
trsa_, trrl_, trra_, tgsl_, tgsa_, tgrl_, tgra_, mhsa_, mhra_, vs_, vr_}, {uco_, 
ufi_,uib_,uii_,upi_,urt_}, {ussv_, urrv_}]:=k1s*(1-ufi)*(1-uco)*(1-
qtgvs)*vs*tg+k3*mhsa*tg-mutgsl*tgsl-k2*(1-urt)*(1-uii)*tgsl; 
TGSA[{th_, ts_, tr_, tg_, mh_, ip_, ie_, thsl_, thsa_, thrl_, thra_, tssl_, tssa_, tsrl_, tsra_, trsl_, 
trsa_, trrl_, trra_, tgsl_, tgsa_, tgrl_, tgra_, mhsa_, mhra_, vs_, vr_}, {uco_, 
ufi_,uib_,uii_,upi_,urt_}, {ussv_, urrv_}]:=k2*(1-urt)*(1-uii)*tgsl-mutgsa*tgsa-is*ie*tgsa; 
TGRL[{th_, ts_, tr_, tg_, mh_, ip_, ie_, thsl_, thsa_, thrl_, thra_, tssl_, tssa_, tsrl_, tsra_, trsl_, 
trsa_, trrl_, trra_, tgsl_, tgsa_, tgrl_, tgra_, mhsa_, mhra_, vs_, vr_}, {uco_, 
ufi_,uib_,uii_,upi_,urt_}, {ussv_, urrv_}]:=k1r*(1-qtgvr)*vr*tg+k3*mhra*tg-mutgrl*tgrl-
k2*tgrl; 
TGRA[{th_, ts_, tr_, tg_, mh_, ip_, ie_, thsl_, thsa_, thrl_, thra_, tssl_, tssa_, tsrl_, tsra_, trsl_, 
trsa_, trrl_, trra_, tgsl_, tgsa_, tgrl_, tgra_, mhsa_, mhra_, vs_, vr_}, {uco_, 
ufi_,uib_,uii_,upi_,urt_}, {ussv_, urrv_}]:=k2*tgrl-mutgra*tgra-ir*ie*tgra; 
MHSA[{th_, ts_, tr_, tg_, mh_, ip_, ie_, thsl_, thsa_, thrl_, thra_, tssl_, tssa_, tsrl_, tsra_, 
trsl_, trsa_, trrl_, trra_, tgsl_, tgsa_, tgrl_, tgra_, mhsa_, mhra_, vs_, vr_}, {uco_, 
ufi_,uib_,uii_,upi_,urt_}, {ussv_, urrv_}]:=k1sm*(1-urt)*(1-upi)*vs*mh-mumhsa*mhsa; 
MHRA[{th_, ts_, tr_, tg_, mh_, ip_, ie_, thsl_, thsa_, thrl_, thra_, tssl_, tssa_, tsrl_, tsra_, 
trsl_, trsa_, trrl_, trra_, tgsl_, tgsa_, tgrl_, tgra_, mhsa_, mhra_, vs_, vr_}, {uco_, 
ufi_,uib_,uii_,upi_,urt_}, {ussv_, urrv_}]:=k1rm*vr*mh-mumhra*mhra; 
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VS[{th_, ts_, tr_, tg_, mh_, ip_, ie_, thsl_, thsa_, thrl_, thra_, tssl_, tssa_, tsrl_, tsra_, trsl_, 





VR[{th_, ts_, tr_, tg_, mh_, ip_, ie_, thsl_, thsa_, thrl_, thra_, tssl_, tssa_, tsrl_, tsra_, trsl_, 






JT[{th_, ts_, tr_, tg_, mh_, ip_, ie_, thsl_, thsa_, thrl_, thra_, tssl_, tssa_, tsrl_, tsra_, trsl_, 
trsa_, trrl_, trra_, tgsl_, tgsa_, tgrl_, tgra_, mhsa_, mhra_, vs_, vr_}, {uco_, 
ufi_,uib_,uii_,upi_,urt_}, {ussv_, urrv_}]:=mh+ip+ie+th+ts+tr+tg-
0.5*(aco*uco^2+afi*ufi^2+aib*uib^2+aii*uii^2+api*upi^2+art*urt^2); 
JV[{th_, ts_, tr_, tg_, mh_, ip_, ie_, thsl_, thsa_, thrl_, thra_, tssl_, tssa_, tsrl_, tsra_, trsl_, 
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HT[X_,U1_,U2_, {l1_, l2_, l3_, l4_, l5_, l6_, l7_, l8_, l9_, l10_, l11_, l12_, l13_, l14_, l15_, 
l16_, l17_, l18_, l19_, l20_, l21_, l22_, l23_, l24_, l25_, l26_, l27_}]:=l01 JT[X, U1, U2] + l1 
T[X, U1, U2] + l2 TS[X, U1, U2]+ l3 TR[X, U1, U2] + l4 TG[X, U1, U2] + l5 MH[X, U1, 
U2] + l6 IP[X, U1, U2] + l7 IE[X, U1, U2] + l8 THSL[X, U1, U2] +  l9 THSA[X, U1, U2] +  
l10 THRL[X, U1, U2] +  l11 THRA[X, U1, U2] +  l12 TSSL[X, U1, U2] +  l13 TSSA[X, U1, 
U2] +  l14 TSRL[X, U1, U2] +  l15 TSRA[X, U1, U2] + l16 TRSL[X, U1, U2] +  l17 
TRSA[X, U1, U2] +  l18 TRRL[X, U1, U2] +  l19 TRRA[X, U1, U2] +   l20 TGSL[X, U1, 
U2] +  l21 TGSA[X, U1, U2] +  l22 TGRL[X, U1, U2] +  l23 TGRA[X, U1, U2] + 
   l24 MHSA[X, U1, U2] +  l25 MHRA[X, U1, U2] +   
   l26 VS[X, U1, U2] + l27 VR[X, U1, U2] ; 
HV[X_,U1_,U2_, {l1_, l2_, l3_, l4_, l5_, l6_, l7_, l8_, l9_, l10_, l11_, l12_, l13_, l14_, l15_, 
l16_, l17_, l18_, l19_, l20_, l21_, l22_, l23_, l24_, l25_, l26_, l27_}]:=l02 JV[X, U1, U2] + 
l1 T[X, U1, U2] + l2 TS[X, U1, U2]+ l3 TR[X, U1, U2] + l4 TG[X, U1, U2] + l5 MH[X, U1, 
U2] + l6 IP[X, U1, U2] + l7 IE[X, U1, U2] + l8 THSL[X, U1, U2] +  l9 THSA[X, U1, U2] +  
l10 THRL[X, U1, U2] +  l11 THRA[X, U1, U2] +  l12 TSSL[X, U1, U2] +  l13 TSSA[X, U1, 
U2] +  l14 TSRL[X, U1, U2] +  l15 TSRA[X, U1, U2] + l16 TRSL[X, U1, U2] +  l17 
TRSA[X, U1, U2] +  l18 TRRL[X, U1, U2] +  l19 TRRA[X, U1, U2] +   l20 TGSL[X, U1, 
U2] +  l21 TGSA[X, U1, U2] +  l22 TGRL[X, U1, U2] +  l23 TGRA[X, U1, U2] + 
   l24 MHSA[X, U1, U2] +  l25 MHRA[X, U1, U2] +   
   l26 VS[X, U1, U2] + l27 VR[X, U1, U2] ; 
l01=1; l02=1; 
EQMAX1[X_, U1_,U2_, L1_]:=Table[D[HT[X, U1, U2, L1],u],{u,U1}] 
EQMAX2[X_, U1_,U2_, L1_]:=Table[D[HV[X, U1, U2, L1],u],{u,U2}] 









il cui determinante è:H2= aco afi - Subscript[a, 12]2 che è >0  se e solo se Subscript[a, 
12]2<aco afi cioè o a12< - o a12> . 
H3terapia=Take[hesicontrolli,3,3]; 
il cui determinante è: H3= - aib H2 che è <0 se e solo se H2 >0 e cioè se e solo se Subscript[a, 
12]2<aco afi cioè o a12< - o a12> . 
H4terapia=Take[hesicontrolli,4,4]; 
il cui determinante è H4= - aii H3= aii aib H2 che è >0 se e solo se H2 >0 e cioè se e solo se 
Subscript[a, 12]2<aco afi cioè o a12< - o a12> . 
H5terapia=Take[hesicontrolli,5,5]; 
il cui determinante è H5= - api H4= - api aii aib H2 che è <0 se e solo se H2 >0 e cioè se e solo 
se Subscript[a, 12]2<aco afi cioè o a12< - o a12> . 
H6terapia=hesicontrolli; 
il cui determinante è H6=  aib H2 [art api aii - Subscript[a, 56]2aii - Subscript[a, 46]2 api] che è 
>0 se e solo se {H2 >0 e [art api aii - Subscript[a, 56]2aii - Subscript[a, 46]2 api]>0}  e cioè se 
e solo se {Subscript[a, 12]2<aco afi cioè o a12< - o a12>  e  Subscript[a, 
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Riassumendo se accadesse che  {H2 >0 e [art api aii - Subscript[a, 56]2aii - Subscript[a, 46]2 
api]>0} allora la matrice hessiana relativa ai controlli della terapia sarebbe definita negativa, 
pertanto l'hamiltoniana sarebbe concava, e quindi le strategie ottime sarebbero: 
Subscript[u, i]*=min {1,max {0,ui^}} per i=1..6 
DET6=Det[H6terapia]//FullSimplify; 
 
equazioni del massimo separate per ESS 
sistmaxsep1={EQMAX1[XT[t],U1T[s], U2T[s], L1T[t]][[1]]==0,EQMAX1[XT[t],U1T[s], 
U2T[s], L1T[t]][[2]]==0, EQMAX1[XT[t],U1T[s], U2T[s], 
L1T[t]][[3]]==0,EQMAX1[XT[t],U1T[s], U2T[s], L1T[t]][[4]]==0,EQMAX1[XT[t],U1T[s], 
U2T[s], L1T[t]][[5]]==0,EQMAX1[XT[t],U1T[s], U2T[s], L1T[t]][[6]]==0}; 
sistmaxsep2={EQMAX2[XT[t],U1T[s], U2T[s], L2T[t]][[1]]==0, EQMAX2[XT[t],U1T[s], 
U2T[s], L2T[t]][[2]]==0  }; 
Timing[soleqmaxsep1=NSolve[sistmaxsep1, {U1T[s][[1]], U1T[s][[2]], U1T[s][[3]], 
U1T[s][[4]], U1T[s][[5]], U1T[s][[6]]}]//Simplify]; 
Timing[soleqmaxsep2=Solve[sistmaxsep2, {U2T[s][[1]], U2T[s][[2]]}]//FullSimplify]; 
vettsoless={1/aco k1s x26[t] ((1.` -1.` qthvs) l11[t] x1[t]-1.` (1.` -1.` qthvs) l18[t] x1[t]-1.` (1.` 
-1.` qtsvs) l112[t] x2[t]+(1.` -1.` qtsvs) l12[t] x2[t]-1.` (1.` -1.` qtrvs) l116[t] x3[t]+(1.` -1.` 
qtrvs) l13[t] x3[t]-1.` (1.` -1.` qtgvs) l120[t] x4[t]+(1.` -1.` qtgvs) l14[t] x4[t]+rhos l126[t] 
((1.` -1.` qthvs) x1[t]+(1.` -1.` qtsvs) x2[t]+(1.` -1.` qtrvs) x3[t]+(1.` -1.` qtgvs) x4[t])) (1.` -
(1.` k1s x26[t] (-1.` (1.` -1.` qthvs) l11[t] x1[t]+(1.` -1.` qthvs) l18[t] x1[t]+(1.` -1.` qtsvs) 
l112[t] x2[t]-1.` (1.` -1.` qtsvs) l12[t] x2[t]+(1.` -1.` qtrvs) l116[t] x3[t]-1.` (1.` -1.` qtrvs) 
l13[t] x3[t]+(1.` -1.` qtgvs) l120[t] x4[t]-1.` (1.` -1.` qtgvs) l14[t] x4[t]-1.` rhos l126[t] ((1.` -
C.1 MATHEMATICA FUNCTIONS FOR SYMBOLIC CALCULATION                113 
 
 
1.` qthvs) x1[t]+(1.` -1.` qtsvs) x2[t]+(1.` -1.` qtrvs) x3[t]+(1.` -1.` qtgvs) x4[t])) (-1.` aco-1.` 
k1s x26[t] (-1.` (1.` -1.` qthvs) l11[t] x1[t]+(1.` -1.` qthvs) l18[t] x1[t]+(1.` -1.` qtsvs) l112[t] 
x2[t]-1.` (1.` -1.` qtsvs) l12[t] x2[t]+(1.` -1.` qtrvs) l116[t] x3[t]-1.` (1.` -1.` qtrvs) l13[t] 
x3[t]+(1.` -1.` qtgvs) l120[t] x4[t]-1.` (1.` -1.` qtgvs) l14[t] x4[t]-1.` rhos l126[t] ((1.` -1.` 
qthvs) x1[t]+(1.` -1.` qtsvs) x2[t]+(1.` -1.` qtrvs) x3[t]+(1.` -1.` qtgvs) x4[t]))))/(1.` aco afi-1.` 
k1s2 x26[t]2 (-1.` (1.` -1.` qthvs) l11[t] x1[t]+(1.` -1.` qthvs) l18[t] x1[t]+(1.` -1.` qtsvs) 
l112[t] x2[t]-1.` (1.` -1.` qtsvs) l12[t] x2[t]+(1.` -1.` qtrvs) l116[t] x3[t]-1.` (1.` -1.` qtrvs) 
l13[t] x3[t]+(1.` -1.` qtgvs) l120[t] x4[t]-1.` (1.` -1.` qtgvs) l14[t] x4[t]-1.` rhos l126[t] ((1.` -
1.` qthvs) x1[t]+(1.` -1.` qtsvs) x2[t]+(1.` -1.` qtrvs) x3[t]+(1.` -1.` qtgvs) x4[t]))2)),-(k1s 
x26[t] ((1.` -1.` qthvs) l11[t] x1[t]-1.` (1.` -1.` qthvs) l18[t] x1[t]-1.` (1.` -1.` qtsvs) l112[t] 
x2[t]+(1.` -1.` qtsvs) l12[t] x2[t]-1.` (1.` -1.` qtrvs) l116[t] x3[t]+(1.` -1.` qtrvs) l13[t] x3[t]-1.` 
(1.` -1.` qtgvs) l120[t] x4[t]+(1.` -1.` qtgvs) l14[t] x4[t]+rhos l126[t] ((1.` -1.` qthvs) 
x1[t]+(1.` -1.` qtsvs) x2[t]+(1.` -1.` qtrvs) x3[t]+(1.` -1.` qtgvs) x4[t])) (-1.` aco-1.` k1s x26[t] 
(-1.` (1.` -1.` qthvs) l11[t] x1[t]+(1.` -1.` qthvs) l18[t] x1[t]+(1.` -1.` qtsvs) l112[t] x2[t]-1.` 
(1.` -1.` qtsvs) l12[t] x2[t]+(1.` -1.` qtrvs) l116[t] x3[t]-1.` (1.` -1.` qtrvs) l13[t] x3[t]+(1.` -1.` 
qtgvs) l120[t] x4[t]-1.` (1.` -1.` qtgvs) l14[t] x4[t]-1.` rhos l126[t] ((1.` -1.` qthvs) x1[t]+(1.` -
1.` qtsvs) x2[t]+(1.` -1.` qtrvs) x3[t]+(1.` -1.` qtgvs) x4[t]))))/(1.` aco afi-1.` k1s2 x26[t]2 (-1.` 
(1.` -1.` qthvs) l11[t] x1[t]+(1.` -1.` qthvs) l18[t] x1[t]+(1.` -1.` qtsvs) l112[t] x2[t]-1.` (1.` -1.` 
qtsvs) l12[t] x2[t]+(1.` -1.` qtrvs) l116[t] x3[t]-1.` (1.` -1.` qtrvs) l13[t] x3[t]+(1.` -1.` qtgvs) 
l120[t] x4[t]-1.` (1.` -1.` qtgvs) l14[t] x4[t]-1.` rhos l126[t] ((1.` -1.` qthvs) x1[t]+(1.` -1.` 
qtsvs) x2[t]+(1.` -1.` qtrvs) x3[t]+(1.` -1.` qtgvs) x4[t]))2),(1.` (l11[t] x1[t]+l12[t] x2[t]+l13[t] 
x3[t]+l14[t] x4[t]))/aib,1/aii (1.` k2 (l112[t] x12[t]-1.` l113[t] x12[t]+l116[t] x16[t]-1.` l117[t] 
x16[t]+l120[t] x20[t]-1.` l121[t] x20[t]+l18[t] x8[t]-1.` l19[t] x8[t])-(1.` k2 (-1.` l112[t] 
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x12[t]+l113[t] x12[t]-1.` l116[t] x16[t]+l117[t] x16[t]-1.` l120[t] x20[t]+l121[t] x20[t]-1.` 
l18[t] x8[t]+l19[t] x8[t]) (1.` api k22 (l112[t] x12[t]-1.` l113[t] x12[t]+l116[t] x16[t]-1.` 
l117[t] x16[t]+l120[t] x20[t]-1.` l121[t] x20[t]+l18[t] x8[t]-1.` l19[t] x8[t]) (-1.` l112[t] 
x12[t]+l113[t] x12[t]-1.` l116[t] x16[t]+l117[t] x16[t]-1.` l120[t] x20[t]+l121[t] x20[t]-1.` 
l18[t] x8[t]+l19[t] x8[t])-1.` aii (-1.` api (k2 l112[t] x12[t]-1.` k2 l113[t] x12[t]+k2 l116[t] 
x16[t]-1.` k2 l117[t] x16[t]+k2 l120[t] x20[t]-1.` k2 l121[t] x20[t]-1.` k1sm l124[t] x26[t] 
x5[t]+k1sm rhos l126[t] x26[t] x5[t]+k1sm l15[t] x26[t] x5[t]+k2 l18[t] x8[t]-1.` k2 l19[t] 
x8[t])-1.` k1sm (l124[t]-1.` rhos l126[t]-1.` l15[t]) x26[t] x5[t] (-1.` pr l126[t] (1.` -1.` u22[s]) 
(x11[t]+x15[t]+x19[t]+x23[t]+x25[t])-(1.` g l126[t] x26[t])/(b2+x26[t])-1.` k1sm l124[t] 
x26[t] x5[t]+k1sm rhos l126[t] x26[t] x5[t]+k1sm l15[t] x26[t] x5[t]-1.` ps l126[t] u21[s] 
(x13[t]+x17[t]+x21[t]+x24[t]+x9[t])))))/(-1.` aii (1.` api art-1.` k1sm2 (l124[t]-1.` rhos 
l126[t]-1.` l15[t])2 x26[t]2 x5[t]2)+1.` api k22 (-1.` l112[t] x12[t]+l113[t] x12[t]-1.` l116[t] 
x16[t]+l117[t] x16[t]-1.` l120[t] x20[t]+l121[t] x20[t]-1.` l18[t] x8[t]+l19[t] x8[t])2)),1/api 
(1.` (-1.` pr l126[t] (1.` -1.` u22[s]) (x11[t]+x15[t]+x19[t]+x23[t]+x25[t])-(1.` g l126[t] 
x26[t])/(b2+x26[t])-1.` k1sm l124[t] x26[t] x5[t]+k1sm rhos l126[t] x26[t] x5[t]+k1sm l15[t] 
x26[t] x5[t]-1.` ps l126[t] u21[s] (x13[t]+x17[t]+x21[t]+x24[t]+x9[t]))-(1.` k1sm (l124[t]-1.` 
rhos l126[t]-1.` l15[t]) x26[t] x5[t] (1.` api k22 (l112[t] x12[t]-1.` l113[t] x12[t]+l116[t] 
x16[t]-1.` l117[t] x16[t]+l120[t] x20[t]-1.` l121[t] x20[t]+l18[t] x8[t]-1.` l19[t] x8[t]) (-1.` 
l112[t] x12[t]+l113[t] x12[t]-1.` l116[t] x16[t]+l117[t] x16[t]-1.` l120[t] x20[t]+l121[t] 
x20[t]-1.` l18[t] x8[t]+l19[t] x8[t])-1.` aii (-1.` api (k2 l112[t] x12[t]-1.` k2 l113[t] x12[t]+k2 
l116[t] x16[t]-1.` k2 l117[t] x16[t]+k2 l120[t] x20[t]-1.` k2 l121[t] x20[t]-1.` k1sm l124[t] 
x26[t] x5[t]+k1sm rhos l126[t] x26[t] x5[t]+k1sm l15[t] x26[t] x5[t]+k2 l18[t] x8[t]-1.` k2 
l19[t] x8[t])-1.` k1sm (l124[t]-1.` rhos l126[t]-1.` l15[t]) x26[t] x5[t] (-1.` pr l126[t] (1.` -1.` 
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u22[s]) (x11[t]+x15[t]+x19[t]+x23[t]+x25[t])-(1.` g l126[t] x26[t])/(b2+x26[t])-1.` k1sm 
l124[t] x26[t] x5[t]+k1sm rhos l126[t] x26[t] x5[t]+k1sm l15[t] x26[t] x5[t]-1.` ps l126[t] 
u21[s] (x13[t]+x17[t]+x21[t]+x24[t]+x9[t])))))/(-1.` aii (1.` api art-1.` k1sm2 (l124[t]-1.` rhos 
l126[t]-1.` l15[t])2 x26[t]2 x5[t]2)+1.` api k22 (-1.` l112[t] x12[t]+l113[t] x12[t]-1.` l116[t] 
x16[t]+l117[t] x16[t]-1.` l120[t] x20[t]+l121[t] x20[t]-1.` l18[t] x8[t]+l19[t] x8[t])2)),-(1.` api 
k22 (l112[t] x12[t]-1.` l113[t] x12[t]+l116[t] x16[t]-1.` l117[t] x16[t]+l120[t] x20[t]-1.` 
l121[t] x20[t]+l18[t] x8[t]-1.` l19[t] x8[t]) (-1.` l112[t] x12[t]+l113[t] x12[t]-1.` l116[t] 
x16[t]+l117[t] x16[t]-1.` l120[t] x20[t]+l121[t] x20[t]-1.` l18[t] x8[t]+l19[t] x8[t])-1.` aii (-1.` 
api (k2 l112[t] x12[t]-1.` k2 l113[t] x12[t]+k2 l116[t] x16[t]-1.` k2 l117[t] x16[t]+k2 l120[t] 
x20[t]-1.` k2 l121[t] x20[t]-1.` k1sm l124[t] x26[t] x5[t]+k1sm rhos l126[t] x26[t] x5[t]+k1sm 
l15[t] x26[t] x5[t]+k2 l18[t] x8[t]-1.` k2 l19[t] x8[t])-1.` k1sm (l124[t]-1.` rhos l126[t]-1.` 
l15[t]) x26[t] x5[t] (-1.` pr l126[t] (1.` -1.` u22[s]) (x11[t]+x15[t]+x19[t]+x23[t]+x25[t])-(1.` 
g l126[t] x26[t])/(b2+x26[t])-1.` k1sm l124[t] x26[t] x5[t]+k1sm rhos l126[t] x26[t] 
x5[t]+k1sm l15[t] x26[t] x5[t]-1.` ps l126[t] u21[s] (x13[t]+x17[t]+x21[t]+x24[t]+x9[t]))))/(-
1.` aii (1.` api art-1.` k1sm2 (l124[t]-1.` rhos l126[t]-1.` l15[t])2 x26[t]2 x5[t]2)+1.` api k22 (-1.` 
l112[t] x12[t]+l113[t] x12[t]-1.` l116[t] x16[t]+l117[t] x16[t]-1.` l120[t] x20[t]+l121[t] 
x20[t]-1.` l18[t] x8[t]+l19[t] x8[t])2),-(1/bsr)1.` (-1.` bsr+1.` ps l227[t] 
(x13[t]+x17[t]+x21[t]+x24[t]+x9[t])-1.` ps l226[t] (1.` -1.` u15[s]) 
(x13[t]+x17[t]+x21[t]+x24[t]+x9[t])),-(1/brs)1.` (-1.` brs-1.` pr l227[t] 
(x11[t]+x15[t]+x19[t]+x23[t]+x25[t])+1.` pr l226[t] (1.` -1.` u15[s]) 
(x11[t]+x15[t]+x19[t]+x23[t]+x25[t])) }; 
UESS={U1T[s][[1]], U1T[s][[2]], U1T[s][[3]], U1T[s][[4]], U1T[s][[5]], 
U1T[s][[6]],U2T[s][[1]], U2T[s][[2]] }; 
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jac=Table[D[vettsoless[[i]], u], {i, 1, 8}, {u,UESS}]//FullSimplify; 
condESSperriga=Table[Sum[Abs[jac[[i,j]]],{j,1,8}],{i,1,8}]//Simplify; 
 
equazioni del massimo unite per controlli ottimi 
sistmax={EQMAX1[XT[t],U1T[t], U2T[t], L1T[t]][[1]]==0,EQMAX1[XT[t],U1T[t], U2T[t], 
L1T[t]][[2]]==0, EQMAX1[XT[t],U1T[t], U2T[t], L1T[t]][[3]]==0,EQMAX1[XT[t],U1T[t], 
U2T[t], L1T[t]][[4]]==0,EQMAX1[XT[t],U1T[t], U2T[t], 
L1T[t]][[5]]==0,EQMAX1[XT[t],U1T[t], U2T[t], L1T[t]][[6]]==0,EQMAX2[XT[t],U1T[t], 
U2T[t], L2T[t]][[1]]==0, EQMAX2[XT[t],U1T[t], U2T[t], L2T[t]][[2]]==0  }; 
Timing[soleqmax=NSolve[sistmax, {U1T[t][[1]], U1T[t][[2]], U1T[t][[3]], U1T[t][[4]], 
U1T[t][[5]],U1T[t][[6]],U2T[t][[1]], U2T[t][[2]]}]]; 
soleqmax={{u11[t]->1/aco 1.` (k1s (1.` -1.` qthvs) l11[t] x1[t] x26[t]-1.` k1s (1.` -1.` qthvs) 
l18[t] x1[t] x26[t]-1.` k1s (1.` -1.` qtsvs) l112[t] x2[t] x26[t]+k1s (1.` -1.` qtsvs) l12[t] x2[t] 
x26[t]-1.` k1s (1.` -1.` qtrvs) l116[t] x26[t] x3[t]+k1s (1.` -1.` qtrvs) l13[t] x26[t] x3[t]-1.` k1s 
(1.` -1.` qtgvs) l120[t] x26[t] x4[t]+k1s (1.` -1.` qtgvs) l14[t] x26[t] x4[t]+k1s rhos l126[t] 
x26[t] ((1.` -1.` qthvs) x1[t]+(1.` -1.` qtsvs) x2[t]+(1.` -1.` qtrvs) x3[t]+(1.` -1.` qtgvs) x4[t]))-
(1.` (-1.` k1s (1.` -1.` qthvs) l11[t] x1[t] x26[t]+k1s (1.` -1.` qthvs) l18[t] x1[t] x26[t]+k1s (1.` 
-1.` qtsvs) l112[t] x2[t] x26[t]-1.` k1s (1.` -1.` qtsvs) l12[t] x2[t] x26[t]+k1s (1.` -1.` qtrvs) 
l116[t] x26[t] x3[t]-1.` k1s (1.` -1.` qtrvs) l13[t] x26[t] x3[t]+k1s (1.` -1.` qtgvs) l120[t] x26[t] 
x4[t]-1.` k1s (1.` -1.` qtgvs) l14[t] x26[t] x4[t]-1.` k1s rhos l126[t] x26[t] ((1.` -1.` qthvs) 
x1[t]+(1.` -1.` qtsvs) x2[t]+(1.` -1.` qtrvs) x3[t]+(1.` -1.` qtgvs) x4[t])) (-1.` aco (k1s (1.` -1.` 
qthvs) l11[t] x1[t] x26[t]-1.` k1s (1.` -1.` qthvs) l18[t] x1[t] x26[t]-1.` k1s (1.` -1.` qtsvs) 
l112[t] x2[t] x26[t]+k1s (1.` -1.` qtsvs) l12[t] x2[t] x26[t]-1.` k1s (1.` -1.` qtrvs) l116[t] x26[t] 
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x3[t]+k1s (1.` -1.` qtrvs) l13[t] x26[t] x3[t]-1.` k1s (1.` -1.` qtgvs) l120[t] x26[t] x4[t]+k1s (1.` 
-1.` qtgvs) l14[t] x26[t] x4[t]+k1s rhos l126[t] x26[t] ((1.` -1.` qthvs) x1[t]+(1.` -1.` qtsvs) 
x2[t]+(1.` -1.` qtrvs) x3[t]+(1.` -1.` qtgvs) x4[t]))-1.` (-1.` k1s (1.` -1.` qthvs) l11[t] x1[t] 
x26[t]+k1s (1.` -1.` qthvs) l18[t] x1[t] x26[t]+k1s (1.` -1.` qtsvs) l112[t] x2[t] x26[t]-1.` k1s 
(1.` -1.` qtsvs) l12[t] x2[t] x26[t]+k1s (1.` -1.` qtrvs) l116[t] x26[t] x3[t]-1.` k1s (1.` -1.` qtrvs) 
l13[t] x26[t] x3[t]+k1s (1.` -1.` qtgvs) l120[t] x26[t] x4[t]-1.` k1s (1.` -1.` qtgvs) l14[t] x26[t] 
x4[t]-1.` k1s rhos l126[t] x26[t] ((1.` -1.` qthvs) x1[t]+(1.` -1.` qtsvs) x2[t]+(1.` -1.` qtrvs) 
x3[t]+(1.` -1.` qtgvs) x4[t])) (k1s (1.` -1.` qthvs) l11[t] x1[t] x26[t]-1.` k1s (1.` -1.` qthvs) 
l18[t] x1[t] x26[t]-1.` k1s (1.` -1.` qtsvs) l112[t] x2[t] x26[t]+k1s (1.` -1.` qtsvs) l12[t] x2[t] 
x26[t]-1.` k1s (1.` -1.` qtrvs) l116[t] x26[t] x3[t]+k1s (1.` -1.` qtrvs) l13[t] x26[t] x3[t]-1.` k1s 
(1.` -1.` qtgvs) l120[t] x26[t] x4[t]+k1s (1.` -1.` qtgvs) l14[t] x26[t] x4[t]+k1s rhos l126[t] 
x26[t] ((1.` -1.` qthvs) x1[t]+(1.` -1.` qtsvs) x2[t]+(1.` -1.` qtrvs) x3[t]+(1.` -1.` qtgvs) 
x4[t]))))/(aco (1.` aco afi-1.` (-1.` k1s (1.` -1.` qthvs) l11[t] x1[t] x26[t]+k1s (1.` -1.` qthvs) 
l18[t] x1[t] x26[t]+k1s (1.` -1.` qtsvs) l112[t] x2[t] x26[t]-1.` k1s (1.` -1.` qtsvs) l12[t] x2[t] 
x26[t]+k1s (1.` -1.` qtrvs) l116[t] x26[t] x3[t]-1.` k1s (1.` -1.` qtrvs) l13[t] x26[t] x3[t]+k1s 
(1.` -1.` qtgvs) l120[t] x26[t] x4[t]-1.` k1s (1.` -1.` qtgvs) l14[t] x26[t] x4[t]-1.` k1s rhos 
l126[t] x26[t] ((1.` -1.` qthvs) x1[t]+(1.` -1.` qtsvs) x2[t]+(1.` -1.` qtrvs) x3[t]+(1.` -1.` qtgvs) 
x4[t]))2)),u12[t]->-(-1.` aco (k1s (1.` -1.` qthvs) l11[t] x1[t] x26[t]-1.` k1s (1.` -1.` qthvs) 
l18[t] x1[t] x26[t]-1.` k1s (1.` -1.` qtsvs) l112[t] x2[t] x26[t]+k1s (1.` -1.` qtsvs) l12[t] x2[t] 
x26[t]-1.` k1s (1.` -1.` qtrvs) l116[t] x26[t] x3[t]+k1s (1.` -1.` qtrvs) l13[t] x26[t] x3[t]-1.` k1s 
(1.` -1.` qtgvs) l120[t] x26[t] x4[t]+k1s (1.` -1.` qtgvs) l14[t] x26[t] x4[t]+k1s rhos l126[t] 
x26[t] ((1.` -1.` qthvs) x1[t]+(1.` -1.` qtsvs) x2[t]+(1.` -1.` qtrvs) x3[t]+(1.` -1.` qtgvs) x4[t]))-
1.` (-1.` k1s (1.` -1.` qthvs) l11[t] x1[t] x26[t]+k1s (1.` -1.` qthvs) l18[t] x1[t] x26[t]+k1s (1.` -
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1.` qtsvs) l112[t] x2[t] x26[t]-1.` k1s (1.` -1.` qtsvs) l12[t] x2[t] x26[t]+k1s (1.` -1.` qtrvs) 
l116[t] x26[t] x3[t]-1.` k1s (1.` -1.` qtrvs) l13[t] x26[t] x3[t]+k1s (1.` -1.` qtgvs) l120[t] x26[t] 
x4[t]-1.` k1s (1.` -1.` qtgvs) l14[t] x26[t] x4[t]-1.` k1s rhos l126[t] x26[t] ((1.` -1.` qthvs) 
x1[t]+(1.` -1.` qtsvs) x2[t]+(1.` -1.` qtrvs) x3[t]+(1.` -1.` qtgvs) x4[t])) (k1s (1.` -1.` qthvs) 
l11[t] x1[t] x26[t]-1.` k1s (1.` -1.` qthvs) l18[t] x1[t] x26[t]-1.` k1s (1.` -1.` qtsvs) l112[t] 
x2[t] x26[t]+k1s (1.` -1.` qtsvs) l12[t] x2[t] x26[t]-1.` k1s (1.` -1.` qtrvs) l116[t] x26[t] 
x3[t]+k1s (1.` -1.` qtrvs) l13[t] x26[t] x3[t]-1.` k1s (1.` -1.` qtgvs) l120[t] x26[t] x4[t]+k1s (1.` 
-1.` qtgvs) l14[t] x26[t] x4[t]+k1s rhos l126[t] x26[t] ((1.` -1.` qthvs) x1[t]+(1.` -1.` qtsvs) 
x2[t]+(1.` -1.` qtrvs) x3[t]+(1.` -1.` qtgvs) x4[t])))/(1.` aco afi-1.` (-1.` k1s (1.` -1.` qthvs) 
l11[t] x1[t] x26[t]+k1s (1.` -1.` qthvs) l18[t] x1[t] x26[t]+k1s (1.` -1.` qtsvs) l112[t] x2[t] 
x26[t]-1.` k1s (1.` -1.` qtsvs) l12[t] x2[t] x26[t]+k1s (1.` -1.` qtrvs) l116[t] x26[t] x3[t]-1.` k1s 
(1.` -1.` qtrvs) l13[t] x26[t] x3[t]+k1s (1.` -1.` qtgvs) l120[t] x26[t] x4[t]-1.` k1s (1.` -1.` 
qtgvs) l14[t] x26[t] x4[t]-1.` k1s rhos l126[t] x26[t] ((1.` -1.` qthvs) x1[t]+(1.` -1.` qtsvs) 
x2[t]+(1.` -1.` qtrvs) x3[t]+(1.` -1.` qtgvs) x4[t]))2),u13[t]->(1.` (l11[t] x1[t]+l12[t] 
x2[t]+l13[t] x3[t]+l14[t] x4[t]))/aib,u14[t]->1/aii 1.` (k2 l112[t] x12[t]-1.` k2 l113[t] 
x12[t]+k2 l116[t] x16[t]-1.` k2 l117[t] x16[t]+k2 l120[t] x20[t]-1.` k2 l121[t] x20[t]+k2 l18[t] 
x8[t]-1.` k2 l19[t] x8[t])-1/aii 1.` (-1.` k2 l112[t] x12[t]+k2 l113[t] x12[t]-1.` k2 l116[t] 
x16[t]+k2 l117[t] x16[t]-1.` k2 l120[t] x20[t]+k2 l121[t] x20[t]-1.` k2 l18[t] x8[t]+k2 l19[t] 
x8[t]) ((1.` (1.` bsr pr l126[t] (x11[t]+x15[t]+x19[t]+x23[t]+x25[t]) (1.` brs-1.` pr l226[t] 
(x11[t]+x15[t]+x19[t]+x23[t]+x25[t])+pr l227[t] (x11[t]+x15[t]+x19[t]+x23[t]+x25[t]))-1.` 
brs (-1.` bsr (-1.` pr l126[t] (x11[t]+x15[t]+x19[t]+x23[t]+x25[t])-(1.` g l126[t] 
x26[t])/(b2+x26[t])-1.` k1sm l124[t] x26[t] x5[t]+k1sm rhos l126[t] x26[t] x5[t]+k1sm l15[t] 
x26[t] x5[t])+1.` ps l126[t] (x13[t]+x17[t]+x21[t]+x24[t]+x9[t]) (1.` bsr+ps l226[t] 
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(x13[t]+x17[t]+x21[t]+x24[t]+x9[t])-1.` ps l227[t] 
(x13[t]+x17[t]+x21[t]+x24[t]+x9[t])))))/(brs bsr (k1sm l124[t] x26[t] x5[t]-1.` k1sm rhos 
l126[t] x26[t] x5[t]-1.` k1sm l15[t] x26[t] x5[t]))-(1.` (1.` bsr pr2 l126[t] l226[t] 
(x11[t]+x15[t]+x19[t]+x23[t]+x25[t])2-1.` brs (1.` api bsr-1.` ps2 l126[t] l226[t] 
(x13[t]+x17[t]+x21[t]+x24[t]+x9[t])2)) (1.` brs bsr (k1sm l124[t] x26[t] x5[t]-1.` k1sm rhos 
l126[t] x26[t] x5[t]-1.` k1sm l15[t] x26[t] x5[t]) (-1.` aii (k2 l112[t] x12[t]-1.` k2 l113[t] 
x12[t]+k2 l116[t] x16[t]-1.` k2 l117[t] x16[t]+k2 l120[t] x20[t]-1.` k2 l121[t] x20[t]-1.` k1sm 
l124[t] x26[t] x5[t]+k1sm rhos l126[t] x26[t] x5[t]+k1sm l15[t] x26[t] x5[t]+k2 l18[t] x8[t]-
1.` k2 l19[t] x8[t])-1.` (k2 l112[t] x12[t]-1.` k2 l113[t] x12[t]+k2 l116[t] x16[t]-1.` k2 l117[t] 
x16[t]+k2 l120[t] x20[t]-1.` k2 l121[t] x20[t]+k2 l18[t] x8[t]-1.` k2 l19[t] x8[t]) (-1.` k2 
l112[t] x12[t]+k2 l113[t] x12[t]-1.` k2 l116[t] x16[t]+k2 l117[t] x16[t]-1.` k2 l120[t] 
x20[t]+k2 l121[t] x20[t]-1.` k2 l18[t] x8[t]+k2 l19[t] x8[t]))-1.` (1.` aii art-1.` (-1.` k2 l112[t] 
x12[t]+k2 l113[t] x12[t]-1.` k2 l116[t] x16[t]+k2 l117[t] x16[t]-1.` k2 l120[t] x20[t]+k2 
l121[t] x20[t]-1.` k2 l18[t] x8[t]+k2 l19[t] x8[t])2) (1.` bsr pr l126[t] 
(x11[t]+x15[t]+x19[t]+x23[t]+x25[t]) (1.` brs-1.` pr l226[t] 
(x11[t]+x15[t]+x19[t]+x23[t]+x25[t])+pr l227[t] (x11[t]+x15[t]+x19[t]+x23[t]+x25[t]))-1.` 
brs (-1.` bsr (-1.` pr l126[t] (x11[t]+x15[t]+x19[t]+x23[t]+x25[t])-(1.` g l126[t] 
x26[t])/(b2+x26[t])-1.` k1sm l124[t] x26[t] x5[t]+k1sm rhos l126[t] x26[t] x5[t]+k1sm l15[t] 
x26[t] x5[t])+1.` ps l126[t] (x13[t]+x17[t]+x21[t]+x24[t]+x9[t]) (1.` bsr+ps l226[t] 
(x13[t]+x17[t]+x21[t]+x24[t]+x9[t])-1.` ps l227[t] 
(x13[t]+x17[t]+x21[t]+x24[t]+x9[t]))))))/(brs bsr (k1sm l124[t] x26[t] x5[t]-1.` k1sm rhos 
l126[t] x26[t] x5[t]-1.` k1sm l15[t] x26[t] x5[t]) (-1.` aii brs bsr (k1sm l124[t] x26[t] x5[t]-1.` 
k1sm rhos l126[t] x26[t] x5[t]-1.` k1sm l15[t] x26[t] x5[t])2-1.` (1.` aii art-1.` (-1.` k2 l112[t] 
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x12[t]+k2 l113[t] x12[t]-1.` k2 l116[t] x16[t]+k2 l117[t] x16[t]-1.` k2 l120[t] x20[t]+k2 
l121[t] x20[t]-1.` k2 l18[t] x8[t]+k2 l19[t] x8[t])2) (1.` bsr pr2 l126[t] l226[t] 
(x11[t]+x15[t]+x19[t]+x23[t]+x25[t])2-1.` brs (1.` api bsr-1.` ps2 l126[t] l226[t] 
(x13[t]+x17[t]+x21[t]+x24[t]+x9[t])2))))),u15[t]->-(1.` brs bsr (k1sm l124[t] x26[t] x5[t]-1.` 
k1sm rhos l126[t] x26[t] x5[t]-1.` k1sm l15[t] x26[t] x5[t]) (-1.` aii (k2 l112[t] x12[t]-1.` k2 
l113[t] x12[t]+k2 l116[t] x16[t]-1.` k2 l117[t] x16[t]+k2 l120[t] x20[t]-1.` k2 l121[t] x20[t]-
1.` k1sm l124[t] x26[t] x5[t]+k1sm rhos l126[t] x26[t] x5[t]+k1sm l15[t] x26[t] x5[t]+k2 
l18[t] x8[t]-1.` k2 l19[t] x8[t])-1.` (k2 l112[t] x12[t]-1.` k2 l113[t] x12[t]+k2 l116[t] x16[t]-1.` 
k2 l117[t] x16[t]+k2 l120[t] x20[t]-1.` k2 l121[t] x20[t]+k2 l18[t] x8[t]-1.` k2 l19[t] x8[t]) (-
1.` k2 l112[t] x12[t]+k2 l113[t] x12[t]-1.` k2 l116[t] x16[t]+k2 l117[t] x16[t]-1.` k2 l120[t] 
x20[t]+k2 l121[t] x20[t]-1.` k2 l18[t] x8[t]+k2 l19[t] x8[t]))-1.` (1.` aii art-1.` (-1.` k2 l112[t] 
x12[t]+k2 l113[t] x12[t]-1.` k2 l116[t] x16[t]+k2 l117[t] x16[t]-1.` k2 l120[t] x20[t]+k2 
l121[t] x20[t]-1.` k2 l18[t] x8[t]+k2 l19[t] x8[t])2) (1.` bsr pr l126[t] 
(x11[t]+x15[t]+x19[t]+x23[t]+x25[t]) (1.` brs-1.` pr l226[t] 
(x11[t]+x15[t]+x19[t]+x23[t]+x25[t])+pr l227[t] (x11[t]+x15[t]+x19[t]+x23[t]+x25[t]))-1.` 
brs (-1.` bsr (-1.` pr l126[t] (x11[t]+x15[t]+x19[t]+x23[t]+x25[t])-(1.` g l126[t] 
x26[t])/(b2+x26[t])-1.` k1sm l124[t] x26[t] x5[t]+k1sm rhos l126[t] x26[t] x5[t]+k1sm l15[t] 
x26[t] x5[t])+1.` ps l126[t] (x13[t]+x17[t]+x21[t]+x24[t]+x9[t]) (1.` bsr+ps l226[t] 
(x13[t]+x17[t]+x21[t]+x24[t]+x9[t])-1.` ps l227[t] (x13[t]+x17[t]+x21[t]+x24[t]+x9[t])))))/(-
1.` aii brs bsr (k1sm l124[t] x26[t] x5[t]-1.` k1sm rhos l126[t] x26[t] x5[t]-1.` k1sm l15[t] 
x26[t] x5[t])2-1.` (1.` aii art-1.` (-1.` k2 l112[t] x12[t]+k2 l113[t] x12[t]-1.` k2 l116[t] 
x16[t]+k2 l117[t] x16[t]-1.` k2 l120[t] x20[t]+k2 l121[t] x20[t]-1.` k2 l18[t] x8[t]+k2 l19[t] 
x8[t])2) (1.` bsr pr2 l126[t] l226[t] (x11[t]+x15[t]+x19[t]+x23[t]+x25[t])2-1.` brs (1.` api bsr-
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1.` ps2 l126[t] l226[t] (x13[t]+x17[t]+x21[t]+x24[t]+x9[t])2))),u16[t]->-(1.` (1.` bsr pr l126[t] 
(x11[t]+x15[t]+x19[t]+x23[t]+x25[t]) (1.` brs-1.` pr l226[t] 
(x11[t]+x15[t]+x19[t]+x23[t]+x25[t])+pr l227[t] (x11[t]+x15[t]+x19[t]+x23[t]+x25[t]))-1.` 
brs (-1.` bsr (-1.` pr l126[t] (x11[t]+x15[t]+x19[t]+x23[t]+x25[t])-(1.` g l126[t] 
x26[t])/(b2+x26[t])-1.` k1sm l124[t] x26[t] x5[t]+k1sm rhos l126[t] x26[t] x5[t]+k1sm l15[t] 
x26[t] x5[t])+1.` ps l126[t] (x13[t]+x17[t]+x21[t]+x24[t]+x9[t]) (1.` bsr+ps l226[t] 
(x13[t]+x17[t]+x21[t]+x24[t]+x9[t])-1.` ps l227[t] 
(x13[t]+x17[t]+x21[t]+x24[t]+x9[t])))))/(brs bsr (k1sm l124[t] x26[t] x5[t]-1.` k1sm rhos 
l126[t] x26[t] x5[t]-1.` k1sm l15[t] x26[t] x5[t]))+(1.` (1.` bsr pr2 l126[t] l226[t] 
(x11[t]+x15[t]+x19[t]+x23[t]+x25[t])2-1.` brs (1.` api bsr-1.` ps2 l126[t] l226[t] 
(x13[t]+x17[t]+x21[t]+x24[t]+x9[t])2)) (1.` brs bsr (k1sm l124[t] x26[t] x5[t]-1.` k1sm rhos 
l126[t] x26[t] x5[t]-1.` k1sm l15[t] x26[t] x5[t]) (-1.` aii (k2 l112[t] x12[t]-1.` k2 l113[t] 
x12[t]+k2 l116[t] x16[t]-1.` k2 l117[t] x16[t]+k2 l120[t] x20[t]-1.` k2 l121[t] x20[t]-1.` k1sm 
l124[t] x26[t] x5[t]+k1sm rhos l126[t] x26[t] x5[t]+k1sm l15[t] x26[t] x5[t]+k2 l18[t] x8[t]-
1.` k2 l19[t] x8[t])-1.` (k2 l112[t] x12[t]-1.` k2 l113[t] x12[t]+k2 l116[t] x16[t]-1.` k2 l117[t] 
x16[t]+k2 l120[t] x20[t]-1.` k2 l121[t] x20[t]+k2 l18[t] x8[t]-1.` k2 l19[t] x8[t]) (-1.` k2 
l112[t] x12[t]+k2 l113[t] x12[t]-1.` k2 l116[t] x16[t]+k2 l117[t] x16[t]-1.` k2 l120[t] 
x20[t]+k2 l121[t] x20[t]-1.` k2 l18[t] x8[t]+k2 l19[t] x8[t]))-1.` (1.` aii art-1.` (-1.` k2 l112[t] 
x12[t]+k2 l113[t] x12[t]-1.` k2 l116[t] x16[t]+k2 l117[t] x16[t]-1.` k2 l120[t] x20[t]+k2 
l121[t] x20[t]-1.` k2 l18[t] x8[t]+k2 l19[t] x8[t])2) (1.` bsr pr l126[t] 
(x11[t]+x15[t]+x19[t]+x23[t]+x25[t]) (1.` brs-1.` pr l226[t] 
(x11[t]+x15[t]+x19[t]+x23[t]+x25[t])+pr l227[t] (x11[t]+x15[t]+x19[t]+x23[t]+x25[t]))-1.` 
brs (-1.` bsr (-1.` pr l126[t] (x11[t]+x15[t]+x19[t]+x23[t]+x25[t])-(1.` g l126[t] 
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x26[t])/(b2+x26[t])-1.` k1sm l124[t] x26[t] x5[t]+k1sm rhos l126[t] x26[t] x5[t]+k1sm l15[t] 
x26[t] x5[t])+1.` ps l126[t] (x13[t]+x17[t]+x21[t]+x24[t]+x9[t]) (1.` bsr+ps l226[t] 
(x13[t]+x17[t]+x21[t]+x24[t]+x9[t])-1.` ps l227[t] 
(x13[t]+x17[t]+x21[t]+x24[t]+x9[t]))))))/(brs bsr (k1sm l124[t] x26[t] x5[t]-1.` k1sm rhos 
l126[t] x26[t] x5[t]-1.` k1sm l15[t] x26[t] x5[t]) (-1.` aii brs bsr (k1sm l124[t] x26[t] x5[t]-1.` 
k1sm rhos l126[t] x26[t] x5[t]-1.` k1sm l15[t] x26[t] x5[t])2-1.` (1.` aii art-1.` (-1.` k2 l112[t] 
x12[t]+k2 l113[t] x12[t]-1.` k2 l116[t] x16[t]+k2 l117[t] x16[t]-1.` k2 l120[t] x20[t]+k2 
l121[t] x20[t]-1.` k2 l18[t] x8[t]+k2 l19[t] x8[t])2) (1.` bsr pr2 l126[t] l226[t] 
(x11[t]+x15[t]+x19[t]+x23[t]+x25[t])2-1.` brs (1.` api bsr-1.` ps2 l126[t] l226[t] 
(x13[t]+x17[t]+x21[t]+x24[t]+x9[t])2)))),u21[t]->1/bsr 1.` (1.` bsr+ps l226[t] 
(x13[t]+x17[t]+x21[t]+x24[t]+x9[t])-1.` ps l227[t] (x13[t]+x17[t]+x21[t]+x24[t]+x9[t]))+(1.` 
ps l226[t] (x13[t]+x17[t]+x21[t]+x24[t]+x9[t]) (1.` brs bsr (k1sm l124[t] x26[t] x5[t]-1.` 
k1sm rhos l126[t] x26[t] x5[t]-1.` k1sm l15[t] x26[t] x5[t]) (-1.` aii (k2 l112[t] x12[t]-1.` k2 
l113[t] x12[t]+k2 l116[t] x16[t]-1.` k2 l117[t] x16[t]+k2 l120[t] x20[t]-1.` k2 l121[t] x20[t]-
1.` k1sm l124[t] x26[t] x5[t]+k1sm rhos l126[t] x26[t] x5[t]+k1sm l15[t] x26[t] x5[t]+k2 
l18[t] x8[t]-1.` k2 l19[t] x8[t])-1.` (k2 l112[t] x12[t]-1.` k2 l113[t] x12[t]+k2 l116[t] x16[t]-1.` 
k2 l117[t] x16[t]+k2 l120[t] x20[t]-1.` k2 l121[t] x20[t]+k2 l18[t] x8[t]-1.` k2 l19[t] x8[t]) (-
1.` k2 l112[t] x12[t]+k2 l113[t] x12[t]-1.` k2 l116[t] x16[t]+k2 l117[t] x16[t]-1.` k2 l120[t] 
x20[t]+k2 l121[t] x20[t]-1.` k2 l18[t] x8[t]+k2 l19[t] x8[t]))-1.` (1.` aii art-1.` (-1.` k2 l112[t] 
x12[t]+k2 l113[t] x12[t]-1.` k2 l116[t] x16[t]+k2 l117[t] x16[t]-1.` k2 l120[t] x20[t]+k2 
l121[t] x20[t]-1.` k2 l18[t] x8[t]+k2 l19[t] x8[t])2) (1.` bsr pr l126[t] 
(x11[t]+x15[t]+x19[t]+x23[t]+x25[t]) (1.` brs-1.` pr l226[t] 
(x11[t]+x15[t]+x19[t]+x23[t]+x25[t])+pr l227[t] (x11[t]+x15[t]+x19[t]+x23[t]+x25[t]))-1.` 
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brs (-1.` bsr (-1.` pr l126[t] (x11[t]+x15[t]+x19[t]+x23[t]+x25[t])-(1.` g l126[t] 
x26[t])/(b2+x26[t])-1.` k1sm l124[t] x26[t] x5[t]+k1sm rhos l126[t] x26[t] x5[t]+k1sm l15[t] 
x26[t] x5[t])+1.` ps l126[t] (x13[t]+x17[t]+x21[t]+x24[t]+x9[t]) (1.` bsr+ps l226[t] 
(x13[t]+x17[t]+x21[t]+x24[t]+x9[t])-1.` ps l227[t] 
(x13[t]+x17[t]+x21[t]+x24[t]+x9[t]))))))/(bsr (-1.` aii brs bsr (k1sm l124[t] x26[t] x5[t]-1.` 
k1sm rhos l126[t] x26[t] x5[t]-1.` k1sm l15[t] x26[t] x5[t])2-1.` (1.` aii art-1.` (-1.` k2 l112[t] 
x12[t]+k2 l113[t] x12[t]-1.` k2 l116[t] x16[t]+k2 l117[t] x16[t]-1.` k2 l120[t] x20[t]+k2 
l121[t] x20[t]-1.` k2 l18[t] x8[t]+k2 l19[t] x8[t])2) (1.` bsr pr2 l126[t] l226[t] 
(x11[t]+x15[t]+x19[t]+x23[t]+x25[t])2-1.` brs (1.` api bsr-1.` ps2 l126[t] l226[t] 
(x13[t]+x17[t]+x21[t]+x24[t]+x9[t])2)))),u22[t]->1/brs 1.` (1.` brs-1.` pr l226[t] 
(x11[t]+x15[t]+x19[t]+x23[t]+x25[t])+pr l227[t] (x11[t]+x15[t]+x19[t]+x23[t]+x25[t]))-(1.` 
pr l226[t] (x11[t]+x15[t]+x19[t]+x23[t]+x25[t]) (1.` brs bsr (k1sm l124[t] x26[t] x5[t]-1.` 
k1sm rhos l126[t] x26[t] x5[t]-1.` k1sm l15[t] x26[t] x5[t]) (-1.` aii (k2 l112[t] x12[t]-1.` k2 
l113[t] x12[t]+k2 l116[t] x16[t]-1.` k2 l117[t] x16[t]+k2 l120[t] x20[t]-1.` k2 l121[t] x20[t]-
1.` k1sm l124[t] x26[t] x5[t]+k1sm rhos l126[t] x26[t] x5[t]+k1sm l15[t] x26[t] x5[t]+k2 
l18[t] x8[t]-1.` k2 l19[t] x8[t])-1.` (k2 l112[t] x12[t]-1.` k2 l113[t] x12[t]+k2 l116[t] x16[t]-1.` 
k2 l117[t] x16[t]+k2 l120[t] x20[t]-1.` k2 l121[t] x20[t]+k2 l18[t] x8[t]-1.` k2 l19[t] x8[t]) (-
1.` k2 l112[t] x12[t]+k2 l113[t] x12[t]-1.` k2 l116[t] x16[t]+k2 l117[t] x16[t]-1.` k2 l120[t] 
x20[t]+k2 l121[t] x20[t]-1.` k2 l18[t] x8[t]+k2 l19[t] x8[t]))-1.` (1.` aii art-1.` (-1.` k2 l112[t] 
x12[t]+k2 l113[t] x12[t]-1.` k2 l116[t] x16[t]+k2 l117[t] x16[t]-1.` k2 l120[t] x20[t]+k2 
l121[t] x20[t]-1.` k2 l18[t] x8[t]+k2 l19[t] x8[t])2) (1.` bsr pr l126[t] 
(x11[t]+x15[t]+x19[t]+x23[t]+x25[t]) (1.` brs-1.` pr l226[t] 
(x11[t]+x15[t]+x19[t]+x23[t]+x25[t])+pr l227[t] (x11[t]+x15[t]+x19[t]+x23[t]+x25[t]))-1.` 
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brs (-1.` bsr (-1.` pr l126[t] (x11[t]+x15[t]+x19[t]+x23[t]+x25[t])-(1.` g l126[t] 
x26[t])/(b2+x26[t])-1.` k1sm l124[t] x26[t] x5[t]+k1sm rhos l126[t] x26[t] x5[t]+k1sm l15[t] 
x26[t] x5[t])+1.` ps l126[t] (x13[t]+x17[t]+x21[t]+x24[t]+x9[t]) (1.` bsr+ps l226[t] 
(x13[t]+x17[t]+x21[t]+x24[t]+x9[t])-1.` ps l227[t] 
(x13[t]+x17[t]+x21[t]+x24[t]+x9[t]))))))/(brs (-1.` aii brs bsr (k1sm l124[t] x26[t] x5[t]-1.` 
k1sm rhos l126[t] x26[t] x5[t]-1.` k1sm l15[t] x26[t] x5[t])2-1.` (1.` aii art-1.` (-1.` k2 l112[t] 
x12[t]+k2 l113[t] x12[t]-1.` k2 l116[t] x16[t]+k2 l117[t] x16[t]-1.` k2 l120[t] x20[t]+k2 
l121[t] x20[t]-1.` k2 l18[t] x8[t]+k2 l19[t] x8[t])2) (1.` bsr pr2 l126[t] l226[t] 






EQAGG1[X_, U1_, U2_, L1_]:=Flatten[Map[Thread,{-D[HT[X,U1,U2,L1],{X}]}]]; 
EQAGG2[X_, U1_, U2_, L2_]:=Flatten[Map[Thread,{-D[HV[X,U1,U2,L2],{X}]}]]; 
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CV=Flatten[{T[XT[t], U1T[t], U2T[t]],TS[XT[t], U1T[t], U2T[t]],TR[XT[t], U1T[t], 
U2T[t]],TG[XT[t], U1T[t], U2T[t]], MH[XT[t], U1T[t], U2T[t]], IP[XT[t], U1T[t], U2T[t]], 
IE[XT[t], U1T[t], U2T[t]], THSL[XT[t], U1T[t], U2T[t]], 
     THSA[XT[t], U1T[t], U2T[t]], THRL[XT[t], U1T[t], U2T[t]], THRA[XT[t], U1T[t], 
U2T[t]], TSSL[XT[t], U1T[t], U2T[t]], 
     TSSA[XT[t], U1T[t], U2T[t]], TSRL[XT[t], U1T[t], U2T[t]], TSRA[XT[t], U1T[t], 
U2T[t]], TRSL[XT[t], U1T[t], U2T[t]], 
     TRSA[XT[t], U1T[t], U2T[t]], TRRL[XT[t], U1T[t], U2T[t]], TRRA[XT[t], U1T[t], 
U2T[t]], TGSL[XT[t], U1T[t], U2T[t]], 
     TGSA[XT[t], U1T[t], U2T[t]], TGRL[XT[t], U1T[t], U2T[t]], TGRA[XT[t], U1T[t], 
U2T[t]],  MHSA[XT[t], U1T[t], U2T[t]], 
     MHRA[XT[t], U1T[t], U2T[t]],VS[XT[t], U1T[t], U2T[t]],VR[XT[t], U1T[t], U2T[t]]}]; 
eqx=Flatten[Map[Thread,{XT'[t]== CV}],1]; 











>0,MaxStepFraction->1,MaxStepSize->1, MaxSteps->1000 ]; 
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C.2 Matlab function for numerical calculations
In this appendix we report the Matlab code for the numerical solutions of
concave and non-concave instances. As mentioned in Chapter 3, the algorithm
has long computational time, therefore, in the case of concave instances we
used a simpler algorithm (which will not be reported for typographical





Finally, even randomizations code is not reported, we remember that it
is quite similar to the below code with the difference that each instance is
calculated inside a “for loop” that assigns for all λi,j(t0) random values in
range [0, 1].
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%HIV con Runge-Kutta 
function [z]=hiv_contr_dentro_alg_no_conca_v8(t0,tf,N,sigma) 
tic; 
%%%%%%%%%%%%PARAMETRI 2° ISTANZA H_therapy NON CONCAVA 
aco = 10.; 
afi = 10.; 
aib = 1.; 
aii = 10.; 
api = 10.; 
art = 10.; 
bsr = 10.^(-10); 
brs = 10.^(-11); 
b2 = 1; 
c = 0.03; 
g = 25; 
is =10.^(-308.); 
ir = 10.^(-308.); 
k = 0.000001; 
kprimo = 0.000001; 
k2 = 0.003; 
k1s = 0.0003; 
k1r = 0.00005; 
k1sm = 0.00467; 
k1rm = 0.001; 
k3 = 0.000001; 
muth = 0.02; 
muts = 0.02; 
mutr = 0.02; 
mutg = 0.02; 
mumh = 0.005; 
muip = 0.001; 
muie = 0.1; 
muthsl = 0.1; 
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muthsa = 0.24; 
muthrl = 0.2; 
muthra = 0.5; 
%  
mutssl = 0.1; 
mutssa = 0.24; 
mutsrl = 0.2; 
mutsra = 0.5; 
%  
mutrsl = 0.1; 
mutrsa = 0.24; 
mutrrl = 0.2; 
mutrra = 0.5; 
%  
mutgsl = 0.1; 
mutgsa = 0.24; 
mutgrl = 0.2; 
mutgra = 0.5; 
mumhsa = 0.04; 
mumhra = 0.07; 
muvs = 2.4; 
muvr = 5.; 
oth = 1.; 
ps = 8*10^(-12);   %8*10^(-11.5);  
pr = 5*10^(-12);   %5*10^(-11.5); 
psprimo = 0.020; 
prprimo = 0.001; 
q = 0.5; 
qthvs = 0.; 
qthvr = 0.; 
%  
qtsvs = 0.90; 
qtsvr = 0.; 
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%  
qtrvs = 0.; 
qtrvr = 0.90; 
%  
qtgvs = 0.80; 
qtgvr = 0.80; 
r = 0.03; 
rhos = 1.; 
rhor = 1.; 
s1th = 1.; 
s1mh = 1.; 
ssprimo = 9.7; 
srprimo = 0.0009; 
tmax = 1700.; 
%%%%%%%%%%%%%%%%%%%CONDIZIONI INIZIALI 
ie0 = 10.; 
ip0 = 10.; 
mh0 = 1.; 
th0 = 900.; 
ts0 = 100.; 
tr0 = 100.; 
tg0 = 1.; 
thsl0 = 10.; 
thsa0 = 0.; 
thrl0 = 10.; 
thra0 = 0.; 
tssl0 = 10.; 
tssa0 = 0.; 
tsrl0 = 10.; 
tsra0 = 0.; 
trsl0 = 10.; 
trsa0 = 0.; 
trrl0 = 10.; 
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trra0 = 0.; 
tgsl0 = 10.; 
tgsa0 = 0.; 
tgrl0 = 10.; 
tgra0 = 0.; 
mhsa0 = 10.; 
mhra0 = 10.; 
vs0 = 500.; 
vr0 = 300.; 




%h=(tf-t0)/N; con questo h il modello a volte diverge; 
% conviene usare h=1/N; 
h=1/N; 
h2=h/2; 







































































































































































































































x1=zeros(1,N+1); x2=zeros(1,N+1); x3=zeros(1,N+1); x4=zeros(1,N+1);  
x5=zeros(1,N+1); x6=zeros(1,N+1); x7=zeros(1,N+1); x8=zeros(1,N+1); 
x9=zeros(1,N+1); x10=zeros(1,N+1); x11=zeros(1,N+1); x12=zeros(1,N+1); 
x13=zeros(1,N+1); x14=zeros(1,N+1); x15=zeros(1,N+1); x16=zeros(1,N+1); 
x17=zeros(1,N+1); x18=zeros(1,N+1); x19=zeros(1,N+1); x20=zeros(1,N+1); 
x21=zeros(1,N+1); x22=zeros(1,N+1); x23=zeros(1,N+1); x24=zeros(1,N+1); 
x25=zeros(1,N+1); x26=zeros(1,N+1); 
x27=zeros(1,N+1);x0=[th0;ts0;tr0;tg0;mh0;ip0;ie0;thsl0;thsa0;thrl0;thra0;tssl0;tssa0;... 
    tsrl0;tsra0;trsl0;trsa0;trrl0;trra0;tgsl0;tgsa0;tgrl0;tgra0;mhsa0;... 
    mhra0;vs0;vr0;]; 
x1(:,1)=x0(1); x2(:,1)=x0(2); x3(:,1)=x0(3); x4(:,1)=x0(4); x5(:,1)=x0(5); 
x6(:,1)=x0(6); x7(:,1)=x0(7); x8(:,1)=x0(8); x9(:,1)=x0(9); x10(:,1)=x0(10); 
x11(:,1)=x0(11); x12(:,1)=x0(12); x13(:,1)=x0(13); x14(:,1)=x0(14);  
x15(:,1)=x0(15); x16(:,1)=x0(16); x17(:,1)=x0(17); x18(:,1)=x0(18);  
x19(:,1)=x0(19); x20(:,1)=x0(20); x21(:,1)=x0(21); x22(:,1)=x0(22);  
x23(:,1)=x0(23); x24(:,1)=x0(24); x25(:,1)=x0(25); x26(:,1)=x0(26);  
x27(:,1)=x0(27); 
 
%%%%%%%%%lambda al tempo t0 che massimizzano la randomizzazione 
l11=0.8693*ones(1,N+1); l12=0.5679 *ones(1,N+1); l13=0.1202 *ones(1,N+1);  
l14=0.9703*ones(1,N+1); l15=0.8400*ones(1,N+1); l16=0.0623*ones(1,N+1); 
l17=0.2781*ones(1,N+1); l18=0.4096*ones(1,N+1); l19=0.6268*ones(1,N+1); 
l110=0.9191*ones(1,N+1); l111=0.4152*ones(1,N+1); l112=0.7115*ones(1,N+1); 
l113=0.9709*ones(1,N+1); l114=0.4355*ones(1,N+1); l115=0.6354*ones(1,N+1); 
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l116=0.9016 *ones(1,N+1); l117=0.8716*ones(1,N+1); l118=0.1427*ones(1,N+1); 
l119=0.2006*ones(1,N+1); l120=0.6209*ones(1,N+1); l121=0.7750*ones(1,N+1); 
l122=0.2468*ones(1,N+1); l123=0.3695*ones(1,N+1); l124=0.3411*ones(1,N+1); 
l125=0.4564*ones(1,N+1); l126=0.1708*ones(1,N+1); l127=0.7456*ones(1,N+1); 
%  
l21=0.0980*ones(1,N+1); l22=0.8903*ones(1,N+1); l23=0.0821*ones(1,N+1); 
l24=0.7815*ones(1,N+1); l25=0.8487*ones(1,N+1); l26=0.4509*ones(1,N+1);  
l27=0.6053*ones(1,N+1); l28=0.3545*ones(1,N+1); l29=0.7591*ones(1,N+1); 
l210=0.5894*ones(1,N+1); l211=0.6116*ones(1,N+1); l212=0.8432*ones(1,N+1);  
l213=0.4570*ones(1,N+1); l214=0.8828*ones(1,N+1); l215=0.4936*ones(1,N+1);  
l216=0.6229*ones(1,N+1); l217=0.5622*ones(1,N+1); l218=0.7217*ones(1,N+1);  
l219=0.5468*ones(1,N+1); l220=0.7844*ones(1,N+1); l221=0.4464*ones(1,N+1);  
l222=0.9119*ones(1,N+1); l223=0.0866*ones(1,N+1); l224=0.9989*ones(1,N+1); 
l225=0.7276*ones(1,N+1); l226=0.5584*ones(1,N+1); l227=0.1428*ones(1,N+1); 
% % % lambda_1_max = 
% % % 0.8693    0.5679    0.1202    0.9703    0.8400 
% % % 0.0623    0.2781    0.4096    0.6268    0.9191 
% % % 0.4152    0.7115    0.9709    0.4355    0.6354 
% % % 0.9016    0.8716    0.1427    0.2006    0.6209 
% % % 0.7750    0.2468    0.3695    0.3411    0.4564 
% % % 0.1708    0.7456 
% % % lambda_2_max = 
% % % 0.0980    0.8903    0.0821    0.7815    0.8487 
% % % 0.4509    0.6053    0.3545    0.7591    0.5894 
% % % 0.6116    0.8432    0.4570    0.8828    0.4936 
% % % 0.6229    0.5622    0.7217    0.5468    0.7844 
% % % 0.4464    0.9119    0.0866    0.9989    0.7276 
% % % 0.5584    0.1428 
 
%%%%%%%%%%%%%%% lambda al tempo t0 tutti uguali a 0.1 
% l11=0.1*ones(1,N+1); l12=0.1*ones(1,N+1); l13=0.1*ones(1,N+1);  
% l14=0.1*ones(1,N+1); l15=0.1*ones(1,N+1); l16=0.1*ones(1,N+1); 
% l17=0.1*ones(1,N+1); l18=0.1*ones(1,N+1); l19=0.1*ones(1,N+1); 
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% l110=0.1*ones(1,N+1); l111=0.1*ones(1,N+1); l112=0.1*ones(1,N+1); 
% l113=0.1*ones(1,N+1); l114=0.1*ones(1,N+1); l115=0.1*ones(1,N+1); 
% l116=0.1*ones(1,N+1); l117=0.1*ones(1,N+1); l118=0.1*ones(1,N+1); 
% l119=0.1*ones(1,N+1); l120=0.1*ones(1,N+1); l121=0.1*ones(1,N+1); 
% l122=0.1*ones(1,N+1); l123=0.1*ones(1,N+1); l124=0.1*ones(1,N+1); 
% l125=0.1*ones(1,N+1); l126=0.1*ones(1,N+1); l127=0.1*ones(1,N+1); 
% %  
% l21=0.1*ones(1,N+1); l22=0.1*ones(1,N+1); l23=0.1*ones(1,N+1); 
% l24=0.1*ones(1,N+1); l25=0.1*ones(1,N+1); l26=0.1*ones(1,N+1);  
% l27=0.1*ones(1,N+1); l28=0.1*ones(1,N+1); l29=0.1*ones(1,N+1); 
% l210=0.1*ones(1,N+1); l211=0.1*ones(1,N+1); l212=0.1*ones(1,N+1);  
% l213=0.1*ones(1,N+1); l214=0.1*ones(1,N+1); l215=0.1*ones(1,N+1);  
% l216=0.1*ones(1,N+1); l217=0.1*ones(1,N+1); l218=0.1*ones(1,N+1);  
% l219=0.1*ones(1,N+1); l220=0.1*ones(1,N+1); l221=0.1*ones(1,N+1);  
% l222=0.1*ones(1,N+1); l223=0.1*ones(1,N+1); l224=0.1*ones(1,N+1); 
% l225=0.1*ones(1,N+1); l226=0.1*ones(1,N+1); l227=0.1*ones(1,N+1);x=[x1; x2; x3; x4; 
x5; x6; x7; x8; x9; x10; x11; x12; x13; x14; x15;... 
x16; x17; x18; x19; x20; x21; x22; x23; x24; x25; x26; x27];l1=[l11; l12; l13; l14; l15; l16; 
l17; l18; l19; l110; l111; l112; l113;... 
l114; l115; l116; l117; l118; l119; l120; l121; l122; l123; l124;... 
l125; l126; l127]; 
l2=[l21; l22; l23; l24; l25; l26; l27; l28; l29; l210; l211; l212; l213;... 
l214; l215; l216; l217; l218; l219; l220; l221; l222; l223; l224;... 










while(test<0  && conta<11)    %si potrebbe anche aggiungere   &&  testess<0) 
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    conta=conta+1; 
    oldx=x; 
    oldl1=l1; 
    oldl2=l2; 
    oldu1=u1; 
    oldu2=u2; 
    oldJSI=JSI; 
    oldJV=JV; 
     
      
    %i=1; 
     
    %%%%%%%%%%%FORWARD PROCESS 
    for i=1:N 
   
        %CONTROLLI COEEFICIENTI DI RUNGE KUTTA 1° ORDINE 








































































































































































































































         
        if(a11<0 || a11>1) 
         a11=0; 
        end; 
         
        if(a12<0 || a12>1) 
         a12=0; 
        end; 
         
        if(a13<0 || a13>1) 
         a13=0; 
        end; 
         
        if(a14<0 || a14>1) 
         a14=0; 
        end; 
         
        if(a15<0 || a15>1) 
         a15=0; 
        end; 
         
        if(a16<0 || a16>1) 
         a16=0; 
        end; 
         
         






































































































































         
        eval_HT=eval(fHT); 
         
        [max_HT, id_HT]=nanmax(eval_HT); 
      
        u11(1)=D(id_HT,1); 
        u12(1)=D(id_HT,2); 
        u13(1)=D(id_HT,3); 
        u14(1)=D(id_HT,4); 
        u15(1)=D(id_HT,5); 
        u16(1)=D(id_HT,6); 
         
        u21(1)=u21s; 
        u22(1)=u22s; 
         
         
         
         
         
                 
        %VARIABILI COEEFICIENTI DI RUNGE KUTTA 1° ORDINE 





        kv2(1)=-(muts*x2(i))+u13(1)*x2(i)-k3*x2(i)*(x24(i)+x25(i))+k*x1(i)*x26(i)-k1s*(1-
qtsvs)*(1-u11(1))*(1-u12(1))*x2(i)*x26(i)-k1r*(1-qtsvr)*x2(i)*x27(i);        
kv3(1)=k*x1(i)*x27(i)-mutr*x3(i)+u13(1)*x3(i)-k3*(x24(i)+x25(i))*x3(i)-k1s*(1-qtrvs)*(1-
u11(1))*(1-u12(1))*x26(i)*x3(i)-k1r*(1-qtrvr)*x27(i)*x3(i);        
kv4(1)=kprimo*x1(i)*(x26(i)+x27(i))-mutg*x4(i)+u13(1)*x4(i)-k3*(x24(i)+x25(i))*x4(i)-
k1s*(1-qtgvs)*(1-u11(1))*(1-u12(1))*x26(i)*x4(i)-k1r*(1-qtgvr)*x27(i)*x4(i);        
kv5(1)=s1mh-mumh*x5(i)-k1sm*(1-u15(1))*(1-u16(1))*x26(i)*x5(i)-k1rm*x27(i)*x5(i);        
kv6(1)=-(muip*x6(i))-
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c*q*x6(i)*(x11(i)+x13(i)+x15(i)+x17(i)+x19(i)+x21(i)+x23(i)+x9(i))+c*(x1(i)+x2(i)+x3(i)+
x4(i))*x6(i)*(x11(i)+x13(i)+x15(i)+x17(i)+x19(i)+x21(i)+x23(i)+x9(i));        kv7(1)=-
(muie*x7(i))+c*q*x6(i)*(x11(i)+x13(i)+x15(i)+x17(i)+x19(i)+x21(i)+x23(i)+x9(i));        
kv8(1)=k3*x1(i)*x24(i)+k1s*(1-qthvs)*(1-u11(1))*(1-u12(1))*x1(i)*x26(i)-muthsl*x8(i)-
k2*(1-u14(1))*(1-u16(1))*x8(i);        kv9(1)=k2*(1-u14(1))*(1-u16(1))*x8(i)-muthsa*x9(i)-
is*x7(i)*x9(i);        kv10(1)=-(k2*x10(i))-muthrl*x10(i)+k3*x1(i)*x25(i)+k1r*(1-
qthvr)*x1(i)*x27(i);        kv11(1)=k2*x10(i)-muthra*x11(i)-ir*x11(i)*x7(i);        kv12(1)=-
(mutssl*x12(i))-k2*(1-u14(1))*(1-u16(1))*x12(i)+k3*x2(i)*x24(i)+k1s*(1-qtsvs)*(1-
u11(1))*(1-u12(1))*x2(i)*x26(i);        kv13(1)=k2*(1-u14(1))*(1-u16(1))*x12(i)-
mutssa*x13(i)-is*x13(i)*x7(i);        kv14(1)=-(k2*x14(i))-
mutsrl*x14(i)+k3*x2(i)*x25(i)+k1r*(1-qtsvr)*x2(i)*x27(i);        kv15(1)=k2*x14(i)-
mutsra*x15(i)-ir*x15(i)*x7(i);        kv16(1)=-(mutrsl*x16(i))-k2*(1-u14(1))*(1-
u16(1))*x16(i)+k3*x24(i)*x3(i)+k1s*(1-qtrvs)*(1-u11(1))*(1-u12(1))*x26(i)*x3(i);        
kv17(1)=k2*(1-u14(1))*(1-u16(1))*x16(i)-mutrsa*x17(i)-is*x17(i)*x7(i);        kv18(1)=-
(k2*x18(i))-mutrrl*x18(i)+k3*x25(i)*x3(i)+k1r*(1-qtrvr)*x27(i)*x3(i);        
kv19(1)=k2*x18(i)-mutrra*x19(i)-ir*x19(i)*x7(i);        kv20(1)=-(mutgsl*x20(i))-k2*(1-
u14(1))*(1-u16(1))*x20(i)+k3*x24(i)*x4(i)+k1s*(1-qtgvs)*(1-u11(1))*(1-
u12(1))*x26(i)*x4(i);        kv21(1)=k2*(1-u14(1))*(1-u16(1))*x20(i)-mutgsa*x21(i)-
is*x21(i)*x7(i);        kv22(1)=-(k2*x22(i))-mutgrl*x22(i)+k3*x25(i)*x4(i)+k1r*(1-
qtgvr)*x27(i)*x4(i);        kv23(1)=k2*x22(i)-mutgra*x23(i)-ir*x23(i)*x7(i);        kv24(1)=-
(mumhsa*x24(i))+k1sm*(1-u15(1))*(1-u16(1))*x26(i)*x5(i);        kv25(1)=-









k1rm*rhor*x27(i)*x5(i)+ps*(1-u21(1))*(x13(i)+x17(i)+x21(i)+x24(i)+x9(i));         
         
         
        % Ora troverete molte variabili di appoggio, 
        % sono state usate perchè le espressioni simboliche 
        % prima si sono ricavate da mathematica e poi si sono  
        % dovute incollare in matlab, facendo tutte le correzioni 
        % del caso. Il motivo di questa scelta è legato al fatto 
        % che si è provato a dare in pasto a matlab i sistemi simbolici 
        % per il calcolo delle soluzioni simboliche, ma questo produceva 
        % espressioni enormi di difficile lettura e manipolazione,  
        % anche usando le routines simple, simplify, ecc. 
        %  
         
        %VARIABILI DI APPOGGIO wf per 2° ordine 
        wf1(i)=x1(i)+h2*kv1(1); 
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        wf2(i)=x2(i)+h2*kv2(1); 
        wf3(i)=x3(i)+h2*kv3(1); 
        wf4(i)=x4(i)+h2*kv4(1); 
        wf5(i)=x5(i)+h2*kv5(1); 
        wf6(i)=x6(i)+h2*kv6(1); 
        wf7(i)=x7(i)+h2*kv7(1); 
        wf8(i)=x8(i)+h2*kv8(1); 
        wf9(i)=x9(i)+h2*kv9(1); 
        wf10(i)=x10(i)+h2*kv10(1); 
        wf11(i)=x11(i)+h2*kv11(1); 
        wf12(i)=x12(i)+h2*kv12(1); 
        wf13(i)=x13(i)+h2*kv13(1); 
        wf14(i)=x14(i)+h2*kv14(1); 
        wf15(i)=x15(i)+h2*kv15(1); 
        wf16(i)=x16(i)+h2*kv16(1); 
        wf17(i)=x17(i)+h2*kv17(1); 
        wf18(i)=x18(i)+h2*kv18(1); 
        wf19(i)=x19(i)+h2*kv19(1);         
        wf20(i)=x20(i)+h2*kv20(1);         
        wf21(i)=x21(i)+h2*kv21(1); 
        wf22(i)=x22(i)+h2*kv22(1); 
        wf23(i)=x23(i)+h2*kv23(1); 
        wf24(i)=x24(i)+h2*kv24(1); 
        wf25(i)=x25(i)+h2*kv25(1); 
        wf26(i)=x26(i)+h2*kv26(1); 
        wf27(i)=x27(i)+h2*kv27(1); 
         
         
        %VARIABILI DI APPOGGIO hf per 2° ordine        
        hf11(i)=0.5*(l11(i)+l11(i+1)); 
        hf12(i)=0.5*(l12(i)+l12(i+1)); 
        hf13(i)=0.5*(l13(i)+l13(i+1)); 
        hf14(i)=0.5*(l14(i)+l14(i+1)); 
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        hf15(i)=0.5*(l15(i)+l15(i+1)); 
        hf16(i)=0.5*(l16(i)+l16(i+1)); 
        hf17(i)=0.5*(l17(i)+l17(i+1)); 
        hf18(i)=0.5*(l18(i)+l18(i+1)); 
        hf19(i)=0.5*(l19(i)+l19(i+1)); 
        hf110(i)=0.5*(l110(i)+l110(i+1)); 
        hf111(i)=0.5*(l111(i)+l111(i+1));         
        hf112(i)=0.5*(l112(i)+l112(i+1)); 
        hf113(i)=0.5*(l113(i)+l113(i+1)); 
        hf114(i)=0.5*(l114(i)+l114(i+1)); 
        hf115(i)=0.5*(l115(i)+l115(i+1)); 
        hf116(i)=0.5*(l116(i)+l116(i+1)); 
        hf117(i)=0.5*(l117(i)+l117(i+1)); 
        hf118(i)=0.5*(l118(i)+l118(i+1)); 
        hf119(i)=0.5*(l119(i)+l119(i+1));         
        hf120(i)=0.5*(l120(i)+l120(i+1));         
        hf121(i)=0.5*(l121(i)+l121(i+1)); 
        hf122(i)=0.5*(l122(i)+l122(i+1)); 
        hf123(i)=0.5*(l123(i)+l123(i+1)); 
        hf124(i)=0.5*(l124(i)+l124(i+1)); 
        hf125(i)=0.5*(l125(i)+l125(i+1)); 
        hf126(i)=0.5*(l126(i)+l126(i+1)); 
        hf127(i)=0.5*(l127(i)+l127(i+1)); 
         
        hf21(i)=0.5*(l21(i)+l21(i+1)); 
        hf22(i)=0.5*(l22(i)+l22(i+1)); 
        hf23(i)=0.5*(l23(i)+l23(i+1)); 
        hf24(i)=0.5*(l24(i)+l24(i+1)); 
        hf25(i)=0.5*(l25(i)+l25(i+1)); 
        hf26(i)=0.5*(l26(i)+l26(i+1)); 
        hf27(i)=0.5*(l27(i)+l27(i+1)); 
        hf28(i)=0.5*(l28(i)+l28(i+1)); 
        hf29(i)=0.5*(l29(i)+l29(i+1)); 
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        hf210(i)=0.5*(l210(i)+l210(i+1)); 
        hf211(i)=0.5*(l211(i)+l211(i+1));         
        hf212(i)=0.5*(l212(i)+l212(i+1)); 
        hf213(i)=0.5*(l213(i)+l213(i+1)); 
        hf214(i)=0.5*(l214(i)+l214(i+1)); 
        hf215(i)=0.5*(l215(i)+l215(i+1)); 
        hf216(i)=0.5*(l216(i)+l216(i+1)); 
        hf217(i)=0.5*(l217(i)+l217(i+1)); 
        hf218(i)=0.5*(l218(i)+l218(i+1)); 
        hf219(i)=0.5*(l219(i)+l219(i+1));         
        hf220(i)=0.5*(l220(i)+l220(i+1));         
        hf221(i)=0.5*(l221(i)+l221(i+1)); 
        hf222(i)=0.5*(l222(i)+l222(i+1)); 
        hf223(i)=0.5*(l223(i)+l223(i+1)); 
        hf224(i)=0.5*(l224(i)+l224(i+1)); 
        hf225(i)=0.5*(l225(i)+l225(i+1)); 
        hf226(i)=0.5*(l226(i)+l226(i+1)); 
        hf227(i)=0.5*(l227(i)+l227(i+1)); 
         
         
         
        %CONTROLLI COEEFICIENTI DI RUNGE KUTTA 2° ORDINE 





























































1.*qtrvs)*wf3(i)+(1.-1.*qtgvs)*wf4(i)))^2));        a13= 
















































































1.*ps^2*hf126(i)*hf226(i)*(wf13(i)+wf17(i)+wf21(i)+wf24(i)+wf9(i))^2))));        a16= (-
1.*(1.*bsr*pr*hf126(i)*(wf11(i)+wf15(i)+wf19(i)+wf23(i)+wf25(i))*(1.*brs-














































































































        if(a11<0 || a11>1) 
         a11=0; 
        end; 
         
        if(a12<0 || a12>1) 
         a12=0; 
        end; 
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        if(a13<0 || a13>1) 
         a13=0; 
        end; 
         
        if(a14<0 || a14>1) 
         a14=0; 
        end; 
         
        if(a15<0 || a15>1) 
         a15=0; 
        end; 
         
        if(a16<0 || a16>1) 
         a16=0; 
        end; 
      




































































































































         
         
        eval_HT=eval(fHT); 
        [max_HT, id_HT]=nanmax(eval_HT); 
         
        u11(2)=D(id_HT,1); 
        u12(2)=D(id_HT,2); 
        u13(2)=D(id_HT,3); 
        u14(2)=D(id_HT,4); 
        u15(2)=D(id_HT,5); 
        u16(2)=D(id_HT,6); 
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        u21(2)=u21s; 
        u22(2)=u22s; 
         
        %VARIABILI COEEFICIENTI DI RUNGE KUTTA 2° ORDINE         






        kv2(2)=-(muts*wf2(i))+u13(2)*wf2(i)-k3*wf2(i)*(wf24(i)+wf25(i))+k*wf1(i)*wf26(i)-
k1s*(1-qtsvs)*(1-u11(2))*(1-u12(2))*wf2(i)*wf26(i)-k1r*(1-qtsvr)*wf2(i)*wf27(i);        
kv3(2)=k*wf1(i)*wf27(i)-mutr*wf3(i)+u13(2)*wf3(i)-k3*(wf24(i)+wf25(i))*wf3(i)-k1s*(1-
qtrvs)*(1-u11(2))*(1-u12(2))*wf26(i)*wf3(i)-k1r*(1-qtrvr)*wf27(i)*wf3(i);        
kv4(2)=kprimo*wf1(i)*(wf26(i)+wf27(i))-mutg*wf4(i)+u13(2)*wf4(i)-
k3*(wf24(i)+wf25(i))*wf4(i)-k1s*(1-qtgvs)*(1-u11(2))*(1-u12(2))*wf26(i)*wf4(i)-k1r*(1-
qtgvr)*wf27(i)*wf4(i);        kv5(2)=s1mh-mumh*wf5(i)-k1sm*(1-u15(2))*(1-
u16(2))*wf26(i)*wf5(i)-k1rm*wf27(i)*wf5(i);        kv6(2)=-(muip*wf6(i))-
c*q*wf6(i)*(wf11(i)+wf13(i)+wf15(i)+wf17(i)+wf19(i)+wf21(i)+wf23(i)+wf9(i))+c*(wf1(i)
+wf2(i)+wf3(i)+wf4(i))*wf6(i)*(wf11(i)+wf13(i)+wf15(i)+wf17(i)+wf19(i)+wf21(i)+wf23(i)
+wf9(i));        kv7(2)=-
(muie*wf7(i))+c*q*wf6(i)*(wf11(i)+wf13(i)+wf15(i)+wf17(i)+wf19(i)+wf21(i)+wf23(i)+wf
9(i));        kv8(2)=k3*wf1(i)*wf24(i)+k1s*(1-qthvs)*(1-u11(2))*(1-u12(2))*wf1(i)*wf26(i)-
muthsl*wf8(i)-k2*(1-u14(2))*(1-u16(2))*wf8(i);        kv9(2)=k2*(1-u14(2))*(1-
u16(2))*wf8(i)-muthsa*wf9(i)-is*wf7(i)*wf9(i);        kv10(2)=-(k2*wf10(i))-
muthrl*wf10(i)+k3*wf1(i)*wf25(i)+k1r*(1-qthvr)*wf1(i)*wf27(i);        kv11(2)=k2*wf10(i)-
muthra*wf11(i)-ir*wf11(i)*wf7(i);        kv12(2)=-(mutssl*wf12(i))-k2*(1-u14(2))*(1-
u16(2))*wf12(i)+k3*wf2(i)*wf24(i)+k1s*(1-qtsvs)*(1-u11(2))*(1-u12(2))*wf2(i)*wf26(i);        
kv13(2)=k2*(1-u14(2))*(1-u16(2))*wf12(i)-mutssa*wf13(i)-is*wf13(i)*wf7(i);        
kv14(2)=-(k2*wf14(i))-mutsrl*wf14(i)+k3*wf2(i)*wf25(i)+k1r*(1-qtsvr)*wf2(i)*wf27(i);        
kv15(2)=k2*wf14(i)-mutsra*wf15(i)-ir*wf15(i)*wf7(i);        kv16(2)=-(mutrsl*wf16(i))-
k2*(1-u14(2))*(1-u16(2))*wf16(i)+k3*wf24(i)*wf3(i)+k1s*(1-qtrvs)*(1-u11(2))*(1-
u12(2))*wf26(i)*wf3(i);        kv17(2)=k2*(1-u14(2))*(1-u16(2))*wf16(i)-mutrsa*wf17(i)-
is*wf17(i)*wf7(i);        kv18(2)=-(k2*wf18(i))-mutrrl*wf18(i)+k3*wf25(i)*wf3(i)+k1r*(1-
qtrvr)*wf27(i)*wf3(i);        kv19(2)=k2*wf18(i)-mutrra*wf19(i)-ir*wf19(i)*wf7(i);        
kv20(2)=-(mutgsl*wf20(i))-k2*(1-u14(2))*(1-u16(2))*wf20(i)+k3*wf24(i)*wf4(i)+k1s*(1-
qtgvs)*(1-u11(2))*(1-u12(2))*wf26(i)*wf4(i);        kv21(2)=k2*(1-u14(2))*(1-
u16(2))*wf20(i)-mutgsa*wf21(i)-is*wf21(i)*wf7(i);        kv22(2)=-(k2*wf22(i))-
mutgrl*wf22(i)+k3*wf25(i)*wf4(i)+k1r*(1-qtgvr)*wf27(i)*wf4(i);        kv23(2)=k2*wf22(i)-
mutgra*wf23(i)-ir*wf23(i)*wf7(i);        kv24(2)=-(mumhsa*wf24(i))+k1sm*(1-u15(2))*(1-
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        %VARIABILI DI APPOGGIO wf per 3° ordine 
        wf1(i)=x1(i)+h2*kv1(2); 
        wf2(i)=x2(i)+h2*kv2(2); 
        wf3(i)=x3(i)+h2*kv3(2); 
        wf4(i)=x4(i)+h2*kv4(2); 
        wf5(i)=x5(i)+h2*kv5(2); 
        wf6(i)=x6(i)+h2*kv6(2); 
        wf7(i)=x7(i)+h2*kv7(2); 
        wf8(i)=x8(i)+h2*kv8(2); 
        wf9(i)=x9(i)+h2*kv9(2); 
        wf10(i)=x10(i)+h2*kv10(2); 
        wf11(i)=x11(i)+h2*kv11(2); 
        wf12(i)=x12(i)+h2*kv12(2); 
        wf13(i)=x13(i)+h2*kv13(2); 
        wf14(i)=x14(i)+h2*kv14(2); 
        wf15(i)=x15(i)+h2*kv15(2); 
        wf16(i)=x16(i)+h2*kv16(2); 
        wf17(i)=x17(i)+h2*kv17(2); 
        wf18(i)=x18(i)+h2*kv18(2); 
        wf19(i)=x19(i)+h2*kv19(2);         
        wf20(i)=x20(i)+h2*kv20(2);         
        wf21(i)=x21(i)+h2*kv21(2); 
        wf22(i)=x22(i)+h2*kv22(2); 
        wf23(i)=x23(i)+h2*kv23(2); 
        wf24(i)=x24(i)+h2*kv24(2); 
        wf25(i)=x25(i)+h2*kv25(2); 
        wf26(i)=x26(i)+h2*kv26(2); 
        wf27(i)=x27(i)+h2*kv27(2); 
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        %VARIABILI DI APPOGGIO hf per 3° ordine        
        hf11(i)=0.5*(l11(i)+l11(i+1)); 
        hf12(i)=0.5*(l12(i)+l12(i+1)); 
        hf13(i)=0.5*(l13(i)+l13(i+1)); 
        hf14(i)=0.5*(l14(i)+l14(i+1)); 
        hf15(i)=0.5*(l15(i)+l15(i+1)); 
        hf16(i)=0.5*(l16(i)+l16(i+1)); 
        hf17(i)=0.5*(l17(i)+l17(i+1)); 
        hf18(i)=0.5*(l18(i)+l18(i+1)); 
        hf19(i)=0.5*(l19(i)+l19(i+1)); 
        hf110(i)=0.5*(l110(i)+l110(i+1)); 
        hf111(i)=0.5*(l111(i)+l111(i+1));         
        hf112(i)=0.5*(l112(i)+l112(i+1)); 
        hf113(i)=0.5*(l113(i)+l113(i+1)); 
        hf114(i)=0.5*(l114(i)+l114(i+1)); 
        hf115(i)=0.5*(l115(i)+l115(i+1)); 
        hf116(i)=0.5*(l116(i)+l116(i+1)); 
        hf117(i)=0.5*(l117(i)+l117(i+1)); 
        hf118(i)=0.5*(l118(i)+l118(i+1)); 
        hf119(i)=0.5*(l119(i)+l119(i+1));         
        hf120(i)=0.5*(l120(i)+l120(i+1));         
        hf121(i)=0.5*(l121(i)+l121(i+1)); 
        hf122(i)=0.5*(l122(i)+l122(i+1)); 
        hf123(i)=0.5*(l123(i)+l123(i+1)); 
        hf124(i)=0.5*(l124(i)+l124(i+1)); 
        hf125(i)=0.5*(l125(i)+l125(i+1)); 
        hf126(i)=0.5*(l126(i)+l126(i+1)); 
        hf127(i)=0.5*(l127(i)+l127(i+1)); 
         
        hf21(i)=0.5*(l21(i)+l21(i+1)); 
        hf22(i)=0.5*(l22(i)+l22(i+1)); 
        hf23(i)=0.5*(l23(i)+l23(i+1)); 
        hf24(i)=0.5*(l24(i)+l24(i+1)); 
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        hf25(i)=0.5*(l25(i)+l25(i+1)); 
        hf26(i)=0.5*(l26(i)+l26(i+1)); 
        hf27(i)=0.5*(l27(i)+l27(i+1)); 
        hf28(i)=0.5*(l28(i)+l28(i+1)); 
        hf29(i)=0.5*(l29(i)+l29(i+1)); 
        hf210(i)=0.5*(l210(i)+l210(i+1)); 
        hf211(i)=0.5*(l211(i)+l211(i+1));         
        hf212(i)=0.5*(l212(i)+l212(i+1)); 
        hf213(i)=0.5*(l213(i)+l213(i+1)); 
        hf214(i)=0.5*(l214(i)+l214(i+1)); 
        hf215(i)=0.5*(l215(i)+l215(i+1)); 
        hf216(i)=0.5*(l216(i)+l216(i+1)); 
        hf217(i)=0.5*(l217(i)+l217(i+1)); 
        hf218(i)=0.5*(l218(i)+l218(i+1)); 
        hf219(i)=0.5*(l219(i)+l219(i+1));         
        hf220(i)=0.5*(l220(i)+l220(i+1));         
        hf221(i)=0.5*(l221(i)+l221(i+1)); 
        hf222(i)=0.5*(l222(i)+l222(i+1)); 
        hf223(i)=0.5*(l223(i)+l223(i+1)); 
        hf224(i)=0.5*(l224(i)+l224(i+1)); 
        hf225(i)=0.5*(l225(i)+l225(i+1)); 
        hf226(i)=0.5*(l226(i)+l226(i+1)); 
        hf227(i)=0.5*(l227(i)+l227(i+1));         
         
        %CONTROLLI COEEFICIENTI DI RUNGE KUTTA 3° ORDINE 






























































1.*qtrvs)*wf3(i)+(1.-1.*qtgvs)*wf4(i)))^2));        a13= 































































































































































































   
        if(a11<0 || a11>1) 
         a11=0; 
        end; 
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        if(a12<0 || a12>1) 
         a12=0; 
        end; 
         
        if(a13<0 || a13>1) 
         a13=0; 
        end; 
         
        if(a14<0 || a14>1) 
         a14=0; 
        end; 
         
        if(a15<0 || a15>1) 
         a15=0; 
        end; 
         
        if(a16<0 || a16>1) 
         a16=0; 
        end; 




































































































































     
        eval_HT=eval(fHT); 
         
        [max_HT, id_HT]=nanmax(eval_HT); 
         
        u11(3)=D(id_HT,1); 
        u12(3)=D(id_HT,2); 
        u13(3)=D(id_HT,3); 
        u14(3)=D(id_HT,4); 
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        u15(3)=D(id_HT,5); 
        u16(3)=D(id_HT,6); 
         
        u21(3)=u21s; 
        u22(3)=u22s; 
         
        %VARIABILI COEEFICIENTI DI RUNGE KUTTA 3° ORDINE         






        kv2(3)=-(muts*wf2(i))+u13(3)*wf2(i)-k3*wf2(i)*(wf24(i)+wf25(i))+k*wf1(i)*wf26(i)-
k1s*(1-qtsvs)*(1-u11(3))*(1-u12(3))*wf2(i)*wf26(i)-k1r*(1-qtsvr)*wf2(i)*wf27(i);        
kv3(3)=k*wf1(i)*wf27(i)-mutr*wf3(i)+u13(3)*wf3(i)-k3*(wf24(i)+wf25(i))*wf3(i)-k1s*(1-
qtrvs)*(1-u11(3))*(1-u12(3))*wf26(i)*wf3(i)-k1r*(1-qtrvr)*wf27(i)*wf3(i);        
kv4(3)=kprimo*wf1(i)*(wf26(i)+wf27(i))-mutg*wf4(i)+u13(3)*wf4(i)-
k3*(wf24(i)+wf25(i))*wf4(i)-k1s*(1-qtgvs)*(1-u11(3))*(1-u12(3))*wf26(i)*wf4(i)-k1r*(1-
qtgvr)*wf27(i)*wf4(i);        kv5(3)=s1mh-mumh*wf5(i)-k1sm*(1-u15(3))*(1-
u16(3))*wf26(i)*wf5(i)-k1rm*wf27(i)*wf5(i);        kv6(3)=-(muip*wf6(i))-
c*q*wf6(i)*(wf11(i)+wf13(i)+wf15(i)+wf17(i)+wf19(i)+wf21(i)+wf23(i)+wf9(i))+c*(wf1(i)
+wf2(i)+wf3(i)+wf4(i))*wf6(i)*(wf11(i)+wf13(i)+wf15(i)+wf17(i)+wf19(i)+wf21(i)+wf23(i)
+wf9(i));        kv7(3)=-
(muie*wf7(i))+c*q*wf6(i)*(wf11(i)+wf13(i)+wf15(i)+wf17(i)+wf19(i)+wf21(i)+wf23(i)+wf
9(i));        kv8(3)=k3*wf1(i)*wf24(i)+k1s*(1-qthvs)*(1-u11(3))*(1-u12(3))*wf1(i)*wf26(i)-
muthsl*wf8(i)-k2*(1-u14(3))*(1-u16(3))*wf8(i);        kv9(3)=k2*(1-u14(3))*(1-
u16(3))*wf8(i)-muthsa*wf9(i)-is*wf7(i)*wf9(i);        kv10(3)=-(k2*wf10(i))-
muthrl*wf10(i)+k3*wf1(i)*wf25(i)+k1r*(1-qthvr)*wf1(i)*wf27(i);        kv11(3)=k2*wf10(i)-
muthra*wf11(i)-ir*wf11(i)*wf7(i);        kv12(3)=-(mutssl*wf12(i))-k2*(1-u14(3))*(1-
u16(3))*wf12(i)+k3*wf2(i)*wf24(i)+k1s*(1-qtsvs)*(1-u11(3))*(1-u12(3))*wf2(i)*wf26(i);        
kv13(3)=k2*(1-u14(3))*(1-u16(3))*wf12(i)-mutssa*wf13(i)-is*wf13(i)*wf7(i);        
kv14(3)=-(k2*wf14(i))-mutsrl*wf14(i)+k3*wf2(i)*wf25(i)+k1r*(1-qtsvr)*wf2(i)*wf27(i);        
kv15(3)=k2*wf14(i)-mutsra*wf15(i)-ir*wf15(i)*wf7(i);        kv16(3)=-(mutrsl*wf16(i))-
k2*(1-u14(3))*(1-u16(3))*wf16(i)+k3*wf24(i)*wf3(i)+k1s*(1-qtrvs)*(1-u11(3))*(1-
u12(3))*wf26(i)*wf3(i);        kv17(3)=k2*(1-u14(3))*(1-u16(3))*wf16(i)-mutrsa*wf17(i)-
is*wf17(i)*wf7(i);        kv18(3)=-(k2*wf18(i))-mutrrl*wf18(i)+k3*wf25(i)*wf3(i)+k1r*(1-
qtrvr)*wf27(i)*wf3(i);        kv19(3)=k2*wf18(i)-mutrra*wf19(i)-ir*wf19(i)*wf7(i);        
kv20(3)=-(mutgsl*wf20(i))-k2*(1-u14(3))*(1-u16(3))*wf20(i)+k3*wf24(i)*wf4(i)+k1s*(1-
qtgvs)*(1-u11(3))*(1-u12(3))*wf26(i)*wf4(i);        kv21(3)=k2*(1-u14(3))*(1-
u16(3))*wf20(i)-mutgsa*wf21(i)-is*wf21(i)*wf7(i);        kv22(3)=-(k2*wf22(i))-
mutgrl*wf22(i)+k3*wf25(i)*wf4(i)+k1r*(1-qtgvr)*wf27(i)*wf4(i);        kv23(3)=k2*wf22(i)-
mutgra*wf23(i)-ir*wf23(i)*wf7(i);        kv24(3)=-(mumhsa*wf24(i))+k1sm*(1-u15(3))*(1-
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        %VARIABILI DI APPOGGIO wf per 4° ordine 
        wf1(i)=x1(i)+h*kv1(3); 
        wf2(i)=x2(i)+h*kv2(3); 
        wf3(i)=x3(i)+h*kv3(3); 
        wf4(i)=x4(i)+h*kv4(3); 
        wf5(i)=x5(i)+h*kv5(3); 
        wf6(i)=x6(i)+h*kv6(3); 
        wf7(i)=x7(i)+h*kv7(3); 
        wf8(i)=x8(i)+h*kv8(3); 
        wf9(i)=x9(i)+h*kv9(3); 
        wf10(i)=x10(i)+h*kv10(3); 
        wf11(i)=x11(i)+h*kv11(3); 
        wf12(i)=x12(i)+h*kv12(3); 
        wf13(i)=x13(i)+h*kv13(3); 
        wf14(i)=x14(i)+h*kv14(3); 
        wf15(i)=x15(i)+h*kv15(3); 
        wf16(i)=x16(i)+h*kv16(3); 
        wf17(i)=x17(i)+h*kv17(3); 
        wf18(i)=x18(i)+h*kv18(3); 
        wf19(i)=x19(i)+h*kv19(3);         
        wf20(i)=x20(i)+h*kv20(3);         
        wf21(i)=x21(i)+h*kv21(3); 
        wf22(i)=x22(i)+h*kv22(3); 
        wf23(i)=x23(i)+h*kv23(3); 
        wf24(i)=x24(i)+h*kv24(3); 
        wf25(i)=x25(i)+h*kv25(3); 
        wf26(i)=x26(i)+h*kv26(3); 
        wf27(i)=x27(i)+h*kv27(3); 
         
         
        %VARIABILI DI APPOGGIO hf per 4° ordine        
        hf11(i)=(l11(i+1)); 
        hf12(i)=(l12(i+1)); 
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        hf13(i)=(l13(i+1)); 
        hf14(i)=(l14(i+1)); 
        hf15(i)=(l15(i+1)); 
        hf16(i)=(l16(i+1)); 
        hf17(i)=(l17(i+1)); 
        hf18(i)=(l18(i+1)); 
        hf19(i)=(l19(i+1)); 
        hf110(i)=(l110(i+1)); 
        hf111(i)=(l111(i+1));         
        hf112(i)=(l112(i+1)); 
        hf113(i)=(l113(i+1)); 
        hf114(i)=(l114(i+1)); 
        hf115(i)=(l115(i+1)); 
        hf116(i)=(l116(i+1)); 
        hf117(i)=(l117(i+1)); 
        hf118(i)=(l118(i+1)); 
        hf119(i)=(l119(i+1));         
        hf120(i)=(l120(i+1));         
        hf121(i)=(l121(i+1)); 
        hf122(i)=(l122(i+1)); 
        hf123(i)=(l123(i+1)); 
        hf124(i)=(l124(i+1)); 
        hf125(i)=(l125(i+1)); 
        hf126(i)=(l126(i+1)); 
        hf127(i)=(l127(i+1)); 
         
        hf21(i)=(l21(i+1)); 
        hf22(i)=(l22(i+1)); 
        hf23(i)=(l23(i+1)); 
        hf24(i)=(l24(i+1)); 
        hf25(i)=(l25(i+1)); 
        hf26(i)=(l26(i+1)); 
        hf27(i)=(l27(i+1)); 
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        hf28(i)=(l28(i+1)); 
        hf29(i)=(l29(i+1)); 
        hf210(i)=(l210(i+1)); 
        hf211(i)=(l211(i+1));         
        hf212(i)=(l212(i+1)); 
        hf213(i)=(l213(i+1)); 
        hf214(i)=(l214(i+1)); 
        hf215(i)=(l215(i+1)); 
        hf216(i)=(l216(i+1)); 
        hf217(i)=(l217(i+1)); 
        hf218(i)=(l218(i+1)); 
        hf219(i)=(l219(i+1));         
        hf220(i)=(l220(i+1));         
        hf221(i)=(l221(i+1)); 
        hf222(i)=(l222(i+1)); 
        hf223(i)=(l223(i+1)); 
        hf224(i)=(l224(i+1)); 
        hf225(i)=(l225(i+1)); 
        hf226(i)=(l226(i+1)); 
        hf227(i)=(l227(i+1));         
         
         
        %CONTROLLI COEEFICIENTI DI RUNGE KUTTA 4° ORDINE 





























































1.*qtrvs)*wf3(i)+(1.-1.*qtgvs)*wf4(i)))^2));        a13= 
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        if(a11<0 || a11>1) 
         a11=0; 
        end; 
         
        if(a12<0 || a12>1) 
         a12=0; 
        end; 
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        if(a13<0 || a13>1) 
         a13=0; 
        end; 
         
        if(a14<0 || a14>1) 
         a14=0; 
        end; 
         
        if(a15<0 || a15>1) 
         a15=0; 
        end; 
         
        if(a16<0 || a16>1) 
         a16=0; 



































































































































,1,a16;0,0,0,0,1,1;0,0,0,0,1,0;0,0,0,0,0,a16;0,0,0,0,0,1;0,0,0,0,0,0];   
         
        eval_HT=eval(fHT); 
         
        [max_HT, id_HT]=nanmax(eval_HT); 
                 
        u11(4)=D(id_HT,1); 
        u12(4)=D(id_HT,2); 
        u13(4)=D(id_HT,3); 
        u14(4)=D(id_HT,4); 
        u15(4)=D(id_HT,5); 
        u16(4)=D(id_HT,6); 
         
        u21(4)=u21s; 
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        u22(4)=u22s;        
         
   
        %VARIABILI COEEFICIENTI DI RUNGE KUTTA 4° ORDINE         






        kv2(4)=-(muts*wf2(i))+u13(4)*wf2(i)-k3*wf2(i)*(wf24(i)+wf25(i))+k*wf1(i)*wf26(i)-
k1s*(1-qtsvs)*(1-u11(4))*(1-u12(4))*wf2(i)*wf26(i)-k1r*(1-qtsvr)*wf2(i)*wf27(i);        
kv3(4)=k*wf1(i)*wf27(i)-mutr*wf3(i)+u13(4)*wf3(i)-k3*(wf24(i)+wf25(i))*wf3(i)-k1s*(1-
qtrvs)*(1-u11(4))*(1-u12(4))*wf26(i)*wf3(i)-k1r*(1-qtrvr)*wf27(i)*wf3(i);        
kv4(4)=kprimo*wf1(i)*(wf26(i)+wf27(i))-mutg*wf4(i)+u13(4)*wf4(i)-
k3*(wf24(i)+wf25(i))*wf4(i)-k1s*(1-qtgvs)*(1-u11(4))*(1-u12(4))*wf26(i)*wf4(i)-k1r*(1-
qtgvr)*wf27(i)*wf4(i);        kv5(4)=s1mh-mumh*wf5(i)-k1sm*(1-u15(4))*(1-
u16(4))*wf26(i)*wf5(i)-k1rm*wf27(i)*wf5(i);        kv6(4)=-(muip*wf6(i))-
c*q*wf6(i)*(wf11(i)+wf13(i)+wf15(i)+wf17(i)+wf19(i)+wf21(i)+wf23(i)+wf9(i))+c*(wf1(i)
+wf2(i)+wf3(i)+wf4(i))*wf6(i)*(wf11(i)+wf13(i)+wf15(i)+wf17(i)+wf19(i)+wf21(i)+wf23(i)
+wf9(i));        kv7(4)=-
(muie*wf7(i))+c*q*wf6(i)*(wf11(i)+wf13(i)+wf15(i)+wf17(i)+wf19(i)+wf21(i)+wf23(i)+wf
9(i));        kv8(4)=k3*wf1(i)*wf24(i)+k1s*(1-qthvs)*(1-u11(4))*(1-u12(4))*wf1(i)*wf26(i)-
muthsl*wf8(i)-k2*(1-u14(4))*(1-u16(4))*wf8(i);        kv9(4)=k2*(1-u14(4))*(1-
u16(4))*wf8(i)-muthsa*wf9(i)-is*wf7(i)*wf9(i);        kv10(4)=-(k2*wf10(i))-
muthrl*wf10(i)+k3*wf1(i)*wf25(i)+k1r*(1-qthvr)*wf1(i)*wf27(i);        kv11(4)=k2*wf10(i)-
muthra*wf11(i)-ir*wf11(i)*wf7(i);        kv12(4)=-(mutssl*wf12(i))-k2*(1-u14(4))*(1-
u16(4))*wf12(i)+k3*wf2(i)*wf24(i)+k1s*(1-qtsvs)*(1-u11(4))*(1-u12(4))*wf2(i)*wf26(i);        
kv13(4)=k2*(1-u14(4))*(1-u16(4))*wf12(i)-mutssa*wf13(i)-is*wf13(i)*wf7(i);        
kv14(4)=-(k2*wf14(i))-mutsrl*wf14(i)+k3*wf2(i)*wf25(i)+k1r*(1-qtsvr)*wf2(i)*wf27(i);        
kv15(4)=k2*wf14(i)-mutsra*wf15(i)-ir*wf15(i)*wf7(i);        kv16(4)=-(mutrsl*wf16(i))-
k2*(1-u14(4))*(1-u16(4))*wf16(i)+k3*wf24(i)*wf3(i)+k1s*(1-qtrvs)*(1-u11(4))*(1-
u12(4))*wf26(i)*wf3(i);        kv17(4)=k2*(1-u14(4))*(1-u16(4))*wf16(i)-mutrsa*wf17(i)-
is*wf17(i)*wf7(i);        kv18(4)=-(k2*wf18(i))-mutrrl*wf18(i)+k3*wf25(i)*wf3(i)+k1r*(1-
qtrvr)*wf27(i)*wf3(i);        kv19(4)=k2*wf18(i)-mutrra*wf19(i)-ir*wf19(i)*wf7(i);        
kv20(4)=-(mutgsl*wf20(i))-k2*(1-u14(4))*(1-u16(4))*wf20(i)+k3*wf24(i)*wf4(i)+k1s*(1-
qtgvs)*(1-u11(4))*(1-u12(4))*wf26(i)*wf4(i);        kv21(4)=k2*(1-u14(4))*(1-
u16(4))*wf20(i)-mutgsa*wf21(i)-is*wf21(i)*wf7(i);        kv22(4)=-(k2*wf22(i))-
mutgrl*wf22(i)+k3*wf25(i)*wf4(i)+k1r*(1-qtgvr)*wf27(i)*wf4(i);        kv23(4)=k2*wf22(i)-
mutgra*wf23(i)-ir*wf23(i)*wf7(i);        kv24(4)=-(mumhsa*wf24(i))+k1sm*(1-u15(4))*(1-










         
         
        %RUNGE KUTTA 4° ORDINE (EULERO) PER LE VARIABILI 
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        x1(i+1)=x1(i)+(h/6)*(kv1(1)+2*kv1(2)+2*kv1(3)+kv1(4)); 
        x2(i+1)=x2(i)+(h/6)*(kv2(1)+2*kv2(2)+2*kv2(3)+kv2(4)); 
        x3(i+1)=x3(i)+(h/6)*(kv3(1)+2*kv3(2)+2*kv3(3)+kv3(4)); 
        x4(i+1)=x4(i)+(h/6)*(kv4(1)+2*kv4(2)+2*kv4(3)+kv4(4)); 
        x5(i+1)=x5(i)+(h/6)*(kv5(1)+2*kv5(2)+2*kv5(3)+kv5(4)); 
        x6(i+1)=x6(i)+(h/6)*(kv6(1)+2*kv6(2)+2*kv6(3)+kv6(4)); 
        x7(i+1)=x7(i)+(h/6)*(kv7(1)+2*kv7(2)+2*kv7(3)+kv7(4)); 
        x8(i+1)=x8(i)+(h/6)*(kv8(1)+2*kv8(2)+2*kv8(3)+kv8(4)); 
        x9(i+1)=x9(i)+(h/6)*(kv9(1)+2*kv9(2)+2*kv9(3)+kv9(4)); 
        x10(i+1)=x10(i)+(h/6)*(kv10(1)+2*kv10(2)+2*kv10(3)+kv10(4)); 
        x11(i+1)=x11(i)+(h/6)*(kv11(1)+2*kv11(2)+2*kv11(3)+kv11(4)); 
        x12(i+1)=x12(i)+(h/6)*(kv12(1)+2*kv12(2)+2*kv12(3)+kv12(4)); 
        x13(i+1)=x13(i)+(h/6)*(kv13(1)+2*kv13(2)+2*kv13(3)+kv13(4)); 
        x14(i+1)=x14(i)+(h/6)*(kv14(1)+2*kv14(2)+2*kv14(3)+kv14(4)); 
        x15(i+1)=x15(i)+(h/6)*(kv15(1)+2*kv15(2)+2*kv15(3)+kv15(4)); 
        x16(i+1)=x16(i)+(h/6)*(kv16(1)+2*kv16(2)+2*kv16(3)+kv16(4)); 
        x17(i+1)=x17(i)+(h/6)*(kv17(1)+2*kv17(2)+2*kv17(3)+kv17(4)); 
        x18(i+1)=x18(i)+(h/6)*(kv18(1)+2*kv18(2)+2*kv18(3)+kv18(4)); 
        x19(i+1)=x19(i)+(h/6)*(kv19(1)+2*kv19(2)+2*kv19(3)+kv19(4)); 
        x20(i+1)=x20(i)+(h/6)*(kv20(1)+2*kv20(2)+2*kv20(3)+kv20(4)); 
        x21(i+1)=x21(i)+(h/6)*(kv21(1)+2*kv21(2)+2*kv21(3)+kv21(4)); 
        x22(i+1)=x22(i)+(h/6)*(kv22(1)+2*kv22(2)+2*kv22(3)+kv22(4)); 
        x23(i+1)=x23(i)+(h/6)*(kv23(1)+2*kv23(2)+2*kv23(3)+kv23(4)); 
        x24(i+1)=x24(i)+(h/6)*(kv24(1)+2*kv24(2)+2*kv24(3)+kv24(4)); 
        x25(i+1)=x25(i)+(h/6)*(kv25(1)+2*kv25(2)+2*kv25(3)+kv25(4)); 
        x26(i+1)=x26(i)+(h/6)*(kv26(1)+2*kv26(2)+2*kv26(3)+kv26(4)); 
        x27(i+1)=x27(i)+(h/6)*(kv27(1)+2*kv27(2)+2*kv27(3)+kv27(4)); 
             
    end %%%%%%%%%%%%%%%%%%%%%%%%%end for FORWARD PROCESS 
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    %%%%%%%%%%%%%%%BACKWARD PROCESS 
    for j=1:N 
        i=N+2-j; 
         
        %CONTROLLI COEEFICIENTI DI RUNGE KUTTA 1° ORDINE 





































































































































































































































        if(a11<0 || a11>1) 
         a11=0; 
        end; 
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        if(a12<0 || a12>1) 
         a12=0; 
        end; 
         
        if(a13<0 || a13>1) 
         a13=0; 
        end; 
         
        if(a14<0 || a14>1) 
         a14=0; 
        end; 
         
        if(a15<0 || a15>1) 
         a15=0; 
        end; 
         
        if(a16<0 || a16>1) 
         a16=0; 
        end; 




































































































































         
        eval_HT=eval(fHT); 
         
        [max_HT, id_HT]=nanmax(eval_HT); 
         
        u11(1)=D(id_HT,1); 
        u12(1)=D(id_HT,2); 
        u13(1)=D(id_HT,3); 
        u14(1)=D(id_HT,4); 
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        u15(1)=D(id_HT,5); 
        u16(1)=D(id_HT,6); 
         
        u21(1)=u21s; 
        u22(1)=u22s;             
         
        %LAMBDA1(1) 

























c*l16(i)*x6(i)*(x11(i)+x13(i)+x15(i)+x17(i)+x19(i)+x21(i)+x23(i)+x9(i));        ka15(1)=-1-
k1sm*l124(i)*(1-u15(1))*(1-u16(1))*x26(i)+k1sm*rhos*l126(i)*(1-u15(1))*(1-
u16(1))*x26(i)-k1rm*l125(i)*x27(i)+k1rm*rhor*l127(i)*x27(i)-l15(i)*(-mumh-k1sm*(1-
u15(1))*(1-u16(1))*x26(i)-k1rm*x27(i));        ka16(1)=-1-
c*q*l17(i)*(x11(i)+x13(i)+x15(i)+x17(i)+x19(i)+x21(i)+x23(i)+x9(i))-l16(i)*(-muip-
c*q*(x11(i)+x13(i)+x15(i)+x17(i)+x19(i)+x21(i)+x23(i)+x9(i))+c*(x1(i)+x2(i)+x3(i)+x4(i))*
(x11(i)+x13(i)+x15(i)+x17(i)+x19(i)+x21(i)+x23(i)+x9(i)));        ka17(1)=-
1+muie*l17(i)+ir*l111(i)*x11(i)+is*l113(i)*x13(i)+ir*l115(i)*x15(i)+is*l117(i)*x17(i)+ir*l1
19(i)*x19(i)+is*l121(i)*x21(i)+ir*l123(i)*x23(i)+is*l19(i)*x9(i);        ka18(1)=-(l18(i)*(-
muthsl-k2*(1-u14(1))*(1-u16(1))))-k2*l19(i)*(1-u14(1))*(1-u16(1))+(r*l11(i)*x1(i))/tmax;        
ka19(1)=-(ps*l127(i)*(1-u21(1)))-ps*l126(i)*(1-u15(1))*u21(1)+(r*l11(i)*x1(i))/tmax-
c*q*l17(i)*x6(i)-l16(i)*(-(c*q*x6(i))+c*(x1(i)+x2(i)+x3(i)+x4(i))*x6(i))-l19(i)*(-muthsa-
is*x7(i));        ka110(1)=-((-k2-muthrl)*l110(i))-k2*l111(i)+(r*l11(i)*x1(i))/tmax;        
ka111(1)=-(pr*l126(i)*(1-u15(1))*(1-u22(1)))-pr*l127(i)*u22(1)+(r*l11(i)*x1(i))/tmax-
c*q*l17(i)*x6(i)-l16(i)*(-(c*q*x6(i))+c*(x1(i)+x2(i)+x3(i)+x4(i))*x6(i))-l111(i)*(-muthra-
ir*x7(i));        ka112(1)=-(l112(i)*(-mutssl-k2*(1-u14(1))*(1-u16(1))))-k2*l113(i)*(1-
u14(1))*(1-u16(1))+(r*l11(i)*x1(i))/tmax;        ka113(1)=-(ps*l127(i)*(1-u21(1)))-
ps*l126(i)*(1-u15(1))*u21(1)+(r*l11(i)*x1(i))/tmax-c*q*l17(i)*x6(i)-l16(i)*(-
(c*q*x6(i))+c*(x1(i)+x2(i)+x3(i)+x4(i))*x6(i))-l113(i)*(-mutssa-is*x7(i));        ka114(1)=-((-
k2-mutsrl)*l114(i))-k2*l115(i)+(r*l11(i)*x1(i))/tmax;        ka115(1)=-(pr*l126(i)*(1-
u15(1))*(1-u22(1)))-pr*l127(i)*u22(1)+(r*l11(i)*x1(i))/tmax-c*q*l17(i)*x6(i)-l16(i)*(-
(c*q*x6(i))+c*(x1(i)+x2(i)+x3(i)+x4(i))*x6(i))-l115(i)*(-mutsra-ir*x7(i));        ka116(1)=-




u16(1))+(r*l11(i)*x1(i))/tmax;        ka117(1)=-(ps*l127(i)*(1-u21(1)))-ps*l126(i)*(1-
u15(1))*u21(1)+(r*l11(i)*x1(i))/tmax-c*q*l17(i)*x6(i)-l16(i)*(-
(c*q*x6(i))+c*(x1(i)+x2(i)+x3(i)+x4(i))*x6(i))-l117(i)*(-mutrsa-is*x7(i));        ka118(1)=-((-
k2-mutrrl)*l118(i))-k2*l119(i)+(r*l11(i)*x1(i))/tmax;        ka119(1)=-(pr*l126(i)*(1-
u15(1))*(1-u22(1)))-pr*l127(i)*u22(1)+(r*l11(i)*x1(i))/tmax-c*q*l17(i)*x6(i)-l16(i)*(-
(c*q*x6(i))+c*(x1(i)+x2(i)+x3(i)+x4(i))*x6(i))-l119(i)*(-mutrra-ir*x7(i));        ka120(1)=-
(l120(i)*(-mutgsl-k2*(1-u14(1))*(1-u16(1))))-k2*l121(i)*(1-u14(1))*(1-
u16(1))+(r*l11(i)*x1(i))/tmax;        ka121(1)=-(ps*l127(i)*(1-u21(1)))-ps*l126(i)*(1-
u15(1))*u21(1)+(r*l11(i)*x1(i))/tmax-c*q*l17(i)*x6(i)-l16(i)*(-
(c*q*x6(i))+c*(x1(i)+x2(i)+x3(i)+x4(i))*x6(i))-l121(i)*(-mutgsa-is*x7(i));        ka122(1)=-((-
k2-mutgrl)*l122(i))-k2*l123(i)+(r*l11(i)*x1(i))/tmax;        ka123(1)=-(pr*l126(i)*(1-
u15(1))*(1-u22(1)))-pr*l127(i)*u22(1)+(r*l11(i)*x1(i))/tmax-c*q*l17(i)*x6(i)-l16(i)*(-
(c*q*x6(i))+c*(x1(i)+x2(i)+x3(i)+x4(i))*x6(i))-l123(i)*(-mutgra-ir*x7(i));        
ka124(1)=mumhsa*l124(i)-ps*l127(i)*(1-u21(1))-ps*l126(i)*(1-
u15(1))*u21(1)+k3*l11(i)*x1(i)-k3*l18(i)*x1(i)-k3*l112(i)*x2(i)+k3*l12(i)*x2(i)-
k3*l116(i)*x3(i)+k3*l13(i)*x3(i)-k3*l120(i)*x4(i)+k3*l14(i)*x4(i);        
ka125(1)=mumhra*l125(i)-pr*l126(i)*(1-u15(1))*(1-u22(1))-
pr*l127(i)*u22(1)+k3*l11(i)*x1(i)-k3*l110(i)*x1(i)-k3*l114(i)*x2(i)+k3*l12(i)*x2(i)-

















         
        %LAMBDA2(1) 
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c*l26(i)*x6(i)*(x11(i)+x13(i)+x15(i)+x17(i)+x19(i)+x21(i)+x23(i)+x9(i));        ka25(1)=-
(k1sm*l224(i)*(1-u15(1))*(1-u16(1))*x26(i))+k1sm*rhos*l226(i)*(1-u15(1))*(1-
u16(1))*x26(i)-k1rm*l225(i)*x27(i)+k1rm*rhor*l227(i)*x27(i)-l25(i)*(-mumh-k1sm*(1-
u15(1))*(1-u16(1))*x26(i)-k1rm*x27(i));        ka26(1)=-
(c*q*l27(i)*(x11(i)+x13(i)+x15(i)+x17(i)+x19(i)+x21(i)+x23(i)+x9(i)))-l26(i)*(-muip-
c*q*(x11(i)+x13(i)+x15(i)+x17(i)+x19(i)+x21(i)+x23(i)+x9(i))+c*(x1(i)+x2(i)+x3(i)+x4(i))*
(x11(i)+x13(i)+x15(i)+x17(i)+x19(i)+x21(i)+x23(i)+x9(i)));        
ka27(1)=muie*l27(i)+ir*l211(i)*x11(i)+is*l213(i)*x13(i)+ir*l215(i)*x15(i)+is*l217(i)*x17(i
)+ir*l219(i)*x19(i)+is*l221(i)*x21(i)+ir*l223(i)*x23(i)+is*l29(i)*x9(i);        ka28(1)=-1-
l28(i)*(-muthsl-k2*(1-u14(1))*(1-u16(1)))-k2*l29(i)*(1-u14(1))*(1-
u16(1))+(r*l21(i)*x1(i))/tmax;        ka29(1)= -1-ps*l227(i)*(1-u21(1))-ps*l226(i)*(1-
u15(1))*u21(1)+(r*l21(i)*x1(i))/tmax-c*q*l27(i)*x6(i)-l26(i)*(-
(c*q*x6(i))+c*(x1(i)+x2(i)+x3(i)+x4(i))*x6(i))-l29(i)*(-muthsa-is*x7(i));        ka210(1)=-1-(-
k2-muthrl)*l210(i)-k2*l211(i)+(r*l21(i)*x1(i))/tmax;        ka211(1)= -1-pr*l226(i)*(1-
u15(1))*(1-u22(1))-pr*l227(i)*u22(1)+(r*l21(i)*x1(i))/tmax-c*q*l27(i)*x6(i)-l26(i)*(-
(c*q*x6(i))+c*(x1(i)+x2(i)+x3(i)+x4(i))*x6(i))-l211(i)*(-muthra-ir*x7(i));        ka212(1)=-1-
l212(i)*(-mutssl-k2*(1-u14(1))*(1-u16(1)))-k2*l213(i)*(1-u14(1))*(1-
u16(1))+(r*l21(i)*x1(i))/tmax;        ka213(1)=-1-ps*l227(i)*(1-u21(1))-ps*l226(i)*(1-
u15(1))*u21(1)+(r*l21(i)*x1(i))/tmax-c*q*l27(i)*x6(i)-l26(i)*(-
(c*q*x6(i))+c*(x1(i)+x2(i)+x3(i)+x4(i))*x6(i))-l213(i)*(-mutssa-is*x7(i));        ka214(1)=-1-
(-k2-mutsrl)*l214(i)-k2*l215(i)+(r*l21(i)*x1(i))/tmax;        ka215(1)=-1-pr*l226(i)*(1-
u15(1))*(1-u22(1))-pr*l227(i)*u22(1)+(r*l21(i)*x1(i))/tmax-c*q*l27(i)*x6(i)-l26(i)*(-
(c*q*x6(i))+c*(x1(i)+x2(i)+x3(i)+x4(i))*x6(i))-l215(i)*(-mutsra-ir*x7(i));        ka216(1)=-1-
l216(i)*(-mutrsl-k2*(1-u14(1))*(1-u16(1)))-k2*l217(i)*(1-u14(1))*(1-
u16(1))+(r*l21(i)*x1(i))/tmax;        ka217(1)=-1-ps*l227(i)*(1-u21(1))-ps*l226(i)*(1-
u15(1))*u21(1)+(r*l21(i)*x1(i))/tmax-c*q*l27(i)*x6(i)-l26(i)*(-
(c*q*x6(i))+c*(x1(i)+x2(i)+x3(i)+x4(i))*x6(i))-l217(i)*(-mutrsa-is*x7(i));        ka218(1)=-1-
(-k2-mutrrl)*l218(i)-k2*l219(i)+(r*l21(i)*x1(i))/tmax;        ka219(1)=-1-pr*l226(i)*(1-
u15(1))*(1-u22(1))-pr*l227(i)*u22(1)+(r*l21(i)*x1(i))/tmax-c*q*l27(i)*x6(i)-l26(i)*(-
(c*q*x6(i))+c*(x1(i)+x2(i)+x3(i)+x4(i))*x6(i))-l219(i)*(-mutrra-ir*x7(i));        ka220(1)=-1-
l220(i)*(-mutgsl-k2*(1-u14(1))*(1-u16(1)))-k2*l221(i)*(1-u14(1))*(1-
u16(1))+(r*l21(i)*x1(i))/tmax;        ka221(1)=-1-ps*l227(i)*(1-u21(1))-ps*l226(i)*(1-
u15(1))*u21(1)+(r*l21(i)*x1(i))/tmax-c*q*l27(i)*x6(i)-l26(i)*(-
(c*q*x6(i))+c*(x1(i)+x2(i)+x3(i)+x4(i))*x6(i))-l221(i)*(-mutgsa-is*x7(i));        ka222(1)=-1-
(-k2-mutgrl)*l222(i)-k2*l223(i)+(r*l21(i)*x1(i))/tmax;        ka223(1)=-1-pr*l226(i)*(1-
u15(1))*(1-u22(1))-pr*l227(i)*u22(1)+(r*l21(i)*x1(i))/tmax-c*q*l27(i)*x6(i)-l26(i)*(-
(c*q*x6(i))+c*(x1(i)+x2(i)+x3(i)+x4(i))*x6(i))-l223(i)*(-mutgra-ir*x7(i));        
ka224(1)=mumhsa*l224(i)-ps*l227(i)*(1-u21(1))-ps*l226(i)*(1-
u15(1))*u21(1)+k3*l21(i)*x1(i)-k3*l28(i)*x1(i)-k3*l212(i)*x2(i)+k3*l22(i)*x2(i)-
k3*l216(i)*x3(i)+k3*l23(i)*x3(i)-k3*l220(i)*x4(i)+k3*l24(i)*x4(i);        
ka225(1)=mumhra*l225(i)-pr*l226(i)*(1-u15(1))*(1-u22(1))-
pr*l227(i)*u22(1)+k3*l21(i)*x1(i)-k3*l210(i)*x1(i)-k3*l214(i)*x2(i)+k3*l22(i)*x2(i)-










k1sm*rhos*(1-u15(1))*(1-u16(1))*x5(i));        ka227(1)=-1-k1r*(1-qthvr)*l210(i)*x1(i)-
k1r*(1-qtsvr)*l214(i)*x2(i)+k1r*(1-qtsvr)*l22(i)*x2(i)-l21(i)*(-(k*x1(i))-kprimo*x1(i)-








         
        %VARIABILI DI APPOGGIO wb per 2° ordine 
        wb1(i)=0.5*(x1(i)+x1(i-1)); 
        wb2(i)=0.5*(x2(i)+x2(i-1)); 
        wb3(i)=0.5*(x3(i)+x3(i-1)); 
        wb4(i)=0.5*(x4(i)+x4(i-1)); 
        wb5(i)=0.5*(x5(i)+x5(i-1)); 
        wb6(i)=0.5*(x6(i)+x6(i-1)); 
        wb7(i)=0.5*(x7(i)+x7(i-1)); 
        wb8(i)=0.5*(x8(i)+x8(i-1)); 
        wb9(i)=0.5*(x9(i)+x9(i-1)); 
        wb10(i)=0.5*(x10(i)+x10(i-1)); 
        wb11(i)=0.5*(x11(i)+x11(i-1));         
        wb12(i)=0.5*(x12(i)+x12(i-1)); 
        wb13(i)=0.5*(x13(i)+x13(i-1)); 
        wb14(i)=0.5*(x14(i)+x14(i-1)); 
        wb15(i)=0.5*(x15(i)+x15(i-1)); 
        wb16(i)=0.5*(x16(i)+x16(i-1)); 
        wb17(i)=0.5*(x17(i)+x17(i-1)); 
        wb18(i)=0.5*(x18(i)+x18(i-1)); 
        wb19(i)=0.5*(x19(i)+x19(i-1));         
        wb20(i)=0.5*(x20(i)+x20(i-1));         
        wb21(i)=0.5*(x21(i)+x21(i-1)); 
        wb22(i)=0.5*(x22(i)+x22(i-1)); 
        wb23(i)=0.5*(x23(i)+x23(i-1)); 
        wb24(i)=0.5*(x24(i)+x24(i-1)); 
        wb25(i)=0.5*(x25(i)+x25(i-1)); 
        wb26(i)=0.5*(x26(i)+x26(i-1)); 
        wb27(i)=0.5*(x27(i)+x27(i-1)); 
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        %VARIABILI DI APPOGGIO hb per 2° ordine         
        hb11(i)=l11(i)-h2*ka11(1); 
        hb12(i)=l12(i)-h2*ka12(1); 
        hb13(i)=l13(i)-h2*ka13(1); 
        hb14(i)=l14(i)-h2*ka14(1); 
        hb15(i)=l15(i)-h2*ka15(1); 
        hb16(i)=l16(i)-h2*ka16(1); 
        hb17(i)=l17(i)-h2*ka17(1); 
        hb18(i)=l18(i)-h2*ka18(1); 
        hb19(i)=l19(i)-h2*ka19(1); 
        hb110(i)=l110(i)-h2*ka110(1); 
        hb111(i)=l111(i)-h2*ka111(1); 
        hb112(i)=l112(i)-h2*ka112(1); 
        hb113(i)=l113(i)-h2*ka113(1); 
        hb114(i)=l114(i)-h2*ka114(1); 
        hb115(i)=l115(i)-h2*ka115(1); 
        hb116(i)=l116(i)-h2*ka116(1); 
        hb117(i)=l117(i)-h2*ka117(1); 
        hb118(i)=l118(i)-h2*ka118(1); 
        hb119(i)=l119(i)-h2*ka119(1); 
        hb120(i)=l120(i)-h2*ka120(1); 
        hb121(i)=l121(i)-h2*ka121(1); 
        hb122(i)=l122(i)-h2*ka122(1); 
        hb123(i)=l123(i)-h2*ka123(1); 
        hb124(i)=l124(i)-h2*ka124(1); 
        hb125(i)=l125(i)-h2*ka125(1); 
        hb126(i)=l126(i)-h2*ka126(1); 
        hb127(i)=l127(i)-h2*ka127(1);    
         
         
         
        hb21(i)=l21(i)-h2*ka21(1); 
        hb22(i)=l22(i)-h2*ka22(1); 
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        hb23(i)=l23(i)-h2*ka23(1); 
        hb24(i)=l24(i)-h2*ka24(1); 
        hb25(i)=l25(i)-h2*ka25(1); 
        hb26(i)=l26(i)-h2*ka26(1); 
        hb27(i)=l27(i)-h2*ka27(1); 
        hb28(i)=l28(i)-h2*ka28(1); 
        hb29(i)=l29(i)-h2*ka29(1); 
        hb210(i)=l210(i)-h2*ka210(1); 
        hb211(i)=l211(i)-h2*ka211(1); 
        hb212(i)=l212(i)-h2*ka212(1); 
        hb213(i)=l213(i)-h2*ka213(1); 
        hb214(i)=l214(i)-h2*ka214(1); 
        hb215(i)=l215(i)-h2*ka215(1); 
        hb216(i)=l216(i)-h2*ka216(1); 
        hb217(i)=l217(i)-h2*ka217(1); 
        hb218(i)=l218(i)-h2*ka218(1); 
        hb219(i)=l219(i)-h2*ka219(1); 
        hb220(i)=l220(i)-h2*ka220(1); 
        hb221(i)=l221(i)-h2*ka221(1); 
        hb222(i)=l222(i)-h2*ka222(1); 
        hb223(i)=l223(i)-h2*ka223(1); 
        hb224(i)=l224(i)-h2*ka224(1); 
        hb225(i)=l225(i)-h2*ka225(1); 
        hb226(i)=l226(i)-h2*ka226(1); 
        hb227(i)=l227(i)-h2*ka227(1);    
         
      
        %CONTROLLI COEEFICIENTI DI RUNGE KUTTA 2° ORDINE 





























































1.*qtrvs)*wb3(i)+(1.-1.*qtgvs)*wb4(i)))^2));        




















































































































































































































        if(a11<0 || a11>1) 
         a11=0; 
        end; 
         
        if(a12<0 || a12>1) 
         a12=0; 
        end; 
         
        if(a13<0 || a13>1) 
         a13=0; 
        end; 
         
        if(a14<0 || a14>1) 
         a14=0; 
        end; 
         
        if(a15<0 || a15>1) 
         a15=0; 
        end; 
         
        if(a16<0 || a16>1) 
         a16=0; 
        end; 
                 
              






































































































































         
        eval_HT=eval(fHT); 
   
        [max_HT, id_HT]=nanmax(eval_HT); 
         
        u11(2)=D(id_HT,1); 
        u12(2)=D(id_HT,2); 
        u13(2)=D(id_HT,3); 
        u14(2)=D(id_HT,4); 
        u15(2)=D(id_HT,5); 
        u16(2)=D(id_HT,6); 
         
        u21(2)=u21s; 
        u22(2)=u22s;          
         
        %LAMBDA1(2) 





















c*hb16(i)*wb6(i)*(wb11(i)+wb13(i)+wb15(i)+wb17(i)+wb19(i)+wb21(i)+wb23(i)+wb9(i));        
ka14(2)=-1+(r*hb11(i)*wb1(i))/tmax-hb120(i)*(k3*wb24(i)+k1s*(1-qtgvs)*(1-u11(2))*(1-






c*hb16(i)*wb6(i)*(wb11(i)+wb13(i)+wb15(i)+wb17(i)+wb19(i)+wb21(i)+wb23(i)+wb9(i));        
ka15(2)=-1-k1sm*hb124(i)*(1-u15(2))*(1-u16(2))*wb26(i)+k1sm*rhos*hb126(i)*(1-
u15(2))*(1-u16(2))*wb26(i)-k1rm*hb125(i)*wb27(i)+k1rm*rhor*hb127(i)*wb27(i)-





)));        ka17(2)=-
1+muie*hb17(i)+ir*hb111(i)*wb11(i)+is*hb113(i)*wb13(i)+ir*hb115(i)*wb15(i)+is*hb117(i
)*wb17(i)+ir*hb119(i)*wb19(i)+is*hb121(i)*wb21(i)+ir*hb123(i)*wb23(i)+is*hb19(i)*wb9(
i);        ka18(2)=-(hb18(i)*(-muthsl-k2*(1-u14(2))*(1-u16(2))))-k2*hb19(i)*(1-u14(2))*(1-
u16(2))+(r*hb11(i)*wb1(i))/tmax;        ka19(2)=-(ps*hb127(i)*(1-u21(2)))-ps*hb126(i)*(1-
u15(2))*u21(2)+(r*hb11(i)*wb1(i))/tmax-c*q*hb17(i)*wb6(i)-hb16(i)*(-
(c*q*wb6(i))+c*(wb1(i)+wb2(i)+wb3(i)+wb4(i))*wb6(i))-hb19(i)*(-muthsa-is*wb7(i));        
ka110(2)=-((-k2-muthrl)*hb110(i))-k2*hb111(i)+(r*hb11(i)*wb1(i))/tmax;        ka111(2)=-
(pr*hb126(i)*(1-u15(2))*(1-u22(2)))-pr*hb127(i)*u22(2)+(r*hb11(i)*wb1(i))/tmax-
c*q*hb17(i)*wb6(i)-hb16(i)*(-(c*q*wb6(i))+c*(wb1(i)+wb2(i)+wb3(i)+wb4(i))*wb6(i))-
hb111(i)*(-muthra-ir*wb7(i));        ka112(2)=-(hb112(i)*(-mutssl-k2*(1-u14(2))*(1-
u16(2))))-k2*hb113(i)*(1-u14(2))*(1-u16(2))+(r*hb11(i)*wb1(i))/tmax;        ka113(2)=-
(ps*hb127(i)*(1-u21(2)))-ps*hb126(i)*(1-u15(2))*u21(2)+(r*hb11(i)*wb1(i))/tmax-
c*q*hb17(i)*wb6(i)-hb16(i)*(-(c*q*wb6(i))+c*(wb1(i)+wb2(i)+wb3(i)+wb4(i))*wb6(i))-
hb113(i)*(-mutssa-is*wb7(i));        ka114(2)=-((-k2-mutsrl)*hb114(i))-
k2*hb115(i)+(r*hb11(i)*wb1(i))/tmax;        ka115(2)=-(pr*hb126(i)*(1-u15(2))*(1-u22(2)))-
pr*hb127(i)*u22(2)+(r*hb11(i)*wb1(i))/tmax-c*q*hb17(i)*wb6(i)-hb16(i)*(-
(c*q*wb6(i))+c*(wb1(i)+wb2(i)+wb3(i)+wb4(i))*wb6(i))-hb115(i)*(-mutsra-ir*wb7(i));        
ka116(2)=-(hb116(i)*(-mutrsl-k2*(1-u14(2))*(1-u16(2))))-k2*hb117(i)*(1-u14(2))*(1-
u16(2))+(r*hb11(i)*wb1(i))/tmax;        ka117(2)=-(ps*hb127(i)*(1-u21(2)))-ps*hb126(i)*(1-
u15(2))*u21(2)+(r*hb11(i)*wb1(i))/tmax-c*q*hb17(i)*wb6(i)-hb16(i)*(-
(c*q*wb6(i))+c*(wb1(i)+wb2(i)+wb3(i)+wb4(i))*wb6(i))-hb117(i)*(-mutrsa-is*wb7(i));        
ka118(2)=-((-k2-mutrrl)*hb118(i))-k2*hb119(i)+(r*hb11(i)*wb1(i))/tmax;        ka119(2)=-
(pr*hb126(i)*(1-u15(2))*(1-u22(2)))-pr*hb127(i)*u22(2)+(r*hb11(i)*wb1(i))/tmax-
c*q*hb17(i)*wb6(i)-hb16(i)*(-(c*q*wb6(i))+c*(wb1(i)+wb2(i)+wb3(i)+wb4(i))*wb6(i))-
hb119(i)*(-mutrra-ir*wb7(i));        ka120(2)=-(hb120(i)*(-mutgsl-k2*(1-u14(2))*(1-
u16(2))))-k2*hb121(i)*(1-u14(2))*(1-u16(2))+(r*hb11(i)*wb1(i))/tmax;        ka121(2)=-
(ps*hb127(i)*(1-u21(2)))-ps*hb126(i)*(1-u15(2))*u21(2)+(r*hb11(i)*wb1(i))/tmax-
c*q*hb17(i)*wb6(i)-hb16(i)*(-(c*q*wb6(i))+c*(wb1(i)+wb2(i)+wb3(i)+wb4(i))*wb6(i))-
hb121(i)*(-mutgsa-is*wb7(i));        ka122(2)=-((-k2-mutgrl)*hb122(i))-
k2*hb123(i)+(r*hb11(i)*wb1(i))/tmax;        ka123(2)=-(pr*hb126(i)*(1-u15(2))*(1-u22(2)))-
pr*hb127(i)*u22(2)+(r*hb11(i)*wb1(i))/tmax-c*q*hb17(i)*wb6(i)-hb16(i)*(-




k3*hb120(i)*wb4(i)+k3*hb14(i)*wb4(i);        ka125(2)=mumhra*hb125(i)-pr*hb126(i)*(1-
u15(2))*(1-u22(2))-pr*hb127(i)*u22(2)+k3*hb11(i)*wb1(i)-k3*hb110(i)*wb1(i)-
k3*hb114(i)*wb2(i)+k3*hb12(i)*wb2(i)-k3*hb118(i)*wb3(i)+k3*hb13(i)*wb3(i)-























         
        %LAMBDA2(2) 



























c*hb26(i)*wb6(i)*(wb11(i)+wb13(i)+wb15(i)+wb17(i)+wb19(i)+wb21(i)+wb23(i)+wb9(i));        
ka25(2)=-(k1sm*hb224(i)*(1-u15(2))*(1-u16(2))*wb26(i))+k1sm*rhos*hb226(i)*(1-
u15(2))*(1-u16(2))*wb26(i)-k1rm*hb225(i)*wb27(i)+k1rm*rhor*hb227(i)*wb27(i)-





)));        
ka27(2)=muie*hb27(i)+ir*hb211(i)*wb11(i)+is*hb213(i)*wb13(i)+ir*hb215(i)*wb15(i)+is*h
b217(i)*wb17(i)+ir*hb219(i)*wb19(i)+is*hb221(i)*wb21(i)+ir*hb223(i)*wb23(i)+is*hb29(i)
*wb9(i);        ka28(2)=-1-hb28(i)*(-muthsl-k2*(1-u14(2))*(1-u16(2)))-k2*hb29(i)*(1-
u14(2))*(1-u16(2))+(r*hb21(i)*wb1(i))/tmax;        ka29(2)= -1-ps*hb227(i)*(1-u21(2))-
ps*hb226(i)*(1-u15(2))*u21(2)+(r*hb21(i)*wb1(i))/tmax-c*q*hb27(i)*wb6(i)-hb26(i)*(-
(c*q*wb6(i))+c*(wb1(i)+wb2(i)+wb3(i)+wb4(i))*wb6(i))-hb29(i)*(-muthsa-is*wb7(i));        
ka210(2)=-1-(-k2-muthrl)*hb210(i)-k2*hb211(i)+(r*hb21(i)*wb1(i))/tmax;        ka211(2)= -




hb211(i)*(-muthra-ir*wb7(i));        ka212(2)=-1-hb212(i)*(-mutssl-k2*(1-u14(2))*(1-
u16(2)))-k2*hb213(i)*(1-u14(2))*(1-u16(2))+(r*hb21(i)*wb1(i))/tmax;        ka213(2)=-1-
ps*hb227(i)*(1-u21(2))-ps*hb226(i)*(1-u15(2))*u21(2)+(r*hb21(i)*wb1(i))/tmax-
c*q*hb27(i)*wb6(i)-hb26(i)*(-(c*q*wb6(i))+c*(wb1(i)+wb2(i)+wb3(i)+wb4(i))*wb6(i))-
hb213(i)*(-mutssa-is*wb7(i));        ka214(2)=-1-(-k2-mutsrl)*hb214(i)-
k2*hb215(i)+(r*hb21(i)*wb1(i))/tmax;        ka215(2)=-1-pr*hb226(i)*(1-u15(2))*(1-u22(2))-
pr*hb227(i)*u22(2)+(r*hb21(i)*wb1(i))/tmax-c*q*hb27(i)*wb6(i)-hb26(i)*(-
(c*q*wb6(i))+c*(wb1(i)+wb2(i)+wb3(i)+wb4(i))*wb6(i))-hb215(i)*(-mutsra-ir*wb7(i));        
ka216(2)=-1-hb216(i)*(-mutrsl-k2*(1-u14(2))*(1-u16(2)))-k2*hb217(i)*(1-u14(2))*(1-
u16(2))+(r*hb21(i)*wb1(i))/tmax;        ka217(2)=-1-ps*hb227(i)*(1-u21(2))-ps*hb226(i)*(1-
u15(2))*u21(2)+(r*hb21(i)*wb1(i))/tmax-c*q*hb27(i)*wb6(i)-hb26(i)*(-
(c*q*wb6(i))+c*(wb1(i)+wb2(i)+wb3(i)+wb4(i))*wb6(i))-hb217(i)*(-mutrsa-is*wb7(i));        
ka218(2)=-1-(-k2-mutrrl)*hb218(i)-k2*hb219(i)+(r*hb21(i)*wb1(i))/tmax;        ka219(2)=-1-
pr*hb226(i)*(1-u15(2))*(1-u22(2))-pr*hb227(i)*u22(2)+(r*hb21(i)*wb1(i))/tmax-
c*q*hb27(i)*wb6(i)-hb26(i)*(-(c*q*wb6(i))+c*(wb1(i)+wb2(i)+wb3(i)+wb4(i))*wb6(i))-
hb219(i)*(-mutrra-ir*wb7(i));        ka220(2)=-1-hb220(i)*(-mutgsl-k2*(1-u14(2))*(1-
u16(2)))-k2*hb221(i)*(1-u14(2))*(1-u16(2))+(r*hb21(i)*wb1(i))/tmax;        ka221(2)=-1-
ps*hb227(i)*(1-u21(2))-ps*hb226(i)*(1-u15(2))*u21(2)+(r*hb21(i)*wb1(i))/tmax-
c*q*hb27(i)*wb6(i)-hb26(i)*(-(c*q*wb6(i))+c*(wb1(i)+wb2(i)+wb3(i)+wb4(i))*wb6(i))-
hb221(i)*(-mutgsa-is*wb7(i));        ka222(2)=-1-(-k2-mutgrl)*hb222(i)-
k2*hb223(i)+(r*hb21(i)*wb1(i))/tmax;        ka223(2)=-1-pr*hb226(i)*(1-u15(2))*(1-u22(2))-
pr*hb227(i)*u22(2)+(r*hb21(i)*wb1(i))/tmax-c*q*hb27(i)*wb6(i)-hb26(i)*(-




k3*hb220(i)*wb4(i)+k3*hb24(i)*wb4(i);        ka225(2)=mumhra*hb225(i)-pr*hb226(i)*(1-
u15(2))*(1-u22(2))-pr*hb227(i)*u22(2)+k3*hb21(i)*wb1(i)-k3*hb210(i)*wb1(i)-
k3*hb214(i)*wb2(i)+k3*hb22(i)*wb2(i)-k3*hb218(i)*wb3(i)+k3*hb23(i)*wb3(i)-



















         
        %VARIABILI DI APPOGGIO per 3° ordine 
        wb1(i)=0.5*(x1(i)+x1(i-1)); 
        wb2(i)=0.5*(x2(i)+x2(i-1)); 
        wb3(i)=0.5*(x3(i)+x3(i-1)); 
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        wb4(i)=0.5*(x4(i)+x4(i-1)); 
        wb5(i)=0.5*(x5(i)+x5(i-1)); 
        wb6(i)=0.5*(x6(i)+x6(i-1)); 
        wb7(i)=0.5*(x7(i)+x7(i-1)); 
        wb8(i)=0.5*(x8(i)+x8(i-1)); 
        wb9(i)=0.5*(x9(i)+x9(i-1)); 
        wb10(i)=0.5*(x10(i)+x10(i-1)); 
        wb11(i)=0.5*(x11(i)+x11(i-1));         
        wb12(i)=0.5*(x12(i)+x12(i-1)); 
        wb13(i)=0.5*(x13(i)+x13(i-1)); 
        wb14(i)=0.5*(x14(i)+x14(i-1)); 
        wb15(i)=0.5*(x15(i)+x15(i-1)); 
        wb16(i)=0.5*(x16(i)+x16(i-1)); 
        wb17(i)=0.5*(x17(i)+x17(i-1)); 
        wb18(i)=0.5*(x18(i)+x18(i-1)); 
        wb19(i)=0.5*(x19(i)+x19(i-1));         
        wb20(i)=0.5*(x20(i)+x20(i-1));         
        wb21(i)=0.5*(x21(i)+x21(i-1)); 
        wb22(i)=0.5*(x22(i)+x22(i-1)); 
        wb23(i)=0.5*(x23(i)+x23(i-1)); 
        wb24(i)=0.5*(x24(i)+x24(i-1)); 
        wb25(i)=0.5*(x25(i)+x25(i-1)); 
        wb26(i)=0.5*(x26(i)+x26(i-1)); 
        wb27(i)=0.5*(x27(i)+x27(i-1)); 
         
         
        %VARIABILI DI APPOGGIO hb per 3° ordine         
        hb11(i)=l11(i)-h2*ka11(2); 
        hb12(i)=l12(i)-h2*ka12(2); 
        hb13(i)=l13(i)-h2*ka13(2); 
        hb14(i)=l14(i)-h2*ka14(2); 
        hb15(i)=l15(i)-h2*ka15(2); 
        hb16(i)=l16(i)-h2*ka16(2); 
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        hb17(i)=l17(i)-h2*ka17(2); 
        hb18(i)=l18(i)-h2*ka18(2); 
        hb19(i)=l19(i)-h2*ka19(2); 
        hb110(i)=l110(i)-h2*ka110(2); 
        hb111(i)=l111(i)-h2*ka111(2); 
        hb112(i)=l112(i)-h2*ka112(2); 
        hb113(i)=l113(i)-h2*ka113(2); 
        hb114(i)=l114(i)-h2*ka114(2); 
        hb115(i)=l115(i)-h2*ka115(2); 
        hb116(i)=l116(i)-h2*ka116(2); 
        hb117(i)=l117(i)-h2*ka117(2); 
        hb118(i)=l118(i)-h2*ka118(2); 
        hb119(i)=l119(i)-h2*ka119(2); 
        hb120(i)=l120(i)-h2*ka120(2); 
        hb121(i)=l121(i)-h2*ka121(2); 
        hb122(i)=l122(i)-h2*ka122(2); 
        hb123(i)=l123(i)-h2*ka123(2); 
        hb124(i)=l124(i)-h2*ka124(2); 
        hb125(i)=l125(i)-h2*ka125(2); 
        hb126(i)=l126(i)-h2*ka126(2); 
        hb127(i)=l127(i)-h2*ka127(2);    
         
         
         
        hb21(i)=l21(i)-h2*ka21(2); 
        hb22(i)=l22(i)-h2*ka22(2); 
        hb23(i)=l23(i)-h2*ka23(2); 
        hb24(i)=l24(i)-h2*ka24(2); 
        hb25(i)=l25(i)-h2*ka25(2); 
        hb26(i)=l26(i)-h2*ka26(2); 
        hb27(i)=l27(i)-h2*ka27(2); 
        hb28(i)=l28(i)-h2*ka28(2); 
        hb29(i)=l29(i)-h2*ka29(2); 
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        hb210(i)=l210(i)-h2*ka210(2); 
        hb211(i)=l211(i)-h2*ka211(2); 
        hb212(i)=l212(i)-h2*ka212(2); 
        hb213(i)=l213(i)-h2*ka213(2); 
        hb214(i)=l214(i)-h2*ka214(2); 
        hb215(i)=l215(i)-h2*ka215(2); 
        hb216(i)=l216(i)-h2*ka216(2); 
        hb217(i)=l217(i)-h2*ka217(2); 
        hb218(i)=l218(i)-h2*ka218(2); 
        hb219(i)=l219(i)-h2*ka219(2); 
        hb220(i)=l220(i)-h2*ka220(2); 
        hb221(i)=l221(i)-h2*ka221(2); 
        hb222(i)=l222(i)-h2*ka222(2); 
        hb223(i)=l223(i)-h2*ka223(2); 
        hb224(i)=l224(i)-h2*ka224(2); 
        hb225(i)=l225(i)-h2*ka225(2); 
        hb226(i)=l226(i)-h2*ka226(2); 
        hb227(i)=l227(i)-h2*ka227(2);   
         
         
        %CONTROLLI COEEFICIENTI DI RUNGE KUTTA 3° ORDINE 





























































1.*qtrvs)*wb3(i)+(1.-1.*qtgvs)*wb4(i)))^2));        a13= 




















































































































































































































        if(a11<0 || a11>1) 
         a11=0; 
        end; 
         
        if(a12<0 || a12>1) 
         a12=0; 
        end; 
         
        if(a13<0 || a13>1) 
         a13=0; 
        end; 
         
        if(a14<0 || a14>1) 
         a14=0; 
        end; 
         
        if(a15<0 || a15>1) 
         a15=0; 
        end; 
         
        if(a16<0 || a16>1) 
         a16=0; 





































































































































         
        eval_HT=eval(fHT); 
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        [max_HT, id_HT]=nanmax(eval_HT); 
         
        u11(3)=D(id_HT,1); 
        u12(3)=D(id_HT,2); 
        u13(3)=D(id_HT,3); 
        u14(3)=D(id_HT,4); 
        u15(3)=D(id_HT,5); 
        u16(3)=D(id_HT,6); 
         
        u21(3)=u21s; 
        u22(3)=u22s;          
         
         
        %LAMBDA1(3) 



























c*hb16(i)*wb6(i)*(wb11(i)+wb13(i)+wb15(i)+wb17(i)+wb19(i)+wb21(i)+wb23(i)+wb9(i));        
ka15(3)=-1-k1sm*hb124(i)*(1-u15(3))*(1-u16(3))*wb26(i)+k1sm*rhos*hb126(i)*(1-
u15(3))*(1-u16(3))*wb26(i)-k1rm*hb125(i)*wb27(i)+k1rm*rhor*hb127(i)*wb27(i)-
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2(i)+wb3(i)+wb4(i))*(wb11(i)+wb13(i)+wb15(i)+wb17(i)+wb19(i)+wb21(i)+wb23(i)+wb9(i
)));        ka17(3)=-
1+muie*hb17(i)+ir*hb111(i)*wb11(i)+is*hb113(i)*wb13(i)+ir*hb115(i)*wb15(i)+is*hb117(i
)*wb17(i)+ir*hb119(i)*wb19(i)+is*hb121(i)*wb21(i)+ir*hb123(i)*wb23(i)+is*hb19(i)*wb9(
i);        ka18(3)=-(hb18(i)*(-muthsl-k2*(1-u14(3))*(1-u16(3))))-k2*hb19(i)*(1-u14(3))*(1-
u16(3))+(r*hb11(i)*wb1(i))/tmax;        ka19(3)=-(ps*hb127(i)*(1-u21(3)))-ps*hb126(i)*(1-
u15(3))*u21(3)+(r*hb11(i)*wb1(i))/tmax-c*q*hb17(i)*wb6(i)-hb16(i)*(-
(c*q*wb6(i))+c*(wb1(i)+wb2(i)+wb3(i)+wb4(i))*wb6(i))-hb19(i)*(-muthsa-is*wb7(i));        
ka110(3)=-((-k2-muthrl)*hb110(i))-k2*hb111(i)+(r*hb11(i)*wb1(i))/tmax;        ka111(3)=-
(pr*hb126(i)*(1-u15(3))*(1-u22(3)))-pr*hb127(i)*u22(3)+(r*hb11(i)*wb1(i))/tmax-
c*q*hb17(i)*wb6(i)-hb16(i)*(-(c*q*wb6(i))+c*(wb1(i)+wb2(i)+wb3(i)+wb4(i))*wb6(i))-
hb111(i)*(-muthra-ir*wb7(i));        ka112(3)=-(hb112(i)*(-mutssl-k2*(1-u14(3))*(1-
u16(3))))-k2*hb113(i)*(1-u14(3))*(1-u16(3))+(r*hb11(i)*wb1(i))/tmax;        ka113(3)=-
(ps*hb127(i)*(1-u21(3)))-ps*hb126(i)*(1-u15(3))*u21(3)+(r*hb11(i)*wb1(i))/tmax-
c*q*hb17(i)*wb6(i)-hb16(i)*(-(c*q*wb6(i))+c*(wb1(i)+wb2(i)+wb3(i)+wb4(i))*wb6(i))-
hb113(i)*(-mutssa-is*wb7(i));        ka114(3)=-((-k2-mutsrl)*hb114(i))-
k2*hb115(i)+(r*hb11(i)*wb1(i))/tmax;        ka115(3)=-(pr*hb126(i)*(1-u15(3))*(1-u22(3)))-
pr*hb127(i)*u22(3)+(r*hb11(i)*wb1(i))/tmax-c*q*hb17(i)*wb6(i)-hb16(i)*(-
(c*q*wb6(i))+c*(wb1(i)+wb2(i)+wb3(i)+wb4(i))*wb6(i))-hb115(i)*(-mutsra-ir*wb7(i));        
ka116(3)=-(hb116(i)*(-mutrsl-k2*(1-u14(3))*(1-u16(3))))-k2*hb117(i)*(1-u14(3))*(1-
u16(3))+(r*hb11(i)*wb1(i))/tmax;        ka117(3)=-(ps*hb127(i)*(1-u21(3)))-ps*hb126(i)*(1-
u15(3))*u21(3)+(r*hb11(i)*wb1(i))/tmax-c*q*hb17(i)*wb6(i)-hb16(i)*(-
(c*q*wb6(i))+c*(wb1(i)+wb2(i)+wb3(i)+wb4(i))*wb6(i))-hb117(i)*(-mutrsa-is*wb7(i));        
ka118(3)=-((-k2-mutrrl)*hb118(i))-k2*hb119(i)+(r*hb11(i)*wb1(i))/tmax;        ka119(3)=-
(pr*hb126(i)*(1-u15(3))*(1-u22(3)))-pr*hb127(i)*u22(3)+(r*hb11(i)*wb1(i))/tmax-
c*q*hb17(i)*wb6(i)-hb16(i)*(-(c*q*wb6(i))+c*(wb1(i)+wb2(i)+wb3(i)+wb4(i))*wb6(i))-
hb119(i)*(-mutrra-ir*wb7(i));        ka120(3)=-(hb120(i)*(-mutgsl-k2*(1-u14(3))*(1-
u16(3))))-k2*hb121(i)*(1-u14(3))*(1-u16(3))+(r*hb11(i)*wb1(i))/tmax;        ka121(3)=-
(ps*hb127(i)*(1-u21(3)))-ps*hb126(i)*(1-u15(3))*u21(3)+(r*hb11(i)*wb1(i))/tmax-
c*q*hb17(i)*wb6(i)-hb16(i)*(-(c*q*wb6(i))+c*(wb1(i)+wb2(i)+wb3(i)+wb4(i))*wb6(i))-
hb121(i)*(-mutgsa-is*wb7(i));        ka122(3)=-((-k2-mutgrl)*hb122(i))-
k2*hb123(i)+(r*hb11(i)*wb1(i))/tmax;        ka123(3)=-(pr*hb126(i)*(1-u15(3))*(1-u22(3)))-
pr*hb127(i)*u22(3)+(r*hb11(i)*wb1(i))/tmax-c*q*hb17(i)*wb6(i)-hb16(i)*(-




k3*hb120(i)*wb4(i)+k3*hb14(i)*wb4(i);        ka125(3)=mumhra*hb125(i)-pr*hb126(i)*(1-
u15(3))*(1-u22(3))-pr*hb127(i)*u22(3)+k3*hb11(i)*wb1(i)-k3*hb110(i)*wb1(i)-
k3*hb114(i)*wb2(i)+k3*hb12(i)*wb2(i)-k3*hb118(i)*wb3(i)+k3*hb13(i)*wb3(i)-
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        %LAMBDA2(3) 



























c*hb26(i)*wb6(i)*(wb11(i)+wb13(i)+wb15(i)+wb17(i)+wb19(i)+wb21(i)+wb23(i)+wb9(i));        
ka25(3)=-(k1sm*hb224(i)*(1-u15(3))*(1-u16(3))*wb26(i))+k1sm*rhos*hb226(i)*(1-
u15(3))*(1-u16(3))*wb26(i)-k1rm*hb225(i)*wb27(i)+k1rm*rhor*hb227(i)*wb27(i)-





)));        
ka27(3)=muie*hb27(i)+ir*hb211(i)*wb11(i)+is*hb213(i)*wb13(i)+ir*hb215(i)*wb15(i)+is*h
b217(i)*wb17(i)+ir*hb219(i)*wb19(i)+is*hb221(i)*wb21(i)+ir*hb223(i)*wb23(i)+is*hb29(i)
*wb9(i);        ka28(3)=-1-hb28(i)*(-muthsl-k2*(1-u14(3))*(1-u16(3)))-k2*hb29(i)*(1-
u14(3))*(1-u16(3))+(r*hb21(i)*wb1(i))/tmax;        ka29(3)= -1-ps*hb227(i)*(1-u21(3))-
ps*hb226(i)*(1-u15(3))*u21(3)+(r*hb21(i)*wb1(i))/tmax-c*q*hb27(i)*wb6(i)-hb26(i)*(-
(c*q*wb6(i))+c*(wb1(i)+wb2(i)+wb3(i)+wb4(i))*wb6(i))-hb29(i)*(-muthsa-is*wb7(i));        
ka210(3)=-1-(-k2-muthrl)*hb210(i)-k2*hb211(i)+(r*hb21(i)*wb1(i))/tmax;        ka211(3)= -
1-pr*hb226(i)*(1-u15(3))*(1-u22(3))-pr*hb227(i)*u22(3)+(r*hb21(i)*wb1(i))/tmax-
c*q*hb27(i)*wb6(i)-hb26(i)*(-(c*q*wb6(i))+c*(wb1(i)+wb2(i)+wb3(i)+wb4(i))*wb6(i))-
hb211(i)*(-muthra-ir*wb7(i));        ka212(3)=-1-hb212(i)*(-mutssl-k2*(1-u14(3))*(1-
u16(3)))-k2*hb213(i)*(1-u14(3))*(1-u16(3))+(r*hb21(i)*wb1(i))/tmax;        ka213(3)=-1-
ps*hb227(i)*(1-u21(3))-ps*hb226(i)*(1-u15(3))*u21(3)+(r*hb21(i)*wb1(i))/tmax-
c*q*hb27(i)*wb6(i)-hb26(i)*(-(c*q*wb6(i))+c*(wb1(i)+wb2(i)+wb3(i)+wb4(i))*wb6(i))-
hb213(i)*(-mutssa-is*wb7(i));        ka214(3)=-1-(-k2-mutsrl)*hb214(i)-
k2*hb215(i)+(r*hb21(i)*wb1(i))/tmax;        ka215(3)=-1-pr*hb226(i)*(1-u15(3))*(1-u22(3))-
pr*hb227(i)*u22(3)+(r*hb21(i)*wb1(i))/tmax-c*q*hb27(i)*wb6(i)-hb26(i)*(-
(c*q*wb6(i))+c*(wb1(i)+wb2(i)+wb3(i)+wb4(i))*wb6(i))-hb215(i)*(-mutsra-ir*wb7(i));        
ka216(3)=-1-hb216(i)*(-mutrsl-k2*(1-u14(3))*(1-u16(3)))-k2*hb217(i)*(1-u14(3))*(1-
u16(3))+(r*hb21(i)*wb1(i))/tmax;        ka217(3)=-1-ps*hb227(i)*(1-u21(3))-ps*hb226(i)*(1-
u15(3))*u21(3)+(r*hb21(i)*wb1(i))/tmax-c*q*hb27(i)*wb6(i)-hb26(i)*(-
(c*q*wb6(i))+c*(wb1(i)+wb2(i)+wb3(i)+wb4(i))*wb6(i))-hb217(i)*(-mutrsa-is*wb7(i));        
ka218(3)=-1-(-k2-mutrrl)*hb218(i)-k2*hb219(i)+(r*hb21(i)*wb1(i))/tmax;        ka219(3)=-1-




hb219(i)*(-mutrra-ir*wb7(i));        ka220(3)=-1-hb220(i)*(-mutgsl-k2*(1-u14(3))*(1-
u16(3)))-k2*hb221(i)*(1-u14(3))*(1-u16(3))+(r*hb21(i)*wb1(i))/tmax;        ka221(3)=-1-
ps*hb227(i)*(1-u21(3))-ps*hb226(i)*(1-u15(3))*u21(3)+(r*hb21(i)*wb1(i))/tmax-
c*q*hb27(i)*wb6(i)-hb26(i)*(-(c*q*wb6(i))+c*(wb1(i)+wb2(i)+wb3(i)+wb4(i))*wb6(i))-
hb221(i)*(-mutgsa-is*wb7(i));        ka222(3)=-1-(-k2-mutgrl)*hb222(i)-
k2*hb223(i)+(r*hb21(i)*wb1(i))/tmax;        ka223(3)=-1-pr*hb226(i)*(1-u15(3))*(1-u22(3))-
pr*hb227(i)*u22(3)+(r*hb21(i)*wb1(i))/tmax-c*q*hb27(i)*wb6(i)-hb26(i)*(-




k3*hb220(i)*wb4(i)+k3*hb24(i)*wb4(i);        ka225(3)=mumhra*hb225(i)-pr*hb226(i)*(1-
u15(3))*(1-u22(3))-pr*hb227(i)*u22(3)+k3*hb21(i)*wb1(i)-k3*hb210(i)*wb1(i)-
k3*hb214(i)*wb2(i)+k3*hb22(i)*wb2(i)-k3*hb218(i)*wb3(i)+k3*hb23(i)*wb3(i)-



















         
         
        %VARIABILI DI APPOGGIO per 4° ordine         
        wb1(i)=(x1(i-1)); 
        wb2(i)=(x2(i-1)); 
        wb3(i)=(x3(i-1)); 
        wb4(i)=(x4(i-1)); 
        wb5(i)=(+x5(i-1)); 
        wb6(i)=(x6(i-1)); 
        wb7(i)=(x7(i-1)); 
        wb8(i)=(x8(i-1)); 
        wb9(i)=(x9(i-1)); 
        wb10(i)=(x10(i-1)); 
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        wb11(i)=(x11(i-1));         
        wb12(i)=(x12(i-1)); 
        wb13(i)=(x13(i-1)); 
        wb14(i)=(x14(i-1)); 
        wb15(i)=(x15(i-1)); 
        wb16(i)=(x16(i-1)); 
        wb17(i)=(x17(i-1)); 
        wb18(i)=(x18(i-1)); 
        wb19(i)=(x19(i-1));         
        wb20(i)=(x20(i-1));         
        wb21(i)=(x21(i-1)); 
        wb22(i)=(x22(i-1)); 
        wb23(i)=(x23(i-1)); 
        wb24(i)=(x24(i-1)); 
        wb25(i)=(x25(i-1)); 
        wb26(i)=(x26(i-1)); 
        wb27(i)=(x27(i-1)); 
         
         
        %VARIABILI DI APPOGGIO hb per 4° ordine         
        hb11(i)=l11(i)-h*ka11(3); 
        hb12(i)=l12(i)-h*ka12(3); 
        hb13(i)=l13(i)-h*ka13(3); 
        hb14(i)=l14(i)-h*ka14(3); 
        hb15(i)=l15(i)-h*ka15(3); 
        hb16(i)=l16(i)-h*ka16(3); 
        hb17(i)=l17(i)-h*ka17(3); 
        hb18(i)=l18(i)-h*ka18(3); 
        hb19(i)=l19(i)-h*ka19(3); 
        hb110(i)=l110(i)-h*ka110(3); 
        hb111(i)=l111(i)-h*ka111(3); 
        hb112(i)=l112(i)-h*ka112(3); 
        hb113(i)=l113(i)-h*ka113(3); 
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        hb114(i)=l114(i)-h*ka114(3); 
        hb115(i)=l115(i)-h*ka115(3); 
        hb116(i)=l116(i)-h*ka116(3); 
        hb117(i)=l117(i)-h*ka117(3); 
        hb118(i)=l118(i)-h*ka118(3); 
        hb119(i)=l119(i)-h*ka119(3); 
        hb120(i)=l120(i)-h*ka120(3); 
        hb121(i)=l121(i)-h*ka121(3); 
        hb122(i)=l122(i)-h*ka122(3); 
        hb123(i)=l123(i)-h*ka123(3); 
        hb124(i)=l124(i)-h*ka124(3); 
        hb125(i)=l125(i)-h*ka125(3); 
        hb126(i)=l126(i)-h*ka126(3); 
        hb127(i)=l127(i)-h*ka127(3);    
         
         
         
        hb21(i)=l21(i)-h*ka21(3); 
        hb22(i)=l22(i)-h*ka22(3); 
        hb23(i)=l23(i)-h*ka23(3); 
        hb24(i)=l24(i)-h*ka24(3); 
        hb25(i)=l25(i)-h*ka25(3); 
        hb26(i)=l26(i)-h*ka26(3); 
        hb27(i)=l27(i)-h*ka27(3); 
        hb28(i)=l28(i)-h*ka28(3); 
        hb29(i)=l29(i)-h*ka29(3); 
        hb210(i)=l210(i)-h*ka210(3); 
        hb211(i)=l211(i)-h*ka211(3); 
        hb212(i)=l212(i)-h*ka212(3); 
        hb213(i)=l213(i)-h*ka213(3); 
        hb214(i)=l214(i)-h*ka214(3); 
        hb215(i)=l215(i)-h*ka215(3); 
        hb216(i)=l216(i)-h*ka216(3); 
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        hb217(i)=l217(i)-h*ka217(3); 
        hb218(i)=l218(i)-h*ka218(3); 
        hb219(i)=l219(i)-h*ka219(3); 
        hb220(i)=l220(i)-h*ka220(3); 
        hb221(i)=l221(i)-h*ka221(3); 
        hb222(i)=l222(i)-h*ka222(3); 
        hb223(i)=l223(i)-h*ka223(3); 
        hb224(i)=l224(i)-h*ka224(3); 
        hb225(i)=l225(i)-h*ka225(3); 
        hb226(i)=l226(i)-h*ka226(3); 
        hb227(i)=l227(i)-h*ka227(3);   
         
         
        %CONTROLLI COEEFICIENTI DI RUNGE KUTTA 4° ORDINE 
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1.*qtgvs)*hb14(i)*wb26(i)*wb4(i)-1.*k1s*rhos*hb126(i)*wb26(i)*((1.-
























1.*qtrvs)*wb3(i)+(1.-1.*qtgvs)*wb4(i)))^2));        


















































































































































































































        if(a11<0 || a11>1) 
         a11=0; 
        end; 
         
        if(a12<0 || a12>1) 
         a12=0; 
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        end; 
         
        if(a13<0 || a13>1) 
         a13=0; 
        end; 
         
        if(a14<0 || a14>1) 
         a14=0; 
        end; 
         
        if(a15<0 || a15>1) 
         a15=0; 
        end; 
         
        if(a16<0 || a16>1) 
         a16=0; 
        end; 




































































































































         
        eval_HT=eval(fHT); 
         
        [max_HT, id_HT]=nanmax(eval_HT); 
         
        u11(4)=D(id_HT,1); 
        u12(4)=D(id_HT,2); 
        u13(4)=D(id_HT,3); 
        u14(4)=D(id_HT,4); 
        u15(4)=D(id_HT,5); 
        u16(4)=D(id_HT,6); 
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        u21(4)=u21s; 
        u22(4)=u22s;           
         
         
        %LAMBDA1(4) 



























c*hb16(i)*wb6(i)*(wb11(i)+wb13(i)+wb15(i)+wb17(i)+wb19(i)+wb21(i)+wb23(i)+wb9(i));        
ka15(4)=-1-k1sm*hb124(i)*(1-u15(4))*(1-u16(4))*wb26(i)+k1sm*rhos*hb126(i)*(1-
u15(4))*(1-u16(4))*wb26(i)-k1rm*hb125(i)*wb27(i)+k1rm*rhor*hb127(i)*wb27(i)-





)));        ka17(4)=-
1+muie*hb17(i)+ir*hb111(i)*wb11(i)+is*hb113(i)*wb13(i)+ir*hb115(i)*wb15(i)+is*hb117(i
)*wb17(i)+ir*hb119(i)*wb19(i)+is*hb121(i)*wb21(i)+ir*hb123(i)*wb23(i)+is*hb19(i)*wb9(
i);        ka18(4)=-(hb18(i)*(-muthsl-k2*(1-u14(4))*(1-u16(4))))-k2*hb19(i)*(1-u14(4))*(1-
u16(4))+(r*hb11(i)*wb1(i))/tmax;        ka19(4)=-(ps*hb127(i)*(1-u21(4)))-ps*hb126(i)*(1-
u15(4))*u21(4)+(r*hb11(i)*wb1(i))/tmax-c*q*hb17(i)*wb6(i)-hb16(i)*(-
(c*q*wb6(i))+c*(wb1(i)+wb2(i)+wb3(i)+wb4(i))*wb6(i))-hb19(i)*(-muthsa-is*wb7(i));        
ka110(4)=-((-k2-muthrl)*hb110(i))-k2*hb111(i)+(r*hb11(i)*wb1(i))/tmax;        ka111(4)=-
(pr*hb126(i)*(1-u15(4))*(1-u22(4)))-pr*hb127(i)*u22(4)+(r*hb11(i)*wb1(i))/tmax-
c*q*hb17(i)*wb6(i)-hb16(i)*(-(c*q*wb6(i))+c*(wb1(i)+wb2(i)+wb3(i)+wb4(i))*wb6(i))-
hb111(i)*(-muthra-ir*wb7(i));        ka112(4)=-(hb112(i)*(-mutssl-k2*(1-u14(4))*(1-
u16(4))))-k2*hb113(i)*(1-u14(4))*(1-u16(4))+(r*hb11(i)*wb1(i))/tmax;        ka113(4)=-
(ps*hb127(i)*(1-u21(4)))-ps*hb126(i)*(1-u15(4))*u21(4)+(r*hb11(i)*wb1(i))/tmax-
c*q*hb17(i)*wb6(i)-hb16(i)*(-(c*q*wb6(i))+c*(wb1(i)+wb2(i)+wb3(i)+wb4(i))*wb6(i))-
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hb113(i)*(-mutssa-is*wb7(i));        ka114(4)=-((-k2-mutsrl)*hb114(i))-
k2*hb115(i)+(r*hb11(i)*wb1(i))/tmax;        ka115(4)=-(pr*hb126(i)*(1-u15(4))*(1-u22(4)))-
pr*hb127(i)*u22(4)+(r*hb11(i)*wb1(i))/tmax-c*q*hb17(i)*wb6(i)-hb16(i)*(-
(c*q*wb6(i))+c*(wb1(i)+wb2(i)+wb3(i)+wb4(i))*wb6(i))-hb115(i)*(-mutsra-ir*wb7(i));        
ka116(4)=-(hb116(i)*(-mutrsl-k2*(1-u14(4))*(1-u16(4))))-k2*hb117(i)*(1-u14(4))*(1-
u16(4))+(r*hb11(i)*wb1(i))/tmax;        ka117(4)=-(ps*hb127(i)*(1-u21(4)))-ps*hb126(i)*(1-
u15(4))*u21(4)+(r*hb11(i)*wb1(i))/tmax-c*q*hb17(i)*wb6(i)-hb16(i)*(-
(c*q*wb6(i))+c*(wb1(i)+wb2(i)+wb3(i)+wb4(i))*wb6(i))-hb117(i)*(-mutrsa-is*wb7(i));        
ka118(4)=-((-k2-mutrrl)*hb118(i))-k2*hb119(i)+(r*hb11(i)*wb1(i))/tmax;        ka119(4)=-
(pr*hb126(i)*(1-u15(4))*(1-u22(4)))-pr*hb127(i)*u22(4)+(r*hb11(i)*wb1(i))/tmax-
c*q*hb17(i)*wb6(i)-hb16(i)*(-(c*q*wb6(i))+c*(wb1(i)+wb2(i)+wb3(i)+wb4(i))*wb6(i))-
hb119(i)*(-mutrra-ir*wb7(i));        ka120(4)=-(hb120(i)*(-mutgsl-k2*(1-u14(4))*(1-
u16(4))))-k2*hb121(i)*(1-u14(4))*(1-u16(4))+(r*hb11(i)*wb1(i))/tmax;        ka121(4)=-
(ps*hb127(i)*(1-u21(4)))-ps*hb126(i)*(1-u15(4))*u21(4)+(r*hb11(i)*wb1(i))/tmax-
c*q*hb17(i)*wb6(i)-hb16(i)*(-(c*q*wb6(i))+c*(wb1(i)+wb2(i)+wb3(i)+wb4(i))*wb6(i))-
hb121(i)*(-mutgsa-is*wb7(i));        ka122(4)=-((-k2-mutgrl)*hb122(i))-
k2*hb123(i)+(r*hb11(i)*wb1(i))/tmax;        ka123(4)=-(pr*hb126(i)*(1-u15(4))*(1-u22(4)))-
pr*hb127(i)*u22(4)+(r*hb11(i)*wb1(i))/tmax-c*q*hb17(i)*wb6(i)-hb16(i)*(-




k3*hb120(i)*wb4(i)+k3*hb14(i)*wb4(i);        ka125(4)=mumhra*hb125(i)-pr*hb126(i)*(1-
u15(4))*(1-u22(4))-pr*hb127(i)*u22(4)+k3*hb11(i)*wb1(i)-k3*hb110(i)*wb1(i)-
k3*hb114(i)*wb2(i)+k3*hb12(i)*wb2(i)-k3*hb118(i)*wb3(i)+k3*hb13(i)*wb3(i)-


















qthvr)*wb1(i)+(1-qtsvr)*wb2(i)+(1-qtrvr)*wb3(i)+(1-qtgvr)*wb4(i))-k1rm*rhor*wb5(i));        
%LAMBDA2(4) 






























c*hb26(i)*wb6(i)*(wb11(i)+wb13(i)+wb15(i)+wb17(i)+wb19(i)+wb21(i)+wb23(i)+wb9(i));        
ka25(4)=-(k1sm*hb224(i)*(1-u15(4))*(1-u16(4))*wb26(i))+k1sm*rhos*hb226(i)*(1-
u15(4))*(1-u16(4))*wb26(i)-k1rm*hb225(i)*wb27(i)+k1rm*rhor*hb227(i)*wb27(i)-





)));        
ka27(4)=muie*hb27(i)+ir*hb211(i)*wb11(i)+is*hb213(i)*wb13(i)+ir*hb215(i)*wb15(i)+is*h
b217(i)*wb17(i)+ir*hb219(i)*wb19(i)+is*hb221(i)*wb21(i)+ir*hb223(i)*wb23(i)+is*hb29(i)
*wb9(i);        ka28(4)=-1-hb28(i)*(-muthsl-k2*(1-u14(4))*(1-u16(4)))-k2*hb29(i)*(1-
u14(4))*(1-u16(4))+(r*hb21(i)*wb1(i))/tmax;        ka29(4)= -1-ps*hb227(i)*(1-u21(4))-
ps*hb226(i)*(1-u15(4))*u21(4)+(r*hb21(i)*wb1(i))/tmax-c*q*hb27(i)*wb6(i)-hb26(i)*(-
(c*q*wb6(i))+c*(wb1(i)+wb2(i)+wb3(i)+wb4(i))*wb6(i))-hb29(i)*(-muthsa-is*wb7(i));        
ka210(4)=-1-(-k2-muthrl)*hb210(i)-k2*hb211(i)+(r*hb21(i)*wb1(i))/tmax;        ka211(4)= -
1-pr*hb226(i)*(1-u15(4))*(1-u22(4))-pr*hb227(i)*u22(4)+(r*hb21(i)*wb1(i))/tmax-
c*q*hb27(i)*wb6(i)-hb26(i)*(-(c*q*wb6(i))+c*(wb1(i)+wb2(i)+wb3(i)+wb4(i))*wb6(i))-
hb211(i)*(-muthra-ir*wb7(i));        ka212(4)=-1-hb212(i)*(-mutssl-k2*(1-u14(4))*(1-
u16(4)))-k2*hb213(i)*(1-u14(4))*(1-u16(4))+(r*hb21(i)*wb1(i))/tmax;        ka213(4)=-1-
ps*hb227(i)*(1-u21(4))-ps*hb226(i)*(1-u15(4))*u21(4)+(r*hb21(i)*wb1(i))/tmax-
c*q*hb27(i)*wb6(i)-hb26(i)*(-(c*q*wb6(i))+c*(wb1(i)+wb2(i)+wb3(i)+wb4(i))*wb6(i))-
hb213(i)*(-mutssa-is*wb7(i));        ka214(4)=-1-(-k2-mutsrl)*hb214(i)-
k2*hb215(i)+(r*hb21(i)*wb1(i))/tmax;        ka215(4)=-1-pr*hb226(i)*(1-u15(4))*(1-u22(4))-
pr*hb227(i)*u22(4)+(r*hb21(i)*wb1(i))/tmax-c*q*hb27(i)*wb6(i)-hb26(i)*(-
(c*q*wb6(i))+c*(wb1(i)+wb2(i)+wb3(i)+wb4(i))*wb6(i))-hb215(i)*(-mutsra-ir*wb7(i));        
ka216(4)=-1-hb216(i)*(-mutrsl-k2*(1-u14(4))*(1-u16(4)))-k2*hb217(i)*(1-u14(4))*(1-
u16(4))+(r*hb21(i)*wb1(i))/tmax;        ka217(4)=-1-ps*hb227(i)*(1-u21(4))-ps*hb226(i)*(1-
u15(4))*u21(4)+(r*hb21(i)*wb1(i))/tmax-c*q*hb27(i)*wb6(i)-hb26(i)*(-
(c*q*wb6(i))+c*(wb1(i)+wb2(i)+wb3(i)+wb4(i))*wb6(i))-hb217(i)*(-mutrsa-is*wb7(i));        
ka218(4)=-1-(-k2-mutrrl)*hb218(i)-k2*hb219(i)+(r*hb21(i)*wb1(i))/tmax;        ka219(4)=-1-
pr*hb226(i)*(1-u15(4))*(1-u22(4))-pr*hb227(i)*u22(4)+(r*hb21(i)*wb1(i))/tmax-
c*q*hb27(i)*wb6(i)-hb26(i)*(-(c*q*wb6(i))+c*(wb1(i)+wb2(i)+wb3(i)+wb4(i))*wb6(i))-
hb219(i)*(-mutrra-ir*wb7(i));        ka220(4)=-1-hb220(i)*(-mutgsl-k2*(1-u14(4))*(1-
u16(4)))-k2*hb221(i)*(1-u14(4))*(1-u16(4))+(r*hb21(i)*wb1(i))/tmax;        ka221(4)=-1-
ps*hb227(i)*(1-u21(4))-ps*hb226(i)*(1-u15(4))*u21(4)+(r*hb21(i)*wb1(i))/tmax-
c*q*hb27(i)*wb6(i)-hb26(i)*(-(c*q*wb6(i))+c*(wb1(i)+wb2(i)+wb3(i)+wb4(i))*wb6(i))-
hb221(i)*(-mutgsa-is*wb7(i));        ka222(4)=-1-(-k2-mutgrl)*hb222(i)-
k2*hb223(i)+(r*hb21(i)*wb1(i))/tmax;        ka223(4)=-1-pr*hb226(i)*(1-u15(4))*(1-u22(4))-
pr*hb227(i)*u22(4)+(r*hb21(i)*wb1(i))/tmax-c*q*hb27(i)*wb6(i)-hb26(i)*(-




k3*hb220(i)*wb4(i)+k3*hb24(i)*wb4(i);        ka225(4)=mumhra*hb225(i)-pr*hb226(i)*(1-
u15(4))*(1-u22(4))-pr*hb227(i)*u22(4)+k3*hb21(i)*wb1(i)-k3*hb210(i)*wb1(i)-
k3*hb214(i)*wb2(i)+k3*hb22(i)*wb2(i)-k3*hb218(i)*wb3(i)+k3*hb23(i)*wb3(i)-
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        %RUNGE KUTTA 4° ORDINE PER LE VARIABILI AGG lambda 1 
        l11(i-1)=l11(i)+(h/6)*(ka11(1)+2*ka11(2)+2*ka11(3)+ka11(4)); 
        l12(i-1)=l12(i)+(h/6)*(ka12(1)+2*ka12(2)+2*ka12(3)+ka12(4)); 
        l13(i-1)=l13(i)+(h/6)*(ka13(1)+2*ka13(2)+2*ka13(3)+ka13(4)); 
        l14(i-1)=l14(i)+(h/6)*(ka14(1)+2*ka14(2)+2*ka14(3)+ka14(4)); 
        l15(i-1)=l15(i)+(h/6)*(ka15(1)+2*ka15(2)+2*ka15(3)+ka15(4)); 
        l16(i-1)=l16(i)+(h/6)*(ka16(1)+2*ka16(2)+2*ka16(3)+ka16(4)); 
        l17(i-1)=l17(i)+(h/6)*(ka17(1)+2*ka17(2)+2*ka17(3)+ka17(4)); 
        l18(i-1)=l18(i)+(h/6)*(ka18(1)+2*ka18(2)+2*ka18(3)+ka18(4)); 
        l19(i-1)=l19(i)+(h/6)*(ka19(1)+2*ka19(2)+2*ka19(3)+ka19(4)); 
        l110(i-1)=l110(i)+(h/6)*(ka110(1)+2*ka110(2)+2*ka110(3)+ka110(4)); 
        l111(i-1)=l111(i)+(h/6)*(ka111(1)+2*ka111(2)+2*ka111(3)+ka111(4)); 
        l112(i-1)=l112(i)+(h/6)*(ka112(1)+2*ka112(2)+2*ka112(3)+ka112(4)); 
        l113(i-1)=l113(i)+(h/6)*(ka113(1)+2*ka113(2)+2*ka113(3)+ka113(4)); 
        l114(i-1)=l114(i)+(h/6)*(ka114(1)+2*ka114(2)+2*ka114(3)+ka114(4)); 
        l115(i-1)=l115(i)+(h/6)*(ka115(1)+2*ka115(2)+2*ka115(3)+ka115(4)); 
        l116(i-1)=l116(i)+(h/6)*(ka116(1)+2*ka116(2)+2*ka116(3)+ka116(4)); 
        l117(i-1)=l117(i)+(h/6)*(ka117(1)+2*ka117(2)+2*ka117(3)+ka117(4)); 
        l118(i-1)=l118(i)+(h/6)*(ka118(1)+2*ka118(2)+2*ka118(3)+ka118(4)); 
        l119(i-1)=l119(i)+(h/6)*(ka119(1)+2*ka119(2)+2*ka119(3)+ka119(4)); 
        l120(i-1)=l120(i)+(h/6)*(ka120(1)+2*ka120(2)+2*ka120(3)+ka120(4)); 
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        l121(i-1)=l121(i)+(h/6)*(ka121(1)+2*ka121(2)+2*ka121(3)+ka121(4)); 
        l122(i-1)=l122(i)+(h/6)*(ka122(1)+2*ka122(2)+2*ka122(3)+ka122(4)); 
        l123(i-1)=l123(i)+(h/6)*(ka123(1)+2*ka123(2)+2*ka123(3)+ka123(4)); 
        l124(i-1)=l124(i)+(h/6)*(ka124(1)+2*ka124(2)+2*ka124(3)+ka124(4)); 
        l125(i-1)=l125(i)+(h/6)*(ka125(1)+2*ka125(2)+2*ka125(3)+ka125(4)); 
        l126(i-1)=l126(i)+(h/6)*(ka126(1)+2*ka126(2)+2*ka126(3)+ka126(4)); 
        l127(i-1)=l127(i)+(h/6)*(ka127(1)+2*ka127(2)+2*ka127(3)+ka127(4)); 
         
         
        %RUNGE KUTTA 4° ORDINE  PER LE VARIABILI AGG lambda 2 
        l21(i-1)=l21(i)+(h/6)*(ka21(1)+2*ka21(2)+2*ka21(3)+ka21(4)); 
        l22(i-1)=l22(i)+(h/6)*(ka22(1)+2*ka22(2)+2*ka22(3)+ka22(4)); 
        l23(i-1)=l23(i)+(h/6)*(ka23(1)+2*ka23(2)+2*ka23(3)+ka23(4)); 
        l24(i-1)=l24(i)+(h/6)*(ka24(1)+2*ka24(2)+2*ka24(3)+ka24(4)); 
        l25(i-1)=l25(i)+(h/6)*(ka25(1)+2*ka25(2)+2*ka25(3)+ka25(4)); 
        l26(i-1)=l26(i)+(h/6)*(ka26(1)+2*ka26(2)+2*ka26(3)+ka26(4)); 
        l27(i-1)=l27(i)+(h/6)*(ka27(1)+2*ka27(2)+2*ka27(3)+ka27(4)); 
        l28(i-1)=l28(i)+(h/6)*(ka28(1)+2*ka28(2)+2*ka28(3)+ka28(4)); 
        l29(i-1)=l29(i)+(h/6)*(ka29(1)+2*ka29(2)+2*ka29(3)+ka29(4)); 
        l210(i-1)=l210(i)+(h/6)*(ka210(1)+2*ka210(2)+2*ka210(3)+ka210(4)); 
        l211(i-1)=l211(i)+(h/6)*(ka211(1)+2*ka211(2)+2*ka211(3)+ka211(4)); 
        l212(i-1)=l212(i)+(h/6)*(ka212(1)+2*ka212(2)+2*ka212(3)+ka212(4)); 
        l213(i-1)=l213(i)+(h/6)*(ka213(1)+2*ka213(2)+2*ka213(3)+ka213(4)); 
        l214(i-1)=l214(i)+(h/6)*(ka214(1)+2*ka214(2)+2*ka214(3)+ka214(4)); 
        l215(i-1)=l215(i)+(h/6)*(ka215(1)+2*ka215(2)+2*ka215(3)+ka215(4)); 
        l216(i-1)=l216(i)+(h/6)*(ka216(1)+2*ka216(2)+2*ka216(3)+ka216(4)); 
        l217(i-1)=l217(i)+(h/6)*(ka217(1)+2*ka217(2)+2*ka217(3)+ka217(4)); 
        l218(i-1)=l218(i)+(h/6)*(ka218(1)+2*ka218(2)+2*ka218(3)+ka218(4)); 
        l219(i-1)=l219(i)+(h/6)*(ka219(1)+2*ka219(2)+2*ka219(3)+ka219(4)); 
        l220(i-1)=l220(i)+(h/6)*(ka220(1)+2*ka220(2)+2*ka220(3)+ka220(4)); 
        l221(i-1)=l221(i)+(h/6)*(ka221(1)+2*ka221(2)+2*ka221(3)+ka221(4)); 
        l222(i-1)=l222(i)+(h/6)*(ka222(1)+2*ka222(2)+2*ka222(3)+ka222(4)); 
        l223(i-1)=l223(i)+(h/6)*(ka223(1)+2*ka223(2)+2*ka223(3)+ka223(4)); 
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        l224(i-1)=l224(i)+(h/6)*(ka224(1)+2*ka224(2)+2*ka224(3)+ka224(4)); 
        l225(i-1)=l225(i)+(h/6)*(ka225(1)+2*ka225(2)+2*ka225(3)+ka225(4)); 
        l226(i-1)=l226(i)+(h/6)*(ka226(1)+2*ka226(2)+2*ka226(3)+ka226(4)); 
        l227(i-1)=l227(i)+(h/6)*(ka227(1)+2*ka227(2)+2*ka227(3)+ka227(4)); 
 
    end %%%%%%%%%%%%%end for BACKWARD PROCESS 
     
    x=[x1; x2; x3; x4; x5; x6; x7; x8; x9; x10; x11; x12; x13; x14; x15;... 
    x16; x17; x18; x19; x20; x21; x22; x23; x24; x25; x26; x27]; 
    l1=[l11; l12; l13; l14; l15; l16; l17; l18; l19; l110; l111; l112; l113;... 
    l114; l115; l116; l117; l118; l119; l120; l121; l122; l123; l124;... 
    l125; l126; l127]; 
    l2=[l21; l22; l23; l24; l25; l26; l27; l28; l29; l210; l211; l212; l213;... 
    l214; l215; l216; l217; l218; l219; l220; l221; l222; l223; l224;... 
    l225; l226; l227];    tempx=sigma*sum(abs(x'))-sum((abs(oldx-x))'); 
    testx=min(min(tempx)); 
     
    templ1=sigma*sum(abs(l1'))-sum((abs(oldl1-l1))'); 
    testl1=min(min(templ1)); 
     
    templ2=sigma*sum(abs(l2'))-sum((abs(oldl2-l2))'); 
    testl2=min(min(templ2)); 
     
 display(conta); 
    test=min(testx, min(testl1, testl2)) 
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    % questa parte riguarda i pcontrolliparziali non serve  
    % ma serve a me per vedere cosa succede durante le iterazioni 
    % si può togliere per avere più velocità nelle elaborazioni 
%  %#####################       controlli ottimali parziali +      
%  %#####################    + calcolo concavità parziale   +  
%  %#####################    + calcolo payoff parziali      +  
%  %#####################    + calcolo ESS 1, 2, 3, 4, 5    
%  for i=1:N+1      
%   





























































%      a13=(1.*(l11(i)*x1(i)+l12(i)*x2(i)+l13(i)*x3(i)+l14(i)*x4(i)))/aib; 
%   
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%   
%      if(a11<0 || a11>1) 
%       a11=0; 
%      end; 
%       
%      if(a12<0 || a12>1) 
%       a12=0; 
%      end; 
%       
%      if(a13<0 || a13>1) 
%       a13=0; 
%      end; 
%       
%      if(a14<0 || a14>1) 
%       a14=0; 
%      end; 
%       
%      if(a15<0 || a15>1) 
%       a15=0; 
%      end; 
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%       
%      if(a16<0 || a16>1) 
%       a16=0; 
%      end; 
%               
%      



































































































































%   
%      
%      eval_HT=eval(fHT); 
%    
%       
%      [max_HT, id_HT]=nanmax(eval_HT); 
%       
%       
%      u1(1,i)=D(id_HT,1); 
%      u1(2,i)=D(id_HT,2); 
%      u1(3,i)=D(id_HT,3); 
%      u1(4,i)=D(id_HT,4); 
%      u1(5,i)=D(id_HT,5); 
%      u1(6,i)=D(id_HT,6); 
%       
%      u2(1,i)=u21s; 
%      u2(2,i)=u22s; 
%       
%  %#####   verifica concavità parziale h2 e h6 dei controlli relativi alla terapia 


































































































































































































































%    


















%    
%       
%      %#################     calcolo Payoff parziali 
%      %JTER 
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%         %JV 





%         %##################### Calcolo ESS 1, 2, 3, 4, 5 

































%         ess4(i)=1.*abs((ps*l226(i)*(x13(i)+x17(i)+x21(i)+x24(i)+x9(i)))/bsr); 
%  
%         ess5(i)=1.*abs((pr*l226(i)*(x11(i)+x15(i)+x19(i)+x23(i)+x25(i)))/brs); 
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%         if (ess1(i)>=1 || ess2(i)>=1 || ess3(i)>=1 || ess4(i)>=1 || ess5(i)>=1 ) 
%             testess=-1; 
%         else 
%             testess=1; 
%         end;            
%       
%  
%  end; %###########end controlli ottimali parziali  
%       %##########+ concavità parz + payoff parz + ESS 
%      
%        




%  pay_SI_parziali_2=h*sum(JSI) 




%  pay_V_parziali_2=h*sum(JV) 
%  
%  %#############visualizzazione testESS parziale  
%     display(testess); 
end; %%%%%%%%%%%%%%%%%%%%%%%%%%%%%end  WHILE ESTERNO 
%#####################      controlli ottimali FINALI +      
%#####################    + calcolo concavità FINALI  +  
%#####################    + calcolo payoff FINALI      +  
%#####################    + calcolo ESS 1, 2, 3, 4, 5    
for i=1:N+1      




























































    a13=(1.*(l11(i)*x1(i)+l12(i)*x2(i)+l13(i)*x3(i)+l14(i)*x4(i)))/aib; 













































































































































































        
    if(a11<0 || a11>1) 
     a11=0; 
    end; 
     
    if(a12<0 || a12>1) 
     a12=0; 
    end; 
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    if(a13<0 || a13>1) 
     a13=0; 
    end; 
     
    if(a14<0 || a14>1) 
     a14=0; 
    end; 
     
    if(a15<0 || a15>1) 
     a15=0; 
    end; 
     
    if(a16<0 || a16>1) 
     a16=0; 
    end; 




































































































































     
     
    eval_HT=eval(fHT); 
     
    [max_HT, id_HT]=nanmax(eval_HT); 
     
    u1(1,i)=D(id_HT,1); 
    u1(2,i)=D(id_HT,2); 
    u1(3,i)=D(id_HT,3); 
    u1(4,i)=D(id_HT,4); 
    u1(5,i)=D(id_HT,5); 
    u1(6,i)=D(id_HT,6); 
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    u2(1,i)=u21s; 
    u2(2,i)=u22s; 
     
     
 %##################   verifica concavità FINALE h2 e h6 dei controlli relativi 
alla terapia 
















































































































































































































































     











    












    
     
    %#################     calcolo Payoff FINALI 
    %JTERAPIA 
    JSI(i)=-
0.5*(aco*u1(1,i)^2+afi*u1(2,i)^2+aib*u1(3,i)^2+aii*u1(4,i)^2+api*u1(5,i)^2+art*u1(6,i)^2)+
x1(i)+x2(i)+x3(i)+x4(i)+x5(i)+x6(i)+x7(i); 
    %JVIRUS 
    JV(i)=-0.5*(bsr*(1-u2(1,i))^2+brs*(1-
u2(2,i))^2)+x10(i)+x11(i)+x12(i)+x13(i)+x14(i)+x15(i)+x16(i)+x17(i)+x18(i)+x19(i)+x20(i)
+x21(i)+x22(i)+x23(i)+x26(i)+x27(i)+x8(i)+x9(i); 
     
    %##################### Calcolo ESS 1, 2, 3, 4, 5 FINALI 

































    ess4(i)=1.*abs((ps*l226(i)*(x13(i)+x17(i)+x21(i)+x24(i)+x9(i)))/bsr); 
    ess5(i)=1.*abs((pr*l226(i)*(x11(i)+x15(i)+x19(i)+x23(i)+x25(i)))/brs); 
    if (ess1(i)>=1 || ess2(i)>=1 || ess3(i)>=1 || ess4(i)>=1 || ess5(i)>=1 ) 
        testess=-1; 
    else 
        testess=1; 
    end;            
     
       
end;  %%%%%%%%%%%end controlli ottimali FINALI  





















plot(y(1,:),y(83,:), '- k'); 
legend ('uCO'); 
axis([t0-(tf/20) tf+(tf/20) -0.1 1.1]); 
subplot(3,3,2); 
plot(y(1,:),y(84,:), '- b'); 
legend ('uFI'); 
axis([t0-(tf/20) tf+(tf/20) -0.1 1.1]); 
subplot(3,3,3); 
plot(y(1,:),y(85,:), '- g'); 
legend('uIB'); 
axis([t0-(tf/20) tf+(tf/20) -0.1 1.1]); 
subplot(3,3,4); 
plot(y(1,:),y(86,:), '- k'); 
legend ('uII'); 
axis([t0-(tf/20) tf+(tf/20) -0.1 1.1]); 
subplot(3,3,5); 
plot(y(1,:),y(88,:), '- b'); 
legend ('uRT'); 
axis([t0-(tf/20) tf+(tf/20) -0.1 1.1]); 
subplot(3,3,6); 
plot(y(1,:),y(87,:), '- g'); 
legend ('uPI'); 
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axis([t0-(tf/20) tf+(tf/20) -0.1 1.1]); 
subplot(3,3,7); 
plot(y(1,:),y(90,:), '- m'); 
legend ('uRSv'); 
axis([t0-(tf/20) tf+(tf/20) -0.1 1.1]); 
subplot(3,3,8); 
plot(y(1,:),y(89,:), '- r'); 
legend ('uSRv'); 


























































































title('minore d ordine 2'); 
subplot(3,2,2); 
plot(y(1,:), y(92,:)); 
title('minore d ordine 6'); 
subplot(3,2,3); 
plot(y(1,:), y(94,:)); 
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title('minore d ordine 2'); 
subplot(3,2,4); 
plot(y(1,:), y(95,:)); 
title('minore d ordine 6');%% calcolo e visualizzazione payoff FINALI 
%%%%%%%%%%%%%%%%%%%%%% J therapy 
for i=1:N 
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